---
http_interactions:
- request:
    method: get
    uri: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?api_key=<NCBI_API_KEY>&db=pubmed&term=cancer
    body:
      encoding: US-ASCII
      string: ''
    headers:
      Accept-Encoding:
      - gzip;q=1.0,deflate;q=0.6,identity;q=0.3
      Accept:
      - "*/*"
      User-Agent:
      - Ruby
  response:
    status:
      code: 200
      message: OK
    headers:
      Date:
      - Wed, 17 May 2023 17:59:13 GMT
      Server:
      - Finatra
      Strict-Transport-Security:
      - max-age=31536000; includeSubDomains; preload
      Content-Security-Policy:
      - upgrade-insecure-requests
      Referrer-Policy:
      - origin-when-cross-origin
      Ncbi-Sid:
      - 4E11E38CAE6F6C86_B3C0SID
      Ncbi-Phid:
      - D0BD1EF10BD2F0D500003F0131443EEE.1.1.m_1
      Content-Type:
      - text/xml; charset=UTF-8
      Cache-Control:
      - private
      X-Ratelimit-Limit:
      - '10'
      X-Ratelimit-Remaining:
      - '9'
      Access-Control-Allow-Origin:
      - "*"
      Access-Control-Expose-Headers:
      - X-RateLimit-Limit,X-RateLimit-Remaining
      Set-Cookie:
      - ncbi_sid=4E11E38CAE6F6C86_B3C0SID; domain=.nih.gov; path=/; expires=Fri, 17
        May 2024 17:59:13 GMT
      X-Ua-Compatible:
      - IE=Edge
      X-Xss-Protection:
      - 1; mode=block
      Transfer-Encoding:
      - chunked
    body:
      encoding: ASCII-8BIT
      string: |
        <?xml version="1.0" encoding="UTF-8" ?>
        <!DOCTYPE eSearchResult PUBLIC "-//NLM//DTD esearch 20060628//EN" "https://eutils.ncbi.nlm.nih.gov/eutils/dtd/20060628/esearch.dtd">
        <eSearchResult><Count>4859380</Count><RetMax>20</RetMax><RetStart>0</RetStart><IdList>
        <Id>37195809</Id>
        <Id>37195800</Id>
        <Id>37195795</Id>
        <Id>37195792</Id>
        <Id>37195788</Id>
        <Id>37195787</Id>
        <Id>37195782</Id>
        <Id>37195777</Id>
        <Id>37195776</Id>
        <Id>37195775</Id>
        <Id>37195774</Id>
        <Id>37195773</Id>
        <Id>37195772</Id>
        <Id>37195771</Id>
        <Id>37195770</Id>
        <Id>37195769</Id>
        <Id>37195768</Id>
        <Id>37195767</Id>
        <Id>37195766</Id>
        <Id>37195765</Id>
        </IdList><TranslationSet><Translation>     <From>cancer</From>     <To>"cancer's"[All Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR "cancerization"[All Fields] OR "cancerized"[All Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields] OR "cancers"[All Fields]</To>    </Translation></TranslationSet><QueryTranslation>"cancer s"[All Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR "cancerization"[All Fields] OR "cancerized"[All Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields] OR "cancers"[All Fields]</QueryTranslation></eSearchResult>
  recorded_at: Wed, 17 May 2023 17:59:13 GMT
- request:
    method: get
    uri: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?api_key=<NCBI_API_KEY>&db=pubmed&id=37195809,37195800,37195795,37195792,37195788,37195787,37195782,37195777,37195776,37195775,37195774,37195773,37195772,37195771,37195770,37195769,37195768,37195767,37195766,37195765
    body:
      encoding: US-ASCII
      string: ''
    headers:
      Accept-Encoding:
      - gzip;q=1.0,deflate;q=0.6,identity;q=0.3
      Accept:
      - "*/*"
      User-Agent:
      - Ruby
  response:
    status:
      code: 200
      message: OK
    headers:
      Date:
      - Wed, 17 May 2023 17:59:13 GMT
      Server:
      - Finatra
      Strict-Transport-Security:
      - max-age=31536000; includeSubDomains; preload
      Content-Security-Policy:
      - upgrade-insecure-requests
      Referrer-Policy:
      - origin-when-cross-origin
      Ncbi-Sid:
      - FF27874AADA7B5A5_E116SID
      Ncbi-Phid:
      - 322C36E9C9D0D90500005EE7E15C54AE.1.1.m_3
      Content-Type:
      - text/xml; charset=UTF-8
      Cache-Control:
      - private
      X-Ratelimit-Limit:
      - '10'
      X-Ratelimit-Remaining:
      - '8'
      Access-Control-Allow-Origin:
      - "*"
      Access-Control-Expose-Headers:
      - X-RateLimit-Limit,X-RateLimit-Remaining
      Set-Cookie:
      - ncbi_sid=FF27874AADA7B5A5_E116SID; domain=.nih.gov; path=/; expires=Fri, 17
        May 2024 17:59:13 GMT
      X-Ua-Compatible:
      - IE=Edge
      X-Xss-Protection:
      - 1; mode=block
      Transfer-Encoding:
      - chunked
    body:
      encoding: ASCII-8BIT
      string: |-
        <?xml version="1.0" ?>
        <!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
        <PubmedArticleSet>
        <PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195809</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1940-1574</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Angiology</Title><ISOAbbreviation>Angiology</ISOAbbreviation></Journal><ArticleTitle>Venous Thrombosis Recurrence After Catheter-Related Upper Extremity Deep Venous Thrombosis in Cancer Patients: A Retrospective Analysis.</ArticleTitle><Pagination><StartPage>33197231176985</StartPage><MedlinePgn>33197231176985</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/00033197231176985</ELocationID><Abstract><AbstractText>Long-term indwelling central venous catheters (CVC) are frequently used to secure vascular access to deliver injectable treatment. Catheter-related thrombosis (CRT) occurs in approximately 2-6% of cancer patients. We conducted a single-center retrospective study to assess the rate of venous thromboembolism (VTE) recurrence in cancer patients; 200 patients were included. Mean age was 56 &#xb1; 15.15&#xa0;years, median follow-up duration was 16.5 [range: 10-36] months. The incidence of recurrence was estimated using Gray's method for competing risk with death as the competing event of VTE. Recurrent VTE occurred in 25.5% of patients with a median occurrence time of 6.5 [range: 5-11.25] months. In case of recurrence, 94.6% of patients were treated for cancer and 80.4% of them received anticoagulants; 4 major bleeds and 17 non-major bleeds occurred during follow-up. In multivariate analysis, previous VTE (Hazard Ratio (HR) 2.48 (95% CI 1.42-4.32) and presence of CVC (HR 5.56 (95% CI 1.96-15.75) were significant recurrence risk factors. After a first episode of CRT, 25.5% of patients experienced VTE recurrence as UEDVT in 30 cases (55.5%), PE in 17 cases (31.5%), and DVT in 7 cases (13%), mostly during anticoagulation therapy. Anticoagulation therapy does not avoid CRT in case of cancer and must be balanced with hemorrhagic risk.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hakem</LastName><ForeName>Rabiaa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Vascular Medicine, Amiens-Picardie University Hospital, Amiens, France.</Affiliation><Identifier Source="RINGGOLD">36673</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soudet</LastName><ForeName>Simon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7003-3703</Identifier><AffiliationInfo><Affiliation>Department of Vascular Medicine, Amiens-Picardie University Hospital, Amiens, France.</Affiliation><Identifier Source="RINGGOLD">36673</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>EA CHIMERE, Picardie Jules Verne University, Amiens, France.</Affiliation><Identifier Source="RINGGOLD">7516</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diouf</LastName><ForeName>Momar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>DRCI, Amiens-Picardie University Hospital, Amiens, France.</Affiliation><Identifier Source="RINGGOLD">36673</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sevestre</LastName><ForeName>Marie Antoinette</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Vascular Medicine, Amiens-Picardie University Hospital, Amiens, France.</Affiliation><Identifier Source="RINGGOLD">36673</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>EA CHIMERE, Picardie Jules Verne University, Amiens, France.</Affiliation><Identifier Source="RINGGOLD">7516</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Angiology</MedlineTA><NlmUniqueID>0203706</NlmUniqueID><ISSNLinking>0003-3197</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anticoagulants</Keyword><Keyword MajorTopicYN="N">neoplasms</Keyword><Keyword MajorTopicYN="N">upper extremity deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">venous thrombosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195809</ArticleId><ArticleId IdType="doi">10.1177/00033197231176985</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195800</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-9159</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>International journal of surgery (London, England)</Title><ISOAbbreviation>Int J Surg</ISOAbbreviation></Journal><ArticleTitle>The incidence of perioperative lymphatic complications after radical hysterectomy and pelvic lymphadenectomy between robotic and laparoscopic approach : a systemic review and meta-analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/JS9.0000000000000472</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although many studies have reported perioperative complications after radical hysterectomy and pelvic lymph node dissection using robotic and laparoscopic approaches, the risk of perioperative lymphatic complications has not been well identified. The aim of this meta-analysis is to compare the risks of perioperative lymphatic complications after robotic radical hysterectomy and lymph node dissection (RRHND) with laparoscopic radical hysterectomy and lymph node dissection (LRHND) for early uterine cervical cancer.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We searched the PubMed, Cochrane Library, Web of Science, ScienceDirect, and Google Scholar databases for studies published up to July 2022 comparing perioperative lymphatic complications after RRHND and LRHND while treating early uterine cervical cancer. Related articles and bibliographies of relevant studies were also checked. Two reviewers independently performed the data extraction.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 19 eligible clinical trials (15 retrospective studies and 4 prospective studies) comprising 3,079 patients were included in this analysis. Only 107 patients (3.48%) had perioperative lymphatic complications, of which the most common was lymphedema (n=57, 1.85%), followed by symptomatic lymphocele (n=30, 0.97%), and lymphorrhea (n=15, 0.49%). When all studies were pooled, the odds ratio (OR) for the risk of any lymphatic complication after RRHND compared with LRHND was 1.27 (95% confidence interval: 0.86-1.89; P=0.230). In the subgroup analysis, study quality, country of research, and publication year were not associated with perioperative lymphatic complications.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A meta-analysis of the available current literature suggests that RRHND is not superior to LRHND in terms of perioperative lymphatic complications.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Jong Ha</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Republic of Korea, SIMGOKRO 100 GIL 25 SEO-GU INCHEON METROPOLITAN CITY, 22711, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Bo Wook</ForeName><Initials>BW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Surg</MedlineTA><NlmUniqueID>101228232</NlmUniqueID><ISSNLinking>1743-9159</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195800</ArticleId><ArticleId IdType="doi">10.1097/JS9.0000000000000472</ArticleId><ArticleId IdType="pii">01279778-990000000-00353</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195795</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-3141</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>AJR. American journal of roentgenology</Title><ISOAbbreviation>AJR Am J Roentgenol</ISOAbbreviation></Journal><ArticleTitle>Editorial Comment: The Delicate Balance of Safety and Efficiency.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.2214/AJR.23.29620</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moussa</LastName><ForeName>Amgad M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AJR Am J Roentgenol</MedlineTA><NlmUniqueID>7708173</NlmUniqueID><ISSNLinking>0361-803X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>AJR Am J Roentgenol. 2023 May 3;:</RefSource><PMID Version="1">37132549</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195795</ArticleId><ArticleId IdType="doi">10.2214/AJR.23.29620</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195792</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-3141</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>AJR. American journal of roentgenology</Title><ISOAbbreviation>AJR Am J Roentgenol</ISOAbbreviation></Journal><ArticleTitle>Development and Validation of a Risk Model for Predicting Contrast-Associated Acute Kidney Injury in Patients With Cancer: Evaluation in Over 46,000 CT Scans.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.2214/AJR.23.29139</ELocationID><Abstract><AbstractText><b>Background:</b> Patients with cancer undergo frequent CT examinations using iodinated contrast media and may be uniquely predisposed to contrast-associated acute kidney injury (CA-AKI). <b>Objective:</b> To develop and validate a model for predicting the risk of CA-AKI after contrast-enhanced CT in patients with cancer. <b>Methods:</b> This retrospective study included 25,184 adult patients (mean age, 62.3&#xb1;13.7 years; 12,153 men, 13,031 women) with cancer who underwent 46,593 contrast-enhanced CT scans between January 1, 2016 and June 20, 2020 at one of three academic medical centers. Information was recorded regarding demographics, malignancy type, medication use, baseline laboratory values, and comorbidities. CA-AKI was defined as a &#x2265;0.3-mg/dl increase in serum creatinine from baseline within 48 hours after CT or a &#x2265;1.5-fold increase to the peak measurement within 14 days after CT. Multivariable models accounting for correlated data were used to identify risk factors for CAAKI. A risk score for predicting CA-AKI was created in a development set (n=30,926) and tested in a validation set (n=15,667). <b>Results:</b> CA-AKI occurred after 5.8% (2682/46,593) of scans. The final multivariable model for predicting CA-AKI included hematologic malignancy, diuretic use, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, chronic kidney disease (CKD) stage IIIa, CKD stage IIIb, CKD stage IV or V, serum albumin &lt;3.0 g/dl, platelet count &lt;150 K/mm3, &#x2265;1+ proteinuria on baseline urinalysis, diabetes mellitus, heart failure, and contrast media volume &#x2265;100 ml. A risk score (range, 0-53 points) was created using these variables [most points (13) for CKD stage IV or V, or albumin &lt;3 g/dl]. CA-AKI progressively increased in frequency at higher risk categories. For example, in the validation set, CA-AKI occurred after 2.2% of scans in the lowest risk category (score &#x2264;4) and after 32.7% of scans in the highest risk category (score &#x2265;30). Hosmer-Lemeshow test indicated that the risk score was a good fit (p=.40). <b>Conclusion:</b> This study demonstrates the development and validation of a risk model using readily available clinical data to predict the likelihood of CA-AKI after contrast-enhanced CT in patients with cancer. <b>Clinical Impact:</b> The model may help facilitate appropriate implementation of preventive measures among patients at high risk for CA-AKI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Shruti</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5747-2151</Identifier><AffiliationInfo><Affiliation>Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dana-Farber Cancer Institute, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Motwani</LastName><ForeName>Shveta S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Lahey Hospital and Medical Center, Burlington, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seitter</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chute</LastName><ForeName>Donald F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sise</LastName><ForeName>Meghan E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glazer</LastName><ForeName>Daniel I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>Dana-Farber Cancer Institute, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosner</LastName><ForeName>Bernard A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curhan</LastName><ForeName>Gary C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AJR Am J Roentgenol</MedlineTA><NlmUniqueID>7708173</NlmUniqueID><ISSNLinking>0361-803X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195792</ArticleId><ArticleId IdType="doi">10.2214/AJR.23.29139</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195788</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-9159</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>International journal of surgery (London, England)</Title><ISOAbbreviation>Int J Surg</ISOAbbreviation></Journal><ArticleTitle>A commentary on "Why public health cannot be led by doctors only".</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/JS9.0000000000000465</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Si-Un Frank</ForeName><Initials>SF</Initials><Identifier Source="ORCID">0000-0002-1696-2648</Identifier><AffiliationInfo><Affiliation>Department of Public Health, Brown University, Providence, US.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Economics, Brown University, Providence, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hung</LastName><ForeName>Kuo-Chuan</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hospital and Health Care Administration, College of Recreation and Health Management, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Chong-Chi</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of General Surgery, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Education and Research, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Surg</MedlineTA><NlmUniqueID>101228232</NlmUniqueID><ISSNLinking>1743-9159</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195788</ArticleId><ArticleId IdType="doi">10.1097/JS9.0000000000000465</ArticleId><ArticleId IdType="pii">01279778-990000000-00348</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195787</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-9159</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>International journal of surgery (London, England)</Title><ISOAbbreviation>Int J Surg</ISOAbbreviation></Journal><ArticleTitle>Selective extended dissection for pancreaticoduodenectomy is associated with better survival in pancreatic cancer patients: retrospective cohort study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/JS9.0000000000000437</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with relatively poor survival. Surgery is the first choice for treating patients with early pancreatic cancer. However, the surgical approach and the extent of resection for patients with pancreatic cancer are currently controversial.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We optimized the procedure of standard pancreaticoduodenectomy to selective extended dissection (SED), which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by the tumor. We retrospectively analyzed the clinicopathological data of patients with pancreatic adenocarcinoma who underwent radical surgery in our center from 2011 to 2020. Patients who underwent standard dissection (SD) were matched 2:1 to those who underwent SED using propensity score matching (PSM). The log-rank test and cox regression model were used to analyze survival data. In addition, statistical analyses were performed for the perioperative complications, postoperative pathology and recurrence pattern.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 520 patients were included in the analysis. Among patients with extra-pancreatic perineural invasion (EPNI), disease-free survival (DFS) was significantly longer in those who received SED than in those who received SD (14.5&#xa0;mo vs. 10&#xa0;mo, P&lt;0.05). The incidence of metastasis in No.9 and No.14 lymph nodes was significantly higher in patients with EPNI. In addition, there was no significant difference in the incidence rate of perioperative complications between the two surgical procedures.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Compared with SD, SED exhibits significant prognostic benefit for patients with EPNI. The SED procedure aiming at specific nerve plexus dissection displayed particular efficacy and safety in resectable PDAC patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xiaofan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yuning</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Peijun</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Wenbo</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hongwei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yucheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Zhejiang Provincial People's Hospital, Wenzhou Medical University, 158 Shangtang Road, Hangzhou, 310014, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Chongbiao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Jihui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Song</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Surg</MedlineTA><NlmUniqueID>101228232</NlmUniqueID><ISSNLinking>1743-9159</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195787</ArticleId><ArticleId IdType="doi">10.1097/JS9.0000000000000437</ArticleId><ArticleId IdType="pii">01279778-990000000-00357</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195782</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-9159</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>International journal of surgery (London, England)</Title><ISOAbbreviation>Int J Surg</ISOAbbreviation></Journal><ArticleTitle>Three- versus two-rows circular staplers for left-sided colorectal anastomosis: a propensity score-matched analysis of the iCral 2 and 3 prospective cohorts.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/JS9.0000000000000480</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Since most anastomoses after left-sided colorectal resections are performed with a circular stapler, any technological change in stapling devices may influence the incidence of anastomotic adverse events. The aim of the present study was to analyze the effect of a three-rows circular stapler on anastomotic leakage and related morbidity after left-sided colorectal resections.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A circular stapled anastomosis was performed in 4,255 (50.9%) out of 8,359 patients enrolled in two prospective multicenter studies in Italy, and, after exclusion criteria to reduce heterogeneity, 2,799 (65.8%) cases were retrospectively analyzed through a 1:1 propensity score-matching model including 20 covariates relative to patient characteristics, to surgery and to perioperative management. Two well balanced groups of 425 patients each were obtained: group (A) - true population of interest, anastomosis performed with a 3-rows circular stapler; group (B), - control population, anastomosis performed with a 2-rows circular stapler. The target of inferences was the average treatment effect in the treated (ATT). The primary endpoints were overall and major anastomotic leakage, and overall anastomotic bleeding; the secondary endpoints were overall and major morbidity, and mortality rates. The results of multiple logistic regression analyses for the outcomes, including the 20 covariates selected for matching, were presented as odds ratios (OR) and 95% confidence intervals (95%CI).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Group A vs. group B showed a significantly lower risk of overall anastomotic leakage [2.1 vs. 6.1%; OR 0.33; 95%CI 0.15-0.73; P=.006], major anastomotic leakage [2.1 vs. 5.2%; OR 0.39; 95%CI 0.17-0.87; P=.022], and major morbidity [3.5 vs. 6.6% events; OR 0.47; 95%CI 0.24-0.91; P=.026].</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The use of 3-rows circular staplers independently reduced the risk of anastomotic leakage and related morbidity after left-sided colorectal resection. Twenty-five patients were required to avoid one leakage.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Catarci</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6338-0114</Identifier><AffiliationInfo><Affiliation>General Surgery Unit, Sandro Pertini Hospital, ASL Roma 2.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>General Surgery Unit, "C.&amp;G. Mazzoni" Hospital, Ascoli Piceno.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guadagni</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Surgery Unit, University of L'Aquila.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masedu</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruffo</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>General Surgery Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella (VR).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viola</LastName><ForeName>Massimo Giuseppe</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>General Surgery Unit, Cardinale G. Panico Hospital, Tricase (LE).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borghi</LastName><ForeName>Felice</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Oncologic Surgery Unit, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>General &amp; Oncologic Surgery Unit, Department of Surgery, Santa Croce e Carle Hospital, Cuneo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldazzi</LastName><ForeName>Gianandrea</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>General Surgery Unit, ASST Ovest Milanese, Legnano (MI).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>General Surgery Unit, ASST Nord Milano, Sesto San Giovanni (MI).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scatizzi</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>General Surgery Unit, Santa Maria Annunziata &amp; Serristori Hospital, Firenze; Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Italian ColoRectal Anastomotic Leakage (iCral) study group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Surg</MedlineTA><NlmUniqueID>101228232</NlmUniqueID><ISSNLinking>1743-9159</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195782</ArticleId><ArticleId IdType="doi">10.1097/JS9.0000000000000480</ArticleId><ArticleId IdType="pii">01279778-990000000-00356</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195777</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-336X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>3</Issue><PubDate><MedlineDate>2023 May-Jun 01</MedlineDate></PubDate></JournalIssue><Title>Cancer journal (Sudbury, Mass.)</Title><ISOAbbreviation>Cancer J</ISOAbbreviation></Journal><ArticleTitle>Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms.</ArticleTitle><Pagination><StartPage>203</StartPage><EndPage>211</EndPage><MedlinePgn>203-211</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PPO.0000000000000666</ELocationID><Abstract><AbstractText>Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast burden reduction and hematologic recovery. Despite revision of the IWG criteria in 2006, correlation between IWG-defined responses and patient-focused outcomes, including long-term benefits, remains limited and has potentially contributed to failures of several phase III clinical trials. Several IWG 2006 criteria also lacked clear definitions leading to problems in practical applications and interobserver and intraobserver consistency of response reporting. Although the 2018 revision addressed lower-risk MDS, the most recent update in 2023 redefined responses for higher-risk MDS and has set out to provide clear definitions to enhance consistency while focusing on clinically meaningful outcomes and patient-centered responses. In this review, we analyze the evolution of the MDS response criteria, limitations, and areas of improvement.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stempel</LastName><ForeName>Jessica M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>From the Department of Internal Medicine, Hematology Section, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Zhuoer</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bewersdorf</LastName><ForeName>Jan Philipp</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stahl</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Harvard University, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeidan</LastName><ForeName>Amer M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>From the Department of Internal Medicine, Hematology Section, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer J</MedlineTA><NlmUniqueID>100931981</NlmUniqueID><ISSNLinking>1528-9117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Conflicts of Interest and Source of Funding: M.S. consulted for Curis Oncology and Boston Consulting; served on the advisory board for Novartis and Kymera; and participated in GME activity for Novartis, Curis Oncology, Haymarket Media, and Clinical Care Options (CCO). A.M.Z. is a Leukemia and Lymphoma Society Scholar in Clinical Research. A.M.Z. received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Cardiff Oncology, Incyte, Takeda, Novartis, Shattuck Labs, Geron, Aprea, and ADC Therapeutics. A.M.Z. participated in advisory boards, and/or had a consultancy with and received honoraria from AbbVie, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Servier, Boehringer-Ingelheim, Novartis, Astellas, Daiichi Sankyo, Geron, Taiho, Seattle Genetics, BeyondSpring, Takeda, Ionis, Amgen, Janssen, Genentech, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, Notable, Orum, Mendus, Foran, Syros, and Tyme. A.M.Z. served on clinical trial committees for Novartis, Abbvie, Gilead, Syros, BioCryst, Abbvie, ALX Oncology, Geron, and Celgene/BMS. A.M.Z. received travel support for meetings from Pfizer, Novartis, and Cardiff Oncology. For the remaining authors, none were declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>11</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195777</ArticleId><ArticleId IdType="doi">10.1097/PPO.0000000000000666</ArticleId><ArticleId IdType="pii">00130404-202305000-00013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703&#x2013;1719. doi:10.1038/s41375-022-01613-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-022-01613-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200&#x2013;1228. doi:10.1182/blood.2022015850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022015850</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia JS, Wei AH, Borate U, et al. Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study. Blood. 2020;136:55&#x2013;57. doi:10.1182/blood-2020-139492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2020-139492</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R, Saber W, Martens MJ, et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50&#x2013;75 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021;39:3328&#x2013;3339. doi:10.1200/jco.20.03380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.20.03380</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223&#x2013;232. doi:10.1016/s1470-2045(09)70003-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1470-2045(09)70003-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeidan AM, Davidoff AJ, Long JB, et al. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol. 2016;175:829&#x2013;840. doi:10.1111/bjh.14305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.14305</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki K, Jabbour E, Montalban-Bravo G, et al. Low-dose decitabine versus low-dose azacitidine in lower-risk MDS. NEJM Evid. 2022;1. doi:10.1056/evidoa2200034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/evidoa2200034</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Ge Z. Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis. Front Pharmacol. 2021;12:701690. doi:10.3389/fphar.2021.701690.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.701690</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheson BD, Bennett JM, Kantarjian H, et al. Report of an International Working Group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671&#x2013;3674. doi:10.1182/blood.v96.12.3671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.v96.12.3671</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419&#x2013;425. doi:10.1182/blood-2005-10-4149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2005-10-4149</ArticleId></ArticleIdList></Reference><Reference><Citation>Platzbecker U, Fenaux P, Ad&#xe8;s L, et al. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. Blood. 2019;133:1020&#x2013;1030. doi:10.1182/blood-2018-06-857102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-06-857102</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim N, Pavletic S, Norsworthy KJ. Meaningful response criteria for myelodysplastic syndromes. Br J Haematol. 2022;196:1137&#x2013;1148. doi:10.1111/bjh.17838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17838</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeidan AM, Platzbecker U, Bewersdorf JP, et al. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood. 2023;141:2047&#x2013;2061. doi:10.1182/blood.2022018604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022018604</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079&#x2013;2088.</Citation></Reference><Reference><Citation>Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120:2454&#x2013;2465. doi:10.1182/blood-2012-03-420489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-03-420489</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for myelodysplastic syndromes. NEJM Evid. 2022. doi:10.1056/evidoa2200008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/evidoa2200008</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382:140&#x2013;151. doi:10.1056/nejmoa1908892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1908892</ArticleId></ArticleIdList></Reference><Reference><Citation>Toma A, Kosmider O, Chevret S, et al. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent&#x2013;refractory lower-risk MDS without 5q deletion. Leukemia. 2016;30:897&#x2013;905. doi:10.1038/leu.2015.296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2015.296</ArticleId></ArticleIdList></Reference><Reference><Citation>Platzbecker U, Symeonidis A, Oliva EN, et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia. 2017;31:1944&#x2013;1950. doi:10.1038/leu.2017.192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2017.192</ArticleId></ArticleIdList></Reference><Reference><Citation>National Comprehensive Cancer Network Practice Guidelines in Oncology. Myelodysplastic syndromes. Version 1.2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. Accessed February 1, 2023.</Citation></Reference><Reference><Citation>Gurnari C, Xie Z, Zeidan AM. How I manage transplant ineligible patients with myelodysplastic neoplasms. Clin Hematol Int. 2023;5:8&#x2013;20. doi:10.1007/s44228-022-00024-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s44228-022-00024-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Stauder R, Yu G, Koinig KA, et al. Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. Leukemia. 2018;32:1380&#x2013;1392. doi:10.1038/s41375-018-0089-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-018-0089-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Szende A, Schaefer C, Goss TF, et al. Valuation of transfusion-free living in MDS: results of health utility interviews with patients. Health Qual Life Outcomes. 2009;7:81. doi:10.1186/1477-7525-7-81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-7-81</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliva EN, Finelli C, Santini V, et al. Quality of life and physicians' perception in myelodysplastic syndromes. Am J Blood Res. 2012;2:136&#x2013;147.</Citation></Reference><Reference><Citation>Moukalled NM, El Rassi FA, Temraz SN, et al. Iron overload in patients with myelodysplastic syndromes: an updated overview. Cancer. 2018;124:3979&#x2013;3989. doi:10.1002/cncr.31550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.31550</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen AJG, Essink-Bot ML, Beckers EAM, et al. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol. 2003;121:270&#x2013;274. doi:10.1046/j.1365-2141.2003.04272.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2141.2003.04272.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiriti MAA, Latagliata R, Niscola P, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol. 2005;84:167&#x2013;176. doi:10.1007/s00277-004-0961-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-004-0961-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Stasi R, Abruzzese E, Lanzetta G, et al. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1&#x2013;risk myelodysplastic syndromes. Ann Oncol. 2005;16:1921&#x2013;1927. doi:10.1093/annonc/mdi400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdi400</ArticleId></ArticleIdList></Reference><Reference><Citation>List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456&#x2013;1465. doi:10.1056/nejmoa061292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa061292</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion&#x2013;dependent patients with low-/intermediate-1&#x2013;risk myelodysplastic syndromes with del5q. Blood. 2011;118:3765&#x2013;3776. doi:10.1182/blood-2011-01-330126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-01-330126</ArticleId></ArticleIdList></Reference><Reference><Citation>Santini V, Almeida A, Giagounidis A, et al. The effect of lenalidomide on health-related quality of life in patients with lower-risk non-del(5q) myelodysplastic syndromes: results from the MDS-005 study. Clin Lymphoma Myeloma Leuk. 2018;18:136&#x2013;144.e7. doi:10.1016/j.clml.2017.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clml.2017.12.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliva EN, Platzbecker U, Garcia-Manero G, et al. Health-related quality of life outcomes in patients with myelodysplastic syndromes with ring sideroblasts treated with luspatercept in the MEDALIST phase 3 trial. J Clin Med. 2021;11:27. doi:10.3390/jcm11010027.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11010027</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;dersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte&#x2013;colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26:3607&#x2013;3613. doi:10.1200/jco.2007.15.4906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2007.15.4906</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008;111:574&#x2013;582. doi:10.1182/blood-2007-06-096370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2007-06-096370</ArticleId></ArticleIdList></Reference><Reference><Citation>DeZern AE, Binder G, Rizvi S, et al. Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes. Leuk Lymphoma. 2017;58:2649&#x2013;2656. doi:10.1080/10428194.2017.1312372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10428194.2017.1312372</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenaux P, Santini V, Spiriti MAA, et al. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-&#x3b1; in anemic patients with low-risk MDS. Leukemia. 2018;32:2648&#x2013;2658. doi:10.1038/s41375-018-0118-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-018-0118-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejar R. How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms. Best Pract Res Clin Haematol. 2022;35:101405. doi:10.1016/j.beha.2022.101405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beha.2022.101405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007;109:1705&#x2013;1714. doi:10.1002/cncr.22602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.22602</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Ameri A, Jabbour E, Garcia-Manero G, et al. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. Clin Lymphoma Myeloma Leuk. 2011;11:237&#x2013;241. doi:10.1016/j.clml.2011.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clml.2011.03.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1&#x2013;risk myelodysplastic syndrome and thrombocytopenia. Cancer. 2014;120:1838&#x2013;1846. doi:10.1002/cncr.28663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.28663</ArticleId></ArticleIdList></Reference><Reference><Citation>Platzbecker U, Sekeres MA, Kantarjian H, et al. Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial. Leukemia. 2014;28:2418&#x2013;2421. doi:10.1038/leu.2014.253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2014.253</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliva EN, Alati C, Santini V, et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017;4:e127&#x2013;e136. doi:10.1016/S2352-3026(17)30012-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(17)30012-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Steensma DP, Letendre L, Tefferi A. Clarifications to the standard neutrophil response criteria for clinical trials in myelodysplastic syndromes are needed. Blood. 2001;97:3321&#x2013;3322. doi:10.1182/blood.v97.10.3321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.v97.10.3321</ArticleId></ArticleIdList></Reference><Reference><Citation>Nachtkamp K, Stark R, Strupp C, et al. Causes of death in 2877 patients with myelodysplastic syndromes. Ann Hematol. 2016;95:937&#x2013;944. doi:10.1007/s00277-016-2649-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-016-2649-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Driscoll JJ, Rixe O. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials. Cancer J. 2009;15:401&#x2013;405. doi:10.1097/PPO.0b013e3181bdc2e0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PPO.0b013e3181bdc2e0</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaver JA, Howie LJ, Pelosof L, et al. A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review. JAMA Oncol. 2018;4:849&#x2013;856. doi:10.1001/jamaoncol.2017.5618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2017.5618</ArticleId></ArticleIdList></Reference><Reference><Citation>Gore SD, Fenaux P, Santini V, et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 2013;98:1067&#x2013;1072. doi:10.3324/haematol.2012.074831.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2012.074831</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarjian H, Issa J-PJ, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer. 2006;106:1794&#x2013;1803. doi:10.1002/cncr.21792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.21792</ArticleId></ArticleIdList></Reference><Reference><Citation>Vey N, Bosly A, Guerci A, et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol. 2006;24:2465&#x2013;2471. doi:10.1200/jco.2005.03.9503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2005.03.9503</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurzrock R, Albitar M, Cortes JE, et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol. 2004;22:1287&#x2013;1292. doi:10.1200/JCO.2004.08.082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2004.08.082</ArticleId></ArticleIdList></Reference><Reference><Citation>List AF, Fenaux P, Mufti GJ, et al. Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. J Clin Oncol. 2008;26. doi:10.1200/jco.2008.26.15_suppl.7006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2008.26.15_suppl.7006</ArticleId></ArticleIdList></Reference><Reference><Citation>Komrokji RS, Al Ali NH, Sallman D, et al. Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Cancer Med. 2021;10:447&#x2013;453. doi:10.1002/cam4.3608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.3608</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazha A, Sekeres MA, Garcia-Manero G, et al. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leuk Res. 2016;41:43&#x2013;47. doi:10.1016/j.leukres.2015.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.leukres.2015.12.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeidan AM, Knaus HA, Robinson TM, et al. A multi-center phase I trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure. Clin Cancer Res. 2018;24:3519&#x2013;3527. doi:10.1158/1078-0432.ccr-17-3763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.ccr-17-3763</ArticleId></ArticleIdList></Reference><Reference><Citation>Papageorgiou SG, Kontos CK, Kotsianidis I, et al. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: a retrospective analysis of the Hellenic (Greek) MDS Study Group. Hematol Oncol. 2018;36:693&#x2013;700. doi:10.1002/hon.2551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hon.2551</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Manero G, Fenaux P, Al-Kali A, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:496&#x2013;508. doi:10.1016/S1470-2045(16)00009-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(16)00009-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Manero G, Griffiths EA, Steensma DP, et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020;136:674&#x2013;683. doi:10.1182/blood.2019004143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2019004143</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein EM, Fathi AT, DiNardo CD, et al. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020;7:e309&#x2013;e319. doi:10.1016/S2352-3026(19)30284-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(19)30284-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment. Guidance for Industry. Baltimore, MD: US Food and Drug Administration. Available at: https://www.fda.gov/media/140821/download. Accessed March 11, 2023.</Citation></Reference><Reference><Citation>Dohner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345&#x2013;1377. doi:10.1182/blood.2022016867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022016867</ArticleId></ArticleIdList></Reference><Reference><Citation>Shallis RM, Pollyea DA, Zeidan AM. The complete story of less than complete responses: the evolution and application of acute myeloid leukemia clinical responses. Blood Rev. 2021;48:100806. doi:10.1016/j.blre.2021.100806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2021.100806</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein EM, DiNardo CD, Fathi AT, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019;133:676&#x2013;687. doi:10.1182/blood-2018-08-869008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-08-869008</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137&#x2013;2145. doi:10.1182/blood.2020004856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020004856</ArticleId></ArticleIdList></Reference><Reference><Citation>DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7&#x2013;17. doi:10.1182/blood-2018-08-868752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-08-868752</ArticleId></ArticleIdList></Reference><Reference><Citation>Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135:463&#x2013;471. doi:10.1182/blood.2019002140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2019002140</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner AM, Gavralidis A, Ali NA, et al. Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS). Blood Cancer J. 2022;12:153. doi:10.1038/s41408-022-00748-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-022-00748-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebert M, Komrokji RS, Sekeres MA, et al. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. Leuk Res. 2017;63:72&#x2013;77. doi:10.1016/j.leukres.2017.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.leukres.2017.10.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Jabbour E, Strati P, Cabrero M, et al. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol. 2017;92:351&#x2013;358. doi:10.1002/ajh.24650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.24650</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52&#x2013;57. doi:10.1182/blood-2006-05-021162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-05-021162</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekeres MA, Watts J, Radinoff A, et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia. 2021;35:2119&#x2013;2124. doi:10.1038/s41375-021-01125-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-021-01125-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Ades L, Girshova L, Doronin VA, et al. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Adv. 2022;6:5132&#x2013;5145. doi:10.1182/bloodadvances.2022007334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2022007334</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia JS, Swords RT, Roboz GJ, et al. A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. Leuk Res. 2021;104:106555. doi:10.1016/j.leukres.2021.106555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.leukres.2021.106555</ArticleId></ArticleIdList></Reference><Reference><Citation>Short NJ, Zhou S, Fu C, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia. JAMA Oncol. 2020;6:1890&#x2013;1899. doi:10.1001/jamaoncol.2020.4600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2020.4600</ArticleId></ArticleIdList></Reference><Reference><Citation>Cazzaniga G, de Lorenzo P, Alten J, et al. Predictive value of minimal residual disease in Philadelphia-chromosome&#x2013;positive acute lymphoblastic leukemia treated with imatinib in the European Intergroup Study of post-induction treatment of Philadelphia-chromosome&#x2013;positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica. 2018;103:107&#x2013;115. doi:10.3324/haematol.2017.176917.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2017.176917</ArticleId></ArticleIdList></Reference><Reference><Citation>Paiva B, Puig N, Cedena M-T, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38:784&#x2013;792. doi:10.1200/jco.19.01231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.19.01231</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Kim Y, Kang D, et al. Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Blood Cancer J. 2021;11:109. doi:10.1038/s41408-021-00500-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-021-00500-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378:1189&#x2013;1199. doi:10.1056/nejmoa1716863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1716863</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravandi F, Jorgensen J, Borthakur G, et al. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 2017;123:426&#x2013;435. doi:10.1002/cncr.30361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.30361</ArticleId></ArticleIdList></Reference><Reference><Citation>Hourigan CS, Dillon LW, Gui G, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38:1273&#x2013;1283. doi:10.1200/jco.19.03011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.19.03011</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley SA, Wood BL, Othus M, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102:865&#x2013;873. doi:10.3324/haematol.2016.159343.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2016.159343</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejar R. CHIP, ICUS, CCUS and other four-letter words. Leukemia. 2017;31:1869&#x2013;1871. doi:10.1038/leu.2017.181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2017.181</ArticleId></ArticleIdList></Reference><Reference><Citation>Cluzeau T, Sebert M, Rahm&#xe9; R, et al. Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des My&#xe9;lodysplasies (GFM). J Clin Oncol. 2021;39:1575&#x2013;1583. doi:10.1200/jco.20.02342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.20.02342</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo X, Zhang X, Xu L, et al. Minimal residual disease&#x2013;directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Front Med. 2019;13:354&#x2013;364. doi:10.1007/s11684-018-0665-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-018-0665-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Platzbecker U, Middeke JM, Sockel K, et al. Measurable residual disease&#x2013;guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19:1668&#x2013;1679. doi:10.1016/S1470-2045(18)30580-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(18)30580-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel GA, Efficace F, Buckstein RJ, et al. Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica. 2016;101:781&#x2013;788. doi:10.3324/haematol.2015.140335.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2015.140335</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornblith AB, Herndon JE 2nd, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B Study. J Clin Oncol. 2002;20:2441&#x2013;2452. doi:10.1200/jco.2002.04.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2002.04.044</ArticleId></ArticleIdList></Reference><Reference><Citation>Regnault A, Pompilus F, Ciesluk A, et al. Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30. J Patient Rep Outcomes. 2021;5:60. doi:10.1186/s41687-021-00334-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41687-021-00334-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Haslam A, Herrera-Perez D, Gill J, et al. Patient experience captured by quality-of-life measurement in oncology clinical trials. JAMA Netw Open. 2020;3:e200363. doi:10.1001/jamanetworkopen.2020.0363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.0363</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. Core Patient-Reported Outcomes in Cancer Clinical Trials. Guidance for Industry. US Department of Health and Human Services Food and Drug Administration. June 2021. Available at: https://www.fda.gov/media/149994/download. Accessed February 9, 2023.</Citation></Reference><Reference><Citation>Rochau U, Stojkov I, Conrads-Frank A, et al. Development of a core outcome set for myelodysplastic syndromes&#x2014;a Delphi study from the EUMDS registry group. Br J Haematol. 2020;191:405&#x2013;417. doi:10.1111/bjh.16654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.16654</ArticleId></ArticleIdList></Reference><Reference><Citation>DiNardo KW, Houk A, Shim C, et al. The mental health burden and quality of life impact of myelodysplastic syndromes in patients and their caregivers. Blood. 2022;140(Suppl 1):8122&#x2013;8123. doi:10.1182/blood-2022-155893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2022-155893</ArticleId></ArticleIdList></Reference><Reference><Citation>Papay Rogers K, Miller MF, Fortune EE, et al. Financial toxicity and cost-management behaviors among patients with myelodysplastic syndromes. Blood. 2022;140(Suppl 1):8142&#x2013;8143. doi:10.1182/blood-2022-162378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2022-162378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouchveridze E, Banerjee R, Desai A, et al. Financial toxicity in hematological malignancies: a systematic review. Blood Cancer J. 2022;12:74. doi:10.1038/s41408-022-00671-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-022-00671-z</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195776</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-336X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>3</Issue><PubDate><MedlineDate>2023 May-Jun 01</MedlineDate></PubDate></JournalIssue><Title>Cancer journal (Sudbury, Mass.)</Title><ISOAbbreviation>Cancer J</ISOAbbreviation></Journal><ArticleTitle>Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment.</ArticleTitle><Pagination><StartPage>195</StartPage><EndPage>202</EndPage><MedlinePgn>195-202</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PPO.0000000000000658</ELocationID><Abstract><AbstractText>Myelodysplastic syndromes/neoplasms (MDSs) constitute a heterogeneous group of clonal disorders that are clinically characterized by dysplastic changes in multiple hematopoietic lineages, cytopenias, and a variable risk of progression to acute myeloid leukemia. Patients with MDS are classified as either lower- or higher-risk based on risk stratification tools such as the International Prognostic Scoring System and its revised version, which continue to be the basis for prognosis and treatment selection. Although anemic patients with lower-risk MDS are currently treated with an erythropoiesis-stimulating agent, luspatercept, and transfusions, the telomerase inhibitor imetelstat and the hypoxia-inducible factor &#x3b1; inhibitor roxadustat have shown encouraging early results and are now in phase III clinical trials. For higher-risk MDS patients, hypomethylating agent monotherapy continues to be the standard of care. However, with various novel hypomethylating agent-based combination therapies in advanced clinical testing and an increased emphasis on individualized biomarker-driven treatment decisions, the standard therapy paradigms might change in the future.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bewersdorf</LastName><ForeName>Jan Philipp</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>From the Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Zhuoer</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeidan</LastName><ForeName>Amer M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer J</MedlineTA><NlmUniqueID>100931981</NlmUniqueID><ISSNLinking>1528-9117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Conflicts of Interest and Source of Funding: A.M.Z. received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Cardiff Oncology, Incyte, Takeda, Novartis, Aprea, and ADC Therapeutics. A.M.Z. participated in advisory boards and/or had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Cardiff Oncology, Takeda, Ionis, Amgen, Janssen, Genentech, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, Notable, Orum, Mendus, Foran, Syros, and Tyme. A.M.Z. served on clinical trial committees for Novartis, Abbvie, Gilead, BioCryst, Abbvie, ALX Oncology, Geron, and Celgene/BMS. J.P.B. and Z.X. do not report any conflicts of interest. A.M.Z. is a Leukemia and Lymphoma Society scholar in clinical research. All figures were created with BioRender.com.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>11</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195776</ArticleId><ArticleId IdType="doi">10.1097/PPO.0000000000000658</ArticleId><ArticleId IdType="pii">00130404-202305000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383:1358&#x2013;1374.</Citation></Reference><Reference><Citation>Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703&#x2013;1719.</Citation></Reference><Reference><Citation>Greenberg PL, Stone RM, Al-Kali A, et al. NCCN Guidelines&#xae; Insights: myelodysplastic syndromes, version 3.2022. J Natl Compr Canc Netw. 2022;20:106&#x2013;117.</Citation></Reference><Reference><Citation>Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for myelodysplastic syndromes. NEJM Evid. 2022;1:EVIDoa2200008.</Citation></Reference><Reference><Citation>Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079&#x2013;2088.</Citation></Reference><Reference><Citation>Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120:2454&#x2013;2465.</Citation></Reference><Reference><Citation>Bersanelli M, Travaglino E, Meggendorfer M, et al. Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes. J Clin Oncol. 2021;39:1223&#x2013;1233.</Citation></Reference><Reference><Citation>Nazha A, Komrokji R, Meggendorfer M, et al. Personalized prediction model to risk stratify patients with myelodysplastic syndromes. J Clin Oncol. 2021;39:3737&#x2013;3746.</Citation></Reference><Reference><Citation>Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382:140&#x2013;151.</Citation></Reference><Reference><Citation>Pfeilst&#xf6;cker M, Tuechler H, Sanz G, et al. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016;128:902&#x2013;910.</Citation></Reference><Reference><Citation>Bewersdorf JP, Zeidan AM. Evolving therapies for lower-risk myelodysplastic syndromes. Ann Hematol. 2020;99:677&#x2013;692.</Citation></Reference><Reference><Citation>Bewersdorf JP, Zeidan AM. Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes? Leuk Lymphoma. 2020;61:2295&#x2013;2312.</Citation></Reference><Reference><Citation>List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456&#x2013;1465.</Citation></Reference><Reference><Citation>Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111:86&#x2013;93.</Citation></Reference><Reference><Citation>Oliva EN, Lauseker M, Aloe Spiriti MA, et al. Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence. Cancer Med. 2015;4:1789&#x2013;1797.</Citation></Reference><Reference><Citation>Bewersdorf JP, Zeidan AM. Transforming growth factor (TGF)-beta pathway as a therapeutic target in lower risk myelodysplastic syndromes. Leukemia. 2019;33:1303&#x2013;1312.</Citation></Reference><Reference><Citation>Stahl M, Bewersdorf JP, Giri S, et al. Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. Haematologica. 2020;105:102&#x2013;111.</Citation></Reference><Reference><Citation>Passweg JR, Giagounidis AA, Simcock M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care&#x2014;SAKK 33/99. J Clin Oncol. 2011;29:303&#x2013;309.</Citation></Reference><Reference><Citation>Oliva EN, Alati C, Santini V, et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017;4:e127&#x2013;e136.</Citation></Reference><Reference><Citation>Vicente A, Patel BA, Gutierrez-Rodrigues F, et al. Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome. Haematologica. 2020;105:2785&#x2013;2794.</Citation></Reference><Reference><Citation>Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010;28:437&#x2013;444.</Citation></Reference><Reference><Citation>Fenaux P, Muus P, Kantarjian H, et al. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. Br J Haematol. 2017;178:906&#x2013;913.</Citation></Reference><Reference><Citation>Kantarjian HM, Fenaux P, Sekeres MA, et al. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematol. 2018;5:e117&#x2013;e126.</Citation></Reference><Reference><Citation>Dodillet H, Kreuzer KA, Monsef I, et al. Thrombopoietin mimetics for patients with myelodysplastic syndromes. Cochrane Database Syst Rev. 2017;9:CD009883.</Citation></Reference><Reference><Citation>Dickinson M, Cherif H, Fenaux P, et al. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018;132:2629&#x2013;2638.</Citation></Reference><Reference><Citation>Nakamura R, Saber W, Martens MJ, et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50&#x2013;75 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021;39:3328&#x2013;3339.</Citation></Reference><Reference><Citation>Kr&#xf6;ger N, Sockel K, Wolschke C, et al. Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo study). J Clin Oncol. 2021;39:3318&#x2013;3327.</Citation></Reference><Reference><Citation>Voso MT, Leone G, Piciocchi A, et al. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. Ann Oncol. 2017;28:1547&#x2013;1553.</Citation></Reference><Reference><Citation>Gerds AT, Gooley TA, Estey EH, et al. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant. 2012;18:1211&#x2013;1218.</Citation></Reference><Reference><Citation>Schroeder T, Wegener N, Lauseker M, et al. Comparison between upfront transplantation and different pretransplant cytoreductive treatment approaches in patients with high-risk myelodysplastic syndrome and secondary acute myelogenous leukemia. Biol Blood Marrow Transplant. 2019;25:1550&#x2013;1559.</Citation></Reference><Reference><Citation>Oran B, de Lima M, Garcia-Manero G, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020;4:5580&#x2013;5588.</Citation></Reference><Reference><Citation>Bewersdorf JP, Allen C, Mirza AS, et al. Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation-a systematic review and meta-analysis. Transplant Cell Ther. 2021;27:997.e1&#x2013;997.e11.</Citation></Reference><Reference><Citation>Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376:536&#x2013;547.</Citation></Reference><Reference><Citation>Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223&#x2013;232.</Citation></Reference><Reference><Citation>Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29:1987&#x2013;1996.</Citation></Reference><Reference><Citation>Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794&#x2013;1803.</Citation></Reference><Reference><Citation>Garcia-Manero G, Griffiths EA, Steensma DP, et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020;136:674&#x2013;683.</Citation></Reference><Reference><Citation>Pr&#xe9;bet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:3322&#x2013;3327.</Citation></Reference><Reference><Citation>Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010;116:3830&#x2013;3834.</Citation></Reference><Reference><Citation>Steensma DP, Fenaux P, van Eygen K, et al. Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study. J Clin Oncol. 2021;39:48&#x2013;56.</Citation></Reference><Reference><Citation>Henry DH, Glaspy J, Harrup R, et al. Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: open-label, dose-selection, lead-in stage of a phase 3 study. Am J Hematol. 2022;97:174&#x2013;184.</Citation></Reference><Reference><Citation>Wang X, Hu CS, Petersen B, et al. Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv. 2018;2:2378&#x2013;2388.</Citation></Reference><Reference><Citation>Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med. 2015;373:920&#x2013;928.</Citation></Reference><Reference><Citation>Kubasch AS, Platzbecker U. Setting fire to ESA and EMA resistance: new targeted treatment options in lower risk myelodysplastic syndromes. Int J Mol Sci. 2019;20:3853.</Citation></Reference><Reference><Citation>Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019;381:1001&#x2013;1010.</Citation></Reference><Reference><Citation>Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381:1011&#x2013;1022.</Citation></Reference><Reference><Citation>Garcia JS, Wei AH, Jacoby MA, et al. Molecular responses are observed across mutational spectrum in treatment-na&#xef;ve higher-risk myelodysplastic syndrome patients treated with venetoclax plus azacitidine. Blood. 2021;138:241.</Citation></Reference><Reference><Citation>Zeidan AM, Borate U, Pollyea DA, et al. Venetoclax and azacitidine in the treatment of patients with relapsed/refractory myelodysplastic syndrome. Blood. 2021;138:537.</Citation></Reference><Reference><Citation>Sallman DA, DeZern AE, Garcia-Manero G, et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol. 2021;39:1584&#x2013;1594.</Citation></Reference><Reference><Citation>Cluzeau T, Sebert M, Rahm&#xe9; R, et al. Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe francophone des My&#xe9;lodysplasies (GFM). J Clin Oncol. 2021;39:1575&#x2013;1583.</Citation></Reference><Reference><Citation>Sallman DA, Al Malki MM, Asch AS, et al. S166: magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1B study results. HemaSphere. 2022;6:67&#x2013;68.</Citation></Reference><Reference><Citation>Brunner AM, Esteve J, Porkka K, et al. Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): final analysis from a phase Ib study. Blood. 2021;138:244.</Citation></Reference><Reference><Citation>Ad&#xe8;s L, Girshova L, Doronin VA, et al. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Adv. 2022;6:5132&#x2013;5145.</Citation></Reference><Reference><Citation>DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617&#x2013;629.</Citation></Reference><Reference><Citation>Chen X, Othus M, Wood BL, et al. Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. Leuk Lymphoma. 2021;62:1226&#x2013;1233.</Citation></Reference><Reference><Citation>Estey E, Hasserjian RP, D&#xf6;hner H. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. Blood. 2022;139:323&#x2013;332.</Citation></Reference><Reference><Citation>Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549&#x2013;1556.</Citation></Reference><Reference><Citation>Bewersdorf JP, Shallis RM, Gowda L, et al. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience. Leuk Lymphoma. 2020;61:2180&#x2013;2190.</Citation></Reference><Reference><Citation>Zhang Q, Bykov VJN, Wiman KG, et al. APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. Cell Death Dis. 2018;9:439.</Citation></Reference><Reference><Citation>Lehmann S, Bykov VJ, Ali D, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol. 2012;30:3633&#x2013;3639.</Citation></Reference><Reference><Citation>Aprea therapeutics announces results of primary endpoint from phase 3 trial of eprenetapopt in TP53 mutant myelodysplastic syndromes (MDS). 2020. Available at https://ir.aprea.com/news-releases/news-release-details/aprea-therapeutics-announces-results-primary-endpoint-phase-3. Accessed September 24, 2022.</Citation></Reference><Reference><Citation>Grob T, Al Hinai ASA, Sanders MA, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022;139:2347&#x2013;2354.</Citation></Reference><Reference><Citation>Chao MP, Takimoto CH, Feng DD, et al. Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies. Front Oncol. 2020;9:1380.</Citation></Reference><Reference><Citation>Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286&#x2013;299.</Citation></Reference><Reference><Citation>Zeidan AM, Boss I, Beach CL, et al. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Blood Adv. 2022;6:2207&#x2013;2218.</Citation></Reference><Reference><Citation>Zeidan AM, Boss I, Beach CL, et al. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Blood Adv. 2022;6:2219&#x2013;2229.</Citation></Reference><Reference><Citation>Bewersdorf JP, Shallis RM, Zeidan AM. Immune checkpoint inhibition in myeloid malignancies: moving beyond the PD-1/PD-L1 and CTLA-4 pathways. Blood Rev. 2020;45:100709.</Citation></Reference><Reference><Citation>Sekeres MA, Watts J, Radinoff A, et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia. 2021;35:2119&#x2013;2124.</Citation></Reference><Reference><Citation>Winter S, Shoaie S, Kordasti S, et al. Integrating the &#x201c;immunome&#x201d; in the stratification of myelodysplastic syndromes and future clinical trial design. J Clin Oncol. 2020;38:1723&#x2013;1735.</Citation></Reference><Reference><Citation>Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood. 2019;133:1039&#x2013;1048.</Citation></Reference><Reference><Citation>Smith MA, Choudhary GS, Pellagatti A, et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nat Cell Biol. 2019;21:640&#x2013;650.</Citation></Reference><Reference><Citation>Choudhary GS, Pellagatti A, Agianian B, et al. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. Elife. 2022;11.</Citation></Reference><Reference><Citation>Garcia-Manero G, Winer ES, DeAngelo DJ, et al. Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome. J Clin Oncol. 2022;40:7016.</Citation></Reference><Reference><Citation>McKeown MR, Corces MR, Eaton ML, et al. Superenhancer analysis defines novel epigenomic subtypes of non-APL AML, including an RAR&#x3b1; dependency targetable by SY-1425, a potent and selective RAR&#x3b1; agonist. Cancer Discov. 2017;7:1136&#x2013;1153.</Citation></Reference><Reference><Citation>L&#xfc;bbert M, Grishina O, Schmoor C, et al. Valproate and retinoic acid in combination with decitabine in elderly nonfit patients with acute myeloid leukemia: results of a multicenter, randomized, 2 &#xd7; 2, phase II trial. J Clin Oncol. 2020;38:257&#x2013;270.</Citation></Reference><Reference><Citation>McKeown MR, Johannessen L, Lee E, et al. Antitumor synergy with SY-1425, a selective RAR&#x3b1; agonist, and hypomethylating agents in retinoic acid receptor pathway activated models of acute myeloid leukemia. Haematologica. 2019;104:e138&#x2013;e142.</Citation></Reference><Reference><Citation>Brunner AM, Fell G, Steensma DP. Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly &#x201c;promising&#x201d;? Blood Adv. 2022;6:2854&#x2013;2866.</Citation></Reference><Reference><Citation>Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200&#x2013;1228.</Citation></Reference><Reference><Citation>Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419&#x2013;425.</Citation></Reference><Reference><Citation>Komrokji RS, Al Ali NH, Sallman D, et al. Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Cancer Med. 2021;10:447&#x2013;453.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195775</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-336X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>3</Issue><PubDate><MedlineDate>2023 May-Jun 01</MedlineDate></PubDate></JournalIssue><Title>Cancer journal (Sudbury, Mass.)</Title><ISOAbbreviation>Cancer J</ISOAbbreviation></Journal><ArticleTitle>Novel Therapies in Myelodysplastic Syndrome: Where Do Venetoclax and Isocitrate Dehydrogenase Inhibitors Fit in?</ArticleTitle><Pagination><StartPage>188</StartPage><EndPage>194</EndPage><MedlinePgn>188-194</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PPO.0000000000000657</ELocationID><Abstract><AbstractText>Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic stem cell disorders with treatment approaches tailored to the presence of cytopenias, disease risk, and molecular mutation profile. In higher-risk MDSs, the standard of care are DNA methyltransferase inhibitors, otherwise referred to as hypomethylating agents (HMAs), with consideration for allogeneic hematopoietic stem cell transplantation in appropriate candidates. Given modest complete remission rates (15%-20%) with HMA monotherapy and median overall survival of approximately 18 months, there is much interest in the investigation of combination and targeted treatment approaches. Furthermore, there is no standard treatment approach in patients with progression of disease after HMA therapy. In this review, we aim to summarize the current evidence for the B-cell lymphoma-2 inhibitor, venetoclax, and a variety of isocitrate dehydrogenase inhibitors in the treatment of MDSs along with discussing their potential role in the treatment paradigm of this disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abaza</LastName><ForeName>Yasmin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From the Department of Hematology and Oncology, Northwestern University, Robert Lurie Cancer Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Anand Ashwin</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Section of Hematology/Oncology, Department of Medicine, University of Chicago, IL.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer J</MedlineTA><NlmUniqueID>100931981</NlmUniqueID><ISSNLinking>1528-9117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Conflicts of Interest and Source of Funding: Y.A.: research funding (institution) from ALX Oncology and Biosight and honoraria from Kite, Pfizer, and Bristol Myers Squibb; A.A.P.: research funding (institution) from Kronos Bio and Pfizer and honoraria from AbbVie and Bristol Myers Squibb.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>11</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195775</ArticleId><ArticleId IdType="doi">10.1097/PPO.0000000000000657</ArticleId><ArticleId IdType="pii">00130404-202305000-00011</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383:1358&#x2013;1374. doi:10.1056/NEJMra1904794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1904794</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454&#x2013;2465. doi:10.1182/blood-2012-03-420489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-03-420489</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079&#x2013;2088.</Citation></Reference><Reference><Citation>Bernard E, Tuechler H, Greenberg PL, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022. doi:101056/EVIDoa2200008.</Citation><ArticleIdList><ArticleId IdType="doi">101056/EVIDoa2200008</ArticleId></ArticleIdList></Reference><Reference><Citation>Platzbecker U. Who benefits from allogeneic transplantation for myelodysplastic syndromes?: New insights. Hematology Am Soc Hematol Educ Program. 2013;2013:522&#x2013;528. doi:10.1182/asheducation-2013.1.522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/asheducation-2013.1.522</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223&#x2013;232. doi:10.1016/S1470-2045(09)70003-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(09)70003-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeidan AM, Sekeres MA, Garcia-Manero G, et al. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2016;30:649&#x2013;657. doi:10.1038/leu.2015.283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2015.283</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia JS, Swords RT, Roboz GJ, et al. A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. Leuk Res. 2021;104:106555. doi:10.1016/j.leukres.2021.106555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.leukres.2021.106555</ArticleId></ArticleIdList></Reference><Reference><Citation>Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:3322&#x2013;3327. doi:10.1200/JCO.2011.35.8135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.35.8135</ArticleId></ArticleIdList></Reference><Reference><Citation>Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010;116:3830&#x2013;3834. doi:10.1002/cncr.25247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.25247</ArticleId></ArticleIdList></Reference><Reference><Citation>M Gagn&#xe9; L, Boulay K, Topisirovic I, et al. Oncogenic activities of IDH1/2 mutations: from epigenetics to cellular signaling. Trends Cell Biol. 2017;27:738&#x2013;752. doi:10.1016/j.tcb.2017.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2017.06.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553&#x2013;567. doi:10.1016/j.ccr.2010.11.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2010.11.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Medeiros BC, Fathi AT, DiNardo CD, et al. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017;31:272&#x2013;281. doi:10.1038/leu.2016.275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2016.275</ArticleId></ArticleIdList></Reference><Reference><Citation>Prensner JR, Chinnaiyan AM. Metabolism unhinged: IDH mutations in cancer. Nat Med. 2011;17:291&#x2013;293. doi:10.1038/nm0311-291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0311-291</ArticleId></ArticleIdList></Reference><Reference><Citation>DiNardo CD, Jabbour E, Ravandi F, et al. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. 2016;30:980&#x2013;984. doi:10.1038/leu.2015.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2015.211</ArticleId></ArticleIdList></Reference><Reference><Citation>Molenaar RJ, Thota S, Nagata Y, et al. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia. 2015;29:2134&#x2013;2142. doi:10.1038/leu.2015.91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2015.91</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekeres MA, Othus M, List AF, et al. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017;35:2745&#x2013;2753. doi:10.1200/JCO.2015.66.2510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2015.66.2510</ArticleId></ArticleIdList></Reference><Reference><Citation>DiNardo CD, Schuh AC, Stein EM, et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021;22:1597&#x2013;1608. doi:10.1016/S1470-2045(21)00494-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(21)00494-0</ArticleId></ArticleIdList></Reference><Reference><Citation>DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386&#x2013;2398. doi:10.1056/NEJMoa1716984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1716984</ArticleId></ArticleIdList></Reference><Reference><Citation>Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386:1519&#x2013;1531. doi:10.1056/NEJMoa2117344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2117344</ArticleId></ArticleIdList></Reference><Reference><Citation>Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135:463&#x2013;471. doi:10.1182/blood.2019002140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2019002140</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722&#x2013;731. doi:10.1182/blood-2017-04-779405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2017-04-779405</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebert M, Cluzeau T, Beyne Rauzy O, et al. Ivosidenib monotherapy is effective in patients with IDH1 mutated myelodysplastic syndrome (MDS): the Idiome phase 2 study by the GFM group. Blood. 2021;138(1 Suppl):62&#x2013;62. doi:10.1182/blood-2021-146932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2021-146932</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallman DA, Foran JM, Watts JM, et al. Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): updated enrollment and results of a phase 1 dose-escalation and expansion substudy. J Clin Oncol. 2022;40(16 Suppl):7053&#x2013;7053. doi:10.1200/JCO.2022.40.16_suppl.7053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2022.40.16_suppl.7053</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts JM, Baer MR, Yang J, et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2022;10:e46&#x2013;e58. doi:10.1016/S2352-3026(22)00292-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(22)00292-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein EM, Fathi AT, DiNardo CD, et al. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020;7:e309&#x2013;e319. doi:10.1016/S2352-3026(19)30284-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(19)30284-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Ades L, Dimicoli-Salazar S, Sebert M, et al. Enasidenib (ENA) is effective in patients with IDH2 mutated myelodysplastic syndrome (MDS): the Ideal Phase 2 Study by the GFM Group. Blood. 2021;138(1 Suppl):63&#x2013;63. doi:10.1182/blood-2021-147898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2021-147898</ArticleId></ArticleIdList></Reference><Reference><Citation>DiNardo CD, Venugopal S, Lachowiez CA, et al. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv. 2022. doi:10.1182/bloodadvances.2022008378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2022008378</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419&#x2013;425. doi:10.1182/blood-2005-10-4149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2005-10-4149</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos L, Rouault JP, Sabido O, et al. High expression of BCL-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81:3091&#x2013;3096.</Citation></Reference><Reference><Citation>Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10:375&#x2013;388. doi:10.1016/j.ccr.2006.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2006.10.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12:329&#x2013;341. doi:10.1016/j.stem.2012.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2012.12.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta SV, Shukla SN, Vora HH. Overexpression of BCL2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3. Neoplasma. 2013;60:666&#x2013;675. doi:10.4149/neo_2013_085.</Citation><ArticleIdList><ArticleId IdType="doi">10.4149/neo_2013_085</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106&#x2013;1117. doi:10.1158/2159-8290.CD-16-0313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-16-0313</ArticleId></ArticleIdList></Reference><Reference><Citation>Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202&#x2013;208. doi:10.1038/nm.3048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3048</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S, Cojocari D, Purkal JJ, et al. 5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis. Clin Cancer Res. 2020;26:3371&#x2013;3383. doi:10.1158/1078-0432.CCR-19-1900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-19-1900</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogenberger JM, Delman D, Hansen N, et al. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma. 2015;56:226&#x2013;229. doi:10.3109/10428194.2014.910657.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10428194.2014.910657</ArticleId></ArticleIdList></Reference><Reference><Citation>DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7&#x2013;17. doi:10.1182/blood-2018-08-868752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-08-868752</ArticleId></ArticleIdList></Reference><Reference><Citation>DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617&#x2013;629. doi:10.1056/NEJMoa2012971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2012971</ArticleId></ArticleIdList></Reference><Reference><Citation>Jilg S, Reidel V, Muller-Thomas C, et al. Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients. Leukemia. 2016;30:112&#x2013;123. doi:10.1038/leu.2015.179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2015.179</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker JE, Mufti GJ, Rasool F, et al. The role of apoptosis, proliferation, and the BCL-2&#x2013;related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 2000;96:3932&#x2013;3938.</Citation></Reference><Reference><Citation>Garcia JS, Wei AH, Jacoby MA, et al. Molecular responses are observed across mutational spectrum in treatment-na&#xef;ve higher-risk myelodysplastic syndrome patients treated with venetoclax plus azacitidine. Blood. 2021;138(Supplement 1):241&#x2013;241. doi:10.1182/blood-2021-145613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2021-145613</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeidan AM, Borate U, Pollyea DA, et al. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol. 2023;98:272&#x2013;281. doi:10.1002/ajh.26771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26771</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazinet A, Darbaniyan F, Jabbour E, et al. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1&#x2013;2 study. Lancet Haematol. 2022;9:e756&#x2013;e765. doi:10.1016/S2352-3026(22)00216-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(22)00216-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia JS, Wei AH, Borate U, et al. Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study. Blood. 2020;136(1 Suppl):55&#x2013;57. doi:10.1182/blood-2020-139492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2020-139492</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeidan AM, Garcia JS, Fenaux P, et al. Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-na&#xef;ve higher-risk myelodysplastic syndromes. J Clin Oncol. 2021;39(15 Suppl). doi:10.1200/JCO.2021.39.15_suppl.TPS7054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2021.39.15_suppl.TPS7054</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan SP, Montalban-Bravo G, Ohanian M, et al. Results of a phase 1 trial of azacitidine with venetoclax in relapsed/refractory higher-risk myelodysplastic syndrome (MDS). J Clin Oncol. 2022;40(16 Suppl):e19068. doi:10.1200/JCO.2022.40.16_suppl.e19068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2022.40.16_suppl.e19068</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogenberger JM, Kornblau SM, Pierceall WE, et al. BCL-2 family proteins as 5-azacytidine&#x2013;sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014;28:1657&#x2013;1665. doi:10.1038/leu.2014.44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2014.44</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball BJ, Famulare CA, Stein EM, et al. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020;4:2866&#x2013;2870. doi:10.1182/bloodadvances.2020001482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020001482</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangat N, McCullough K, Johnson I, et al. Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. Am J Hematol. 2022;97:E214&#x2013;E216. doi:10.1002/ajh.26539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26539</ArticleId></ArticleIdList></Reference><Reference><Citation>Komrokji RS, Singh AM, Ali NA, et al. Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome. Blood Cancer J. 2022;12:148. doi:10.1038/s41408-022-00744-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-022-00744-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizi A, Ediriwickrema A, Dutta R, et al. Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leuk Lymphoma. 2020;61:2700&#x2013;2707. doi:10.1080/10428194.2020.1775214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10428194.2020.1775214</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Manero G, Griffiths EA, Steensma DP, et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020;136:674&#x2013;683. doi:10.1182/blood.2019004143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2019004143</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21:178&#x2013;184. doi:10.1038/nm.3788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3788</ArticleId></ArticleIdList></Reference><Reference><Citation>DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791&#x2013;803. doi:10.1182/blood.2019003988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2019003988</ArticleId></ArticleIdList></Reference><Reference><Citation>Cathelin S, Sharon D, Subedi A, et al. Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia. Leukemia. 2022;36:869&#x2013;872. doi:10.1038/s41375-021-01468-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-021-01468-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan SM, Cameron C, Cathelin S, et al. Enasidenib in combination with venetoclax in IDH2-mutated myeloid malignancies: preliminary results of the phase Ib/II Enaven-AML Trial. Blood. 2021;138(1 Suppl):1263&#x2013;1263. doi:10.1182/blood-2021-153660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2021-153660</ArticleId></ArticleIdList></Reference><Reference><Citation>Venugopal S, Takahashi K, Daver N, et al. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 2022;12:10. doi:10.1038/s41408-021-00604-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-021-00604-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Venugopal S, Maiti A, DiNardo CD, et al. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. Am J Hematol. 2021;96:E154&#x2013;E157. doi:10.1002/ajh.26122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26122</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachowiez CA, Borthakur G, Loghavi S, et al. A phase Ib/II study of ivosidenib with venetoclax +/&#x2212; azacitidine in IDH1-mutated myeloid malignancies. J Clin Oncol. 2021;39(15 Suppl):7012. doi:10.1200/JCO.2021.39.15_suppl.7012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2021.39.15_suppl.7012</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan R, Ruvolo VR, Wei J, et al. Inhibition of Mcl-1 with the pan-BCL-2 family inhibitor (&#x2212;)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood. 2015;126:363&#x2013;372. doi:10.1182/blood-2014-10-604975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-10-604975</ArticleId></ArticleIdList></Reference><Reference><Citation>Caenepeel S, Brown SP, Belmontes B, et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 2018;8:1582&#x2013;1597. doi:10.1158/2159-8290.CD-18-0387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-18-0387</ArticleId></ArticleIdList></Reference><Reference><Citation>Moujalled DM, Pomilio G, Ghiurau C, et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia. 2019;33:905&#x2013;917. doi:10.1038/s41375-018-0261-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-018-0261-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsey HE, Fischer MA, Lee T, et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018;8:1566&#x2013;1581. doi:10.1158/2159-8290.CD-18-0140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-18-0140</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogenberger J, Whatcott C, Hansen N, et al. Combined venetoclax and alvocidib in acute myeloid leukemia. Oncotarget. 2017;8:107206&#x2013;107222. doi:10.18632/oncotarget.22284.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.22284</ArticleId></ArticleIdList></Reference><Reference><Citation>Daver NG, Dail M, Garcia JS, et al. Venetoclax and idasanutlin in relapsed/refractory AML: a non-randomized, open-label phase 1b trial. Blood. 2022. doi:10.1182/blood.2022016362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022016362</ArticleId></ArticleIdList></Reference><Reference><Citation>Han L, Zhang Q, Dail M, et al. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. 2020;105:697&#x2013;707. doi:10.3324/haematol.2018.205534.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2018.205534</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Y, Zhang Q, Weng C, et al. Combined blockade of CD47-Sirpa interaction by 5F9 (magrolimab) and azacitidine/venetoclax therapy facilitates macrophage-mediated anti-leukemia efficacy in AML pre-clinical models. Blood. 2021;138(1 Suppl):510&#x2013;510. doi:10.1182/blood-2021-147479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2021-147479</ArticleId></ArticleIdList></Reference><Reference><Citation>Daver N, Perl AE, Maly J, et al. Venetoclax plus gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia. J Clin Oncol. 2022;40:4048&#x2013;4059. doi:10.1200/JCO.22.00602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.22.00602</ArticleId></ArticleIdList></Reference><Reference><Citation>Little RF, Othus M, Assouline S, et al. Umbrella trial in myeloid malignancies: the Myelomatch National Clinical Trials Network Precision Medicine Initiative. Blood. 2022;140(1 Suppl):9057&#x2013;9060. doi:10.1182/blood-2022-169307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2022-169307</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195774</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-336X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>3</Issue><PubDate><MedlineDate>2023 May-Jun 01</MedlineDate></PubDate></JournalIssue><Title>Cancer journal (Sudbury, Mass.)</Title><ISOAbbreviation>Cancer J</ISOAbbreviation></Journal><ArticleTitle>Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes: The Current Landscape and Future Directions.</ArticleTitle><Pagination><StartPage>179</StartPage><EndPage>187</EndPage><MedlinePgn>179-187</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PPO.0000000000000662</ELocationID><Abstract><AbstractText>Myelodysplastic syndromes (MDSs) are characterized by a clonal proliferation of hematopoietic stem cells with potential life-threatening cytopenia(s) and transformation to acute myeloid leukemia. Individualized risk stratification is evolving with new molecular models, such as the Molecular International Prognostic Scoring System, for better estimation of leukemic transformation and overall survival. The only potential cure for MDSs is allogeneic transplant, although it is underutilized in MDSs because of advanced patient age and multiple comorbidities. Optimization of transplant relies on improved identification of high-risk patients pretransplant, using targeted therapies leading to deeper molecular response, developing lower toxicity conditioning regimens, engineering better molecular tools for early detection and relapse monitoring, and adding maintenance treatment strategies for high-risk patients posttransplant. This review provides an overview of transplant in MDSs with updates, future directions, and role for novel therapies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sabile</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Knight Cancer Institute, Oregon Health and Science University, Portland, OR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavletic</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Cancer Institute, Center for Cancer Research, National Institutes of Health, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Migdady</LastName><ForeName>Yazan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From the Knight Cancer Institute, Oregon Health and Science University, Portland, OR.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer J</MedlineTA><NlmUniqueID>100931981</NlmUniqueID><ISSNLinking>1528-9117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>11</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195774</ArticleId><ArticleId IdType="doi">10.1097/PPO.0000000000000662</ArticleId><ArticleId IdType="pii">00130404-202305000-00010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008;100:1542&#x2013;1551.</Citation></Reference><Reference><Citation>Sekeres MA, Taylor J. Diagnosis and treatment of myelodysplastic syndromes: a review. JAMA. 2022;328:872&#x2013;880.</Citation></Reference><Reference><Citation>Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496&#x2013;2506.</Citation></Reference><Reference><Citation>Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014;32:2691&#x2013;2698.</Citation></Reference><Reference><Citation>Anderson J. Allogeneic hematopoietic cell transplantation for myelodysplastic and myeloproliferative disorders. In: Hematopoietic Cell Transplantation. Malden, MA: Blackwell Science; 1999:872&#x2013;886.</Citation></Reference><Reference><Citation>Buckstein R, Wells RA, Zhu N, et al. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. Br J Haematol. 2016;174:88&#x2013;101.</Citation></Reference><Reference><Citation>Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579&#x2013;585.</Citation></Reference><Reference><Citation>Defilipp Z, Ciurea SO, Cutler C, et al. Hematopoietic cell transplantation in the management of myelodysplastic syndrome: an evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. Transplant Cell Ther. 2023;29:71&#x2013;81.</Citation></Reference><Reference><Citation>Kuendgen A, Nomdedeu M, Tuechler H, et al. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification&#x2014;an approach to classification of patients with t-MDS. Leukemia. 2021;35:835&#x2013;849.</Citation></Reference><Reference><Citation>Natelson EA, Pyatt D. Acquired myelodysplasia or myelodysplastic syndrome: clearing the fog. Adv Hematol. 2013;2013:309637.</Citation></Reference><Reference><Citation>Zeidan AM, Al Ali N, Barnard J, et al. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia. 2017;31:1391&#x2013;1397.</Citation></Reference><Reference><Citation>D&#xf6;hner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345&#x2013;1377.</Citation></Reference><Reference><Citation>Diarra A, Duployez N, Fournier E, et al. Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Adv. 2022;6:998&#x2013;1003.</Citation></Reference><Reference><Citation>Gurnari C, McLornan DP. Update on VEXAS and role of allogeneic bone marrow transplant: considerations on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2022;57:1642&#x2013;1648.</Citation></Reference><Reference><Citation>Mekinian A, Zhao LP, Chevret S, et al. A phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML. Leukemia. 2022;36:2739&#x2013;2742.</Citation></Reference><Reference><Citation>Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391&#x2013;2405.</Citation></Reference><Reference><Citation>Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424&#x2013;447.</Citation></Reference><Reference><Citation>de Witte T, Hagemeijer A, Suciu S, et al. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica. 2010;95:1754&#x2013;1761.</Citation></Reference><Reference><Citation>DeFilipp Z, Chen Y-B. How I treat with maintenance therapy after allogeneic HCT. Blood. 2022;141:39&#x2013;48.</Citation></Reference><Reference><Citation>Shaffer BC, Ahn KW, Hu Z-H, et al. Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. J Clin Oncol. 2016;34:1864&#x2013;1871.</Citation></Reference><Reference><Citation>Gutierrez-Rodrigues F, Munger E, Ma X, et al. Differential diagnosis of bone marrow failure syndromes guided by machine learning. Blood. 2022;blood.2022017518.</Citation></Reference><Reference><Citation>Nazha A, Komrokji R, Meggendorfer M, et al. Personalized prediction model to risk stratify patients with myelodysplastic syndromes. J Clin Oncol. 2021;39:3737&#x2013;3746.</Citation></Reference><Reference><Citation>Radakovich N, Nagy M, Nazha A. Machine learning in haematological malignancies. Lancet Haematol. 2020;7:e541&#x2013;e550.</Citation></Reference><Reference><Citation>Radakovich N, Sallman DA, Buckstein R, et al. A machine learning model of response to hypomethylating agents in myelodysplastic syndromes. iScience. 2022;25:104931.</Citation></Reference><Reference><Citation>Shimomura Y, Komukai S, Kitamura T, et al. Identifying the optimal conditioning intensity for stem cell transplantation in patients with myelodysplastic syndrome: a machine learning analysis. Bone Marrow Transplant. 2023;58:186&#x2013;194.</Citation></Reference><Reference><Citation>Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079&#x2013;2088.</Citation></Reference><Reference><Citation>Greenberg P, Attar E, Battiwalla M, et al. Myelodysplastic syndromes. In: NCCN Clinical Practice Guidelines in Oncology Version 1.2023. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2011. Available at: http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf. Accessed February 8, 2023.</Citation></Reference><Reference><Citation>Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia. 1998;12(Suppl 1):S25&#x2013;S29.</Citation></Reference><Reference><Citation>Koreth J, Pidala J, Perez WS, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013;31:2662&#x2013;2670.</Citation></Reference><Reference><Citation>Muffly LS, Kocherginsky M, Stock W, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014;99:1373&#x2013;1379.</Citation></Reference><Reference><Citation>Oliansky DM, Antin JH, Bennett JM, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant. 2009;15:137&#x2013;172.</Citation></Reference><Reference><Citation>Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)&#x2013;specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912&#x2013;2919.</Citation></Reference><Reference><Citation>Baliakas P, Tesi B, Wartiovaara-Kautto U, et al. Nordic guidelines for germline predisposition to myeloid neoplasms in adults: recommendations for genetic diagnosis, clinical management and follow-up. HemaSphere. 2019;3:e321.</Citation></Reference><Reference><Citation>Kennedy AL, Shimamura A. Genetic predisposition to MDS: clinical features and clonal evolution. Blood. 2019;133:1071&#x2013;1085.</Citation></Reference><Reference><Citation>Bortnick R, Wlodarski M, de Haas V, et al. Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome. Bone Marrow Transplant. 2021;56:2732&#x2013;2741.</Citation></Reference><Reference><Citation>Hofmann I, Avagyan S, Stetson A, et al. Comparison of outcomes of myeloablative allogeneic stem cell transplantation for pediatric patients with bone marrow failure, myelodysplastic syndrome and acute myeloid leukemia with and without germline GATA2 mutations. Biol Blood Marrow Transplant. 2020;26:1124&#x2013;1130.</Citation></Reference><Reference><Citation>Makishima H, Saiki R, Nannya Y, et al. Germline DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. 2023;141:534&#x2013;549.</Citation></Reference><Reference><Citation>Saygin C, Roloff G, Hahn CN, et al. Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Adv. 2023;7:549&#x2013;554.</Citation></Reference><Reference><Citation>Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. Blood. 2014;124:2793&#x2013;2803.</Citation></Reference><Reference><Citation>Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376:536&#x2013;547.</Citation></Reference><Reference><Citation>Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for myelodysplastic syndromes. NEJM Evidence. 2022;1:EVIDoa2200008.</Citation></Reference><Reference><Citation>Sabile JMG, Kaempf A, Tomic K, et al. A retrospective validation study comparing the IPSS-M and IPSS-R risk stratification scores in primary and secondary myelodysplastic syndrome (MDS). Blood. 2022;140(Supplement 1):4088&#x2013;4089.</Citation></Reference><Reference><Citation>Gurnari C, Gagelmann N, Badbaran A, et al. Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M. Leukemia. 2023;37:717&#x2013;719.</Citation></Reference><Reference><Citation>List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456&#x2013;1465.</Citation></Reference><Reference><Citation>Robin M, Porcher R, Ad&#xe8;s L, et al. HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome. A prospective study on behalf of SFGM-TC and GFM. Leukemia. 2015;29:1496&#x2013;1501.</Citation></Reference><Reference><Citation>Yahng S-A, Kim M, Kim T-M, et al. Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts. Oncotarget. 2016;8:12342&#x2013;12354.</Citation></Reference><Reference><Citation>Nazha A, Sekeres MA, Garcia-Manero G, et al. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leuk Res. 2016;41:43&#x2013;47.</Citation></Reference><Reference><Citation>Gerds AT, Gooley TA, Estey EH, et al. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant. 2012;18:1211&#x2013;1218.</Citation></Reference><Reference><Citation>Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study b the Soci&#xe9;t&#xe9; Fran&#xe7;aise de Greffe de Moelle et de Th&#xe9;rapie-Cellulaire and the Groupe francophone des My&#xe9;lodysplasies. J Clin Oncol. 2012;30:4533&#x2013;4540.</Citation></Reference><Reference><Citation>Jabbour EJ, Garcia-Manero G, Strati P, et al. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS clinical research consortium. Cancer. 2015;121:876&#x2013;882.</Citation></Reference><Reference><Citation>Lee P, Yim R, Yung Y, et al. Molecular targeted therapy and immunotherapy for myelodysplastic syndrome. Int J Mol Sci. 2021;22:10232.</Citation></Reference><Reference><Citation>Zeidan AM, Borate U, Pollyea DA, et al. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol. 2023;98:272&#x2013;281.</Citation></Reference><Reference><Citation>Azizi A, Ediriwickrema A, Dutta R, et al. Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leuk Lymphoma. 2020;61:2700&#x2013;2707.</Citation></Reference><Reference><Citation>Ball BJ, Famulare CA, Stein EM, et al. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020;4:2866&#x2013;2870.</Citation></Reference><Reference><Citation>Komrokji RS, Singh AM, Ali NA, et al. Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome. Blood Cancer J. 2022;12:148.</Citation></Reference><Reference><Citation>Sallman DA, Elmariah H, Sweet K, et al. Phase 1/1b safety study of Prgn-3006 ultracar-T in patients with relapsed or refractory CD33-positive acute myeloid leukemia and higher risk myelodysplastic syndromes. Blood. 2020;136(Supplement 1):17.</Citation></Reference><Reference><Citation>Patterson MT, Khan SM, Nunes NS, et al. Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects. Blood. 2023;141:659&#x2013;672.</Citation></Reference><Reference><Citation>Festuccia M, Deeg HJ, Gooley TA, et al. Minimal identifiable disease and the role of conditioning intensity in hematopoietic cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia evolving from myelodysplastic syndrome. Biol Blood Marrow Transplant. 2016;22:1227&#x2013;1233.</Citation></Reference><Reference><Citation>Potter VT, Iacobelli S, van Biezen A, et al. Comparison of intensive chemotherapy and hypomethylating agents before allogeneic stem cell transplantation for advanced myelodysplastic syndromes: a study of the myelodysplastic syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2016;22:1615&#x2013;1620.</Citation></Reference><Reference><Citation>Robin M, Porcher R, Zinke-Cerwenka W, et al. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplant. 2017;52:209&#x2013;215.</Citation></Reference><Reference><Citation>Dillon LW, Gui G, Page KM, et al. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. JAMA. 2023;329:745&#x2013;755.</Citation></Reference><Reference><Citation>Deeg HJ, Appelbaum FR. Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Leuk Res. 2000;24:653&#x2013;663.</Citation></Reference><Reference><Citation>Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood. 1993;82:677&#x2013;681.</Citation></Reference><Reference><Citation>Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol. 1996;14:220&#x2013;226.</Citation></Reference><Reference><Citation>Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood. 1996;87:51&#x2013;58.</Citation></Reference><Reference><Citation>Nevill TJ, Fung HC, Shepherd JD, et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood. 1998;92:1910&#x2013;1917.</Citation></Reference><Reference><Citation>Runde V, de Witte T, Arnold R, et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Bone Marrow Transplant. 1998;21:255&#x2013;261.</Citation></Reference><Reference><Citation>Sutton L, Chastang C, Ribaud P, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood. 1996;88:358&#x2013;365.</Citation></Reference><Reference><Citation>Platzbecker U, Schetelig J, Finke J, et al. Allogeneic hematopoietic cell transplantation in patients age 60&#x2013;70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transplant. 2012;18:1415&#x2013;1421.</Citation></Reference><Reference><Citation>McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28:1878&#x2013;1887.</Citation></Reference><Reference><Citation>Lim Z, Brand R, Martino R, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol. 2010;28:405&#x2013;411.</Citation></Reference><Reference><Citation>Nakamura R, Saber W, Martens MJ, et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50&#x2013;75 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021;39:3328&#x2013;3339.</Citation></Reference><Reference><Citation>Wan BA, Nazha A, Starkman R, et al. Revised 15-item MDS-specific frailty scale maintains prognostic potential. Leukemia. 2020;34:3434&#x2013;3438.</Citation></Reference><Reference><Citation>Bhatt VR, Steensma DP. Hematopoietic cell transplantation for myelodysplastic syndromes. J Oncol Pract. 2016;12:786&#x2013;792.</Citation></Reference><Reference><Citation>Nakai K, Kanda Y, Fukuhara S, et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia. 2005;19:396&#x2013;401.</Citation></Reference><Reference><Citation>Bhatt VR, Loberiza FR Jr., Schmit-Pokorny K, et al. Time to insurance approval in private and public payers does not influence survival in patients who undergo hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22:1117&#x2013;1124.</Citation></Reference><Reference><Citation>Bhatt VR, Armitage JO. Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma. Expert Opin Biol Ther. 2016;16:57&#x2013;66.</Citation></Reference><Reference><Citation>Adhikari J, Sharma P, Bhatt VR. Risk of secondary solid malignancies after allogeneic hematopoietic stem cell transplantation and preventive strategies. Future Oncol. 2015;11:3175&#x2013;3185.</Citation></Reference><Reference><Citation>Akhtari M, Bhatt VR, Tandra PK, et al. Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients. Cancer Biol Ther. 2013;14:1077&#x2013;1088.</Citation></Reference><Reference><Citation>Gibson CJ, Kim HT, Zhao L, et al. Donor clonal hematopoiesis and recipient outcomes after transplantation. J Clin Oncol. 2022;40:189&#x2013;201.</Citation></Reference><Reference><Citation>Saber W, Cutler CS, Nakamura R, et al. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood. 2013;122:1974&#x2013;1982.</Citation></Reference><Reference><Citation>Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371:339&#x2013;348.</Citation></Reference><Reference><Citation>Raj K, Eikema D-J, Sheth V, et al. Comparison of outcomes for HLA-matched sibling and haplo-identical donors in myelodysplastic syndromes: report from the Chronic Malignancies Working Party of EBMT. Blood Cancer J. 2022;12:1&#x2013;10.</Citation></Reference><Reference><Citation>Devillier R, Bramanti S, F&#xfc;rst S, et al. T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. Bone Marrow Transplant. 2016;51:194&#x2013;198.</Citation></Reference><Reference><Citation>Kasamon YL, Bola&#xf1;os-Meade J, Prince GT, et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol. 2015;33:3152&#x2013;3161.</Citation></Reference><Reference><Citation>Robin M, Porcher R, Ciceri F, et al. Haploidentical transplant in patients with myelodysplastic syndrome. Blood Adv. 2017;1:1876&#x2013;1883.</Citation></Reference><Reference><Citation>Slade M, DiPersio JF, Westervelt P, et al. Haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide and peripheral blood stem cell grafts in older adults with acute myeloid leukemia or myelodysplastic syndrome. Biol Blood Marrow Transplant. 2017;23:1736&#x2013;1743.</Citation></Reference><Reference><Citation>Grunwald MR, Zhang MJ, Elmariah H, et al. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. Blood Adv. 2021;5:975&#x2013;983.</Citation></Reference><Reference><Citation>Holtan SG, Hamadani M, Wu J, et al. Post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as the new standard for graft-versus-host disease (GVHD) prophylaxis in reduced intensity conditioning: results from phase III BMT CTN 1703. Blood. 2022;140(Supplement 2):LBA-4.</Citation></Reference><Reference><Citation>Guru Murthy GS, Kim S, Hu ZH, et al. Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors. JAMA Oncol. 2022;8:404&#x2013;411.</Citation></Reference><Reference><Citation>Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124:344&#x2013;353.</Citation></Reference><Reference><Citation>Horning SJ, Chao NJ, Negrin RS, et al. The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. Ann Oncol. 1991;2(Suppl 1):47&#x2013;50.</Citation></Reference><Reference><Citation>Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe francophone du My&#xe9;lome 9502 randomized trial. Blood. 2002;99:731&#x2013;735.</Citation></Reference><Reference><Citation>Riddell S, Appelbaum FR, Buckner CD, et al. High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. J Clin Oncol. 1988;6:576&#x2013;582.</Citation></Reference><Reference><Citation>Scott B, Deeg HJ, Storer B, et al. Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML. Leuk Lymphoma. 2004;45:2409&#x2013;2417.</Citation></Reference><Reference><Citation>Oran B, Giralt S, Saliba R, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant. 2007;13:454&#x2013;462.</Citation></Reference><Reference><Citation>Popat U, de Lima MJ, Saliba RM, et al. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant. 2012;47:212&#x2013;216.</Citation></Reference><Reference><Citation>Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756&#x2013;763.</Citation></Reference><Reference><Citation>Scott BL, Pasquini MC, Logan B, et al. Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901. Blood. 2015;126:LBA-8.</Citation></Reference><Reference><Citation>Scott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154&#x2013;1161.</Citation></Reference><Reference><Citation>Kr&#xf6;ger N, Iacobelli S, Franke GN, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial). J Clin Oncol. 2017;35:2157&#x2013;2164.</Citation></Reference><Reference><Citation>Oran B, Ahn KW, Fretham C, et al. Fludarabine and melphalan compared with reduced doses of busulfan and fludarabine improve transplantation outcomes in older patients with myelodysplastic syndromes. Transplant Cell Ther. 2021;27:921.e1&#x2013;921.e10.</Citation></Reference><Reference><Citation>Jain AG, Elmariah H. BMT for myelodysplastic syndrome: when and where and how. Front Oncol. 2021;11:771614.</Citation></Reference><Reference><Citation>Rambaldi A, Grassi A, Masciulli A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16:1525&#x2013;1536.</Citation></Reference><Reference><Citation>Shimoni A, Shem-Tov N, Volchek Y, et al. Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity. Bone Marrow Transplant. 2012;47:1274&#x2013;1282.</Citation></Reference><Reference><Citation>Adhikari J, Sharma P, Bhatt VR. Optimal graft source for allogeneic hematopoietic stem cell transplant: bone marrow or peripheral blood? Future Oncol. 2016;12:1823&#x2013;1832.</Citation></Reference><Reference><Citation>Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126:1033&#x2013;1040.</Citation></Reference><Reference><Citation>Armand P, Kim HT, Zhang M-J, et al. Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant. 2012;18:280&#x2013;288.</Citation></Reference><Reference><Citation>Hourigan CS, Dillon LW, Gui G, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;12:1273&#x2013;1283.</Citation></Reference><Reference><Citation>Brunner AM, Li S, Fathi AT, et al. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016;175:496&#x2013;504.</Citation></Reference><Reference><Citation>Chen Y-B, Li S, Lane AA, et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014;20:2042&#x2013;2048.</Citation></Reference><Reference><Citation>Maziarz RT, Levis M, Patnaik MM, et al. Midostaurin after allogeneic stem cell transplant in patients with FLT3&#x2013;internal tandem duplication&#x2013;positive acute myeloid leukemia. Bone Marrow Transplant. 2021;56:1180&#x2013;1189.</Citation></Reference><Reference><Citation>Perl AE, Larson RA, Podoltsev NA, et al. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022;139:3366&#x2013;3375.</Citation></Reference><Reference><Citation>Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21:1201&#x2013;1212.</Citation></Reference><Reference><Citation>Chen EC, Li S, Eisfeld A-K, et al. Outcomes for patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2021;27:479.e1&#x2013;479.e7.</Citation></Reference><Reference><Citation>Salhotra A, Afkhami M, Yang D, et al. Allogeneic hematopoietic cell transplantation outcomes in patients carrying isocitrate dehydrogenase mutations. Clin Lymphoma Myeloma Leuk. 2019;19:e400&#x2013;e405.</Citation></Reference><Reference><Citation>De Lima M, Oran B, Champlin RE, et al. CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes. Biol Blood Marrow Transplant. 2018;24:2017&#x2013;2024.</Citation></Reference><Reference><Citation>Oshikawa G, Kakihana K, Saito M, et al. Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia. Br J Haematol. 2015;169:756&#x2013;759.</Citation></Reference><Reference><Citation>Platzbecker U, Middeke JM, Sockel K, et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19:1668&#x2013;1679.</Citation></Reference><Reference><Citation>Oran B, de Lima M, Garcia-Manero G, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020;4:5580&#x2013;5588.</Citation></Reference><Reference><Citation>Mishra A, Tamari R, DeZern AE, et al. Eprenetapopt plus Azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2022;40:3985&#x2013;3993.</Citation></Reference><Reference><Citation>Biederstadt A, Rezvani K. How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy. Blood. 2023;141:22&#x2013;38.</Citation></Reference><Reference><Citation>Grayson PC, Patel BA, Young NS. VEXAS syndrome. Blood. 2021;137:3591&#x2013;3594.</Citation></Reference><Reference><Citation>Beck DB, Bodian DL, Shah V, et al. Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population. JAMA. 2023;329:318&#x2013;324.</Citation></Reference><Reference><Citation>Bourbon E, Heiblig M, Gerfaud Valentin M, et al. Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood. 2021;137:3682&#x2013;3684.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195773</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-336X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>3</Issue><PubDate><MedlineDate>2023 May-Jun 01</MedlineDate></PubDate></JournalIssue><Title>Cancer journal (Sudbury, Mass.)</Title><ISOAbbreviation>Cancer J</ISOAbbreviation></Journal><ArticleTitle>Supportive Care for Patients With Myelodysplastic Syndromes.</ArticleTitle><Pagination><StartPage>168</StartPage><EndPage>178</EndPage><MedlinePgn>168-178</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PPO.0000000000000661</ELocationID><Abstract><AbstractText>Myelodysplastic syndromes are a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis, progressive cytopenias, and an innate capability of progressing to acute myeloid leukemia. The most common causes of morbidity and mortality are complications related to myelodysplastic syndromes rather than progression to acute myeloid leukemia. Although supportive care measures are applicable to all patients with myelodysplastic syndromes, they are especially essential in patients with lower-risk disease who have a better prognosis compared with their higher-risk counterparts and require longer-term monitoring of disease and treatment-related complications. In this review, we will address the most frequent complications and supportive care interventions used in patients with myelodysplastic syndromes, including transfusion support, management of iron overload, antimicrobial prophylaxis, important considerations in the era of COVID-19 (coronavirus infectious disease 2019), role of routine immunizations, and palliative care in the myelodysplastic syndrome population.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stempel</LastName><ForeName>Jessica M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Podoltsev</LastName><ForeName>Nikolai A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>From the Department of Internal Medicine, Hematology Section.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dosani</LastName><ForeName>Talib</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer J</MedlineTA><NlmUniqueID>100931981</NlmUniqueID><ISSNLinking>1528-9117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>11</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195773</ArticleId><ArticleId IdType="doi">10.1097/PPO.0000000000000661</ArticleId><ArticleId IdType="pii">00130404-202305000-00009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454&#x2013;2465. doi:10.1182/blood-2012-03-420489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-03-420489</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayyani F, Conley AP, Strom SS, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010;116:2174&#x2013;2179. doi:10.1002/cncr.24984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.24984</ArticleId></ArticleIdList></Reference><Reference><Citation>DeZern AE, Binder G, Rizvi S, et al. Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes. Leuk Lymphoma. 2017;58:2649&#x2013;2656. doi:10.1080/10428194.2017.1312372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10428194.2017.1312372</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood EM, McQuilten ZK. Outpatient transfusions for myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2020;2020:167&#x2013;174. doi:10.1182/hematology.2020000103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/hematology.2020000103</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KLL, Mak WMV, Tam YH, et al. Factors affecting patient-reported outcomes after red blood cell transfusion in medical patients. Transfusion. 2018;58:158&#x2013;167. doi:10.1111/trf.14397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.14397</ArticleId></ArticleIdList></Reference><Reference><Citation>St Lezin E, Karafin MS, Bruhn R, et al. Therapeutic impact of red blood cell transfusion on anemic outpatients: the RETRO study. Transfusion. 2019;59:1934&#x2013;1943. doi:10.1111/trf.15249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.15249</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruhn R, Karafin MS, Hilton JF, et al. Early and sustained improvement in fatigue-related quality of life following red blood cell transfusion in outpatients. Qual Life Res. 2020;29:2737&#x2013;2744. doi:10.1007/s11136-020-02517-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-020-02517-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson JL, Stanworth SJ, Roubinian N, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2016;10:CD002042. doi:10.1002/14651858.CD002042.pub4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD002042.pub4</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, Estcourt LJ, Doree C, et al. Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders. Cochrane Database Syst Rev. 2015;2015:CD011577. doi:10.1002/14651858.CD011577.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD011577.pub2</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen AJG, van den Bosch J, Te Boekhorst PAW, et al. Results of the prematurely terminated TEMPLE randomized controlled trial in patients with myelodysplastic syndrome: liberal versus restrictive red blood cell transfusion threshold. Transfusion. 2020;60:879&#x2013;881. doi:10.1111/trf.15708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.15708</ArticleId></ArticleIdList></Reference><Reference><Citation>Estcourt LJ, Malouf R, Trivella M, et al. Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support. Cochrane Database Syst Rev. 2017;1:CD011305. doi:10.1002/14651858.CD011305.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD011305.pub2</ArticleId></ArticleIdList></Reference><Reference><Citation>Killick SB, Carter C, Culligan D, et al. Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol. 2014;164:503&#x2013;525. doi:10.1111/bjh.12694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.12694</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanasijevic AM, Revette A, Klepin HD, et al. Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions. Leuk Lymphoma. 2020;61:2900&#x2013;2904. doi:10.1080/10428194.2020.1791854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10428194.2020.1791854</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanworth SJ, Killick S, McQuilten ZK, et al. Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. Br J Haematol. 2020;189:279&#x2013;290. doi:10.1111/bjh.16347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.16347</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel GA, Klepin HD, Magnavita ES, et al. Peri-transfusion quality-of-life assessment for patients with myelodysplastic syndromes. Transfusion. 2021;61:2830&#x2013;2836. doi:10.1111/trf.16584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.16584</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson JL, Stanworth SJ, Alexander JH, et al. Clinical trials evaluating red blood cell transfusion thresholds: an updated systematic review and with additional focus on patients with cardiovascular disease. Am Heart J. 2018;200:96&#x2013;101. doi:10.1016/j.ahj.2018.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2018.04.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Singhal D, Kutyna MM, Chhetri R, et al. Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome. Haematologica. 2017;102:2021&#x2013;2029. doi:10.3324/haematol.2017.175752.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2017.175752</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhetri R, Wee LYA, Sinha R, et al. Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: prevalence, characteristic and significance. Haematologica. 2019;104:e451&#x2013;e454. doi:10.3324/haematol.2018.215087.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2018.215087</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Saskin A, Wells RA, et al. Prophylactic RhCE and Kell antigen matching: impact on alloimmunization in transfusion-dependent patients with myelodysplastic syndromes. Vox Sang. 2017;112:79&#x2013;86. doi:10.1111/vox.12455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12455</ArticleId></ArticleIdList></Reference><Reference><Citation>Guelsin GA, Rodrigues C, Visentainer JE, et al. Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome. Blood Transfus. 2015;13:53&#x2013;58. doi:10.2450/2014.0332-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.2450/2014.0332-13</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg SL, Chen E, Sasane M, et al. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need. Transfusion. 2012;52:2131&#x2013;2138. doi:10.1111/j.1537-2995.2012.03626.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2012.03626.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Treleaven J, Gennery A, Marsh J, et al. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. Br J Haematol. 2011;152:35&#x2013;51. doi:10.1111/j.1365-2141.2010.08444.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2010.08444.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev. 2010;24:77&#x2013;124. doi:10.1016/j.tmrv.2009.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmrv.2009.11.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Morrone K, Kambhampati S, et al. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies. Leukemia. 2016;30:536&#x2013;544. doi:10.1038/leu.2015.297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2015.297</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007;109:1705&#x2013;1714. doi:10.1002/cncr.22602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.22602</ArticleId></ArticleIdList></Reference><Reference><Citation>Neukirchen J, Blum S, Kuendgen A, et al. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. Eur J Haematol. 2009;83:477&#x2013;482. doi:10.1111/j.1600-0609.2009.01299.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0609.2009.01299.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1519&#x2013;1538. doi:10.1200/jco.2001.19.5.1519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2001.19.5.1519</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheok KPL, Chhetri R, Wee LYA, et al. The burden of immune-mediated refractoriness to platelet transfusions in myelodysplastic syndromes. Transfusion. 2020;60:2192&#x2013;2198. doi:10.1111/trf.16029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.16029</ArticleId></ArticleIdList></Reference><Reference><Citation>Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337:1861&#x2013;1870. doi:10.1056/nejm199712253372601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejm199712253372601</ArticleId></ArticleIdList></Reference><Reference><Citation>Corash L, Benjamin RJ. The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: the amotosalen-ultraviolet A pathogen reduction treatment model. Transfusion. 2016;56:S29&#x2013;S38. doi:10.1111/trf.13530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.13530</ArticleId></ArticleIdList></Reference><Reference><Citation>Gehrie EA, Frank SM, Visagie M, et al. One-unit compared to two-unit platelet transfusions for adult oncology outpatients. Vox Sang. 2019;114:517&#x2013;522. doi:10.1111/vox.12785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12785</ArticleId></ArticleIdList></Reference><Reference><Citation>Antun AG, Gleason S, Arellano M, et al. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. Cancer. 2013;119:3784&#x2013;3787. doi:10.1002/cncr.28253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.28253</ArticleId></ArticleIdList></Reference><Reference><Citation>Gernsheimer TB, Brown SP, Triulzi DJ, et al. Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial. Blood. 2022;140:1254&#x2013;1262. doi:10.1182/blood.2022016308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022016308</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves AC, Cortesao E, Oliveiros B, et al. Oxidative stress and mitochondrial dysfunction play a role in myelodysplastic syndrome development, diagnosis, and prognosis: a pilot study. Free Radic Res. 2015;49:1081&#x2013;1094. doi:10.3109/10715762.2015.1035268.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10715762.2015.1035268</ArticleId></ArticleIdList></Reference><Reference><Citation>Okabe H, Suzuki T, Uehara E, et al. The bone marrow hematopoietic microenvironment is impaired in iron-overloaded mice. Eur J Haematol. 2014;93:118&#x2013;128. doi:10.1111/ejh.12309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.12309</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui R, Gale RP, Zhu G, et al. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions. Leuk Res. 2014;38:545&#x2013;550. doi:10.1016/j.leukres.2014.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.leukres.2014.01.016</ArticleId></ArticleIdList></Reference><Reference><Citation>De Swart L, Hendriks JCM, Van Der Vorm LN, et al. Second international round robin for the quantification of serum non&#x2013;transferrin-bound iron and labile plasma iron in patients with iron-overload disorders. Haematologica. 2016;101:38&#x2013;45. doi:10.3324/haematol.2015.133983.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2015.133983</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin X, He X, Cao X, et al. Iron overload impairs normal hematopoietic stem and progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice. Haematologica. 2018;103:1627&#x2013;1634. doi:10.3324/haematol.2018.193128.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2018.193128</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva B, Faustino P. An overview of molecular basis of iron metabolism regulation and the associated pathologies. Biochim Biophys Acta. 2015;1852:1347&#x2013;1359. doi:10.1016/j.bbadis.2015.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2015.03.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Santini V, Girelli D, Sanna A, et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PloS One. 2011;6:e23109. doi:10.1371/journal.pone.0023109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023109</ArticleId></ArticleIdList></Reference><Reference><Citation>Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol. 1993;42:81&#x2013;85. doi:10.1002/ajh.2830420116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.2830420116</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg PL, Rigsby CK, Stone RM, et al. NCCN task force: transfusion and Iron overload in patients with myelodysplastic syndromes. J Natl Compr Canc Netw. 2009;7(Suppl 9):S1&#x2013;S16. doi:10.6004/jnccn.2009.0082.</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2009.0082</ArticleId></ArticleIdList></Reference><Reference><Citation>De Swart L, Crouch S, Hoeks M, et al. Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes. Haematologica. 2020;105:632&#x2013;639. doi:10.3324/haematol.2018.212217.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2018.212217</ArticleId></ArticleIdList></Reference><Reference><Citation>Waszczuk-Gajda A, M&#x105;dry K, Machowicz R, et al. Red blood cell transfusion dependency and hyperferritinemia are associated with impaired survival in patients diagnosed with myelodysplastic syndromes: results from the first Polish MDS-PALG Registry. Adv Clin Exp Med. 2016;25:633&#x2013;641. doi:10.17219/acem/62397.</Citation><ArticleIdList><ArticleId IdType="doi">10.17219/acem/62397</ArticleId></ArticleIdList></Reference><Reference><Citation>Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503&#x2013;3510. doi:10.1200/jco.2006.08.5696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2006.08.5696</ArticleId></ArticleIdList></Reference><Reference><Citation>Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res. 2007;31(Suppl 3):S2&#x2013;S6. doi:10.1016/S0145-2126(07)70459-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0145-2126(07)70459-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Malcovati L, Porta MGD, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594&#x2013;7603. doi:10.1200/jco.2005.01.7038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2005.01.7038</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28:2847&#x2013;2852. doi:10.1200/jco.2009.25.2395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2009.25.2395</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy NBA, Myerson S, Schuh AH, et al. Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes. Br J Haematol. 2011;154:521&#x2013;524. doi:10.1111/j.1365-2141.2011.08749.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2011.08749.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin. 2009;25:139&#x2013;147. doi:10.1185/03007990802565867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1185/03007990802565867</ArticleId></ArticleIdList></Reference><Reference><Citation>Noetzli LJ, Mittelman SD, Watanabe RM, et al. Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol. 2012;87:155&#x2013;160. doi:10.1002/ajh.22223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.22223</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassin MA, Soliman A, De Sanctis V, et al. The impact of Iron overload in patients with acute leukemia and myelodysplastic syndrome on hepatic and endocrine functions. Acta Biomed. 2018;89(3-S):18&#x2013;22. doi:10.23750/abm.v89i3-S.7213.</Citation><ArticleIdList><ArticleId IdType="doi">10.23750/abm.v89i3-S.7213</ArticleId></ArticleIdList></Reference><Reference><Citation>Desferal (deferoxamine Mesylate for Injection USP), Vials [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/016267s044lbl.pdf. Accessed March 19, 2023.</Citation></Reference><Reference><Citation>Ferriprox (deferiprone) Tables, for Oral Use [package insert]. Rockville, MD: ApoPharma USA, Inc. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf. Accessed March 19, 2023.</Citation></Reference><Reference><Citation>Ferriprox (Deferiprone) Tables, for Oral Use [package insert]. Toronto, Ontario, Canada: Apotex, Inc. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212266s000lbl.pdf. Accessed March 19, 2023.</Citation></Reference><Reference><Citation>Exjade (Deferasirox) Tablets, for Oral Suspension [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation: Available at: https://www.novartis.com/us-en/sites/novartis_us/files/exjade.pdf?usertrack.filter_applied=true&amp;NovaId=2935376999750894233. Accessed March 19, 2023.</Citation></Reference><Reference><Citation>Jadenu (Deferasirox) Tables, for Oral Use [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corporation. Available at: https://www.novartis.com/us-en/sites/novartis_us/files/jadenu.pdf. Accessed March 19, 2023.</Citation></Reference><Reference><Citation>Hoeks M, Yu G, Langemeijer S, et al. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS Registry. Haematologica. 2020;105:640&#x2013;651. doi:10.3324/haematol.2018.212332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2018.212332</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao C, Zhang Y, Zhao J-G, et al. Analysis of the influencing factors related to liver and cardiac iron overload in MDS patients detected by MRI in the real world. Hematology. 2021;26:123&#x2013;133. doi:10.1080/16078454.2020.1866791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/16078454.2020.1866791</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolte F, H&#xf6;chsmann B, Giagounidis A, et al. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol. 2013;92:191&#x2013;198. doi:10.1007/s00277-012-1594-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-012-1594-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho PJ, Tay L, Teo J, et al. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study). Eur J Haematol. 2017;98:97&#x2013;105. doi:10.1111/ejh.12793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.12793</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydinok Y, Kattamis A, Cappellini MD, et al. Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood. 2015;125:3868&#x2013;3877. doi:10.1182/blood-2014-07-586677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-07-586677</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Yang N, Meng S, et al. Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis. Clin Exp Med. 2020;20:1&#x2013;9. doi:10.1007/s10238-019-00592-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-019-00592-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Mainous AG, Tanner RJ, Hulihan MM, et al. The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome. Br J Haematol. 2014;167:720&#x2013;723. doi:10.1111/bjh.13053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.13053</ArticleId></ArticleIdList></Reference><Reference><Citation>Remacha &#xc1;F, Arrizabalaga B, Villegas A, et al. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. Ann Hematol. 2015;94:779&#x2013;787. doi:10.1007/s00277-014-2274-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-014-2274-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Shi P, Liu J, et al. Efficacy and safety of iron chelator for transfusion-dependent patients with myelodysplastic syndrome: a meta-analysis. Hematology. 2019;24:669&#x2013;678. doi:10.1080/16078454.2019.1666218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/16078454.2019.1666218</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyons RM, Marek BJ, Paley C, et al. Relation between chelation and clinical outcomes in lower-risk patients with patients with myelodysplastic syndromes: registry analysis at 5 years. Leuk Res. 2017;56:88&#x2013;95. doi:10.1016/j.leukres.2017.01.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.leukres.2017.01.033</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmar A, Leitch HA, Wells RA, et al. Iron chelation is associated with improved survival adjusting for disease and patient related characteristics in low/Int-1 risk MDS at the time of first transfusion dependence: a MDS-CAN study. Blood. 2015;126.</Citation></Reference><Reference><Citation>Zeidan AM, Hendrick F, Friedmann E, et al. Deferasirox therapy is associated with reduced mortality risk in a Medicare population with myelodysplastic syndromes. J Comp Eff Res. 2015;4:327&#x2013;340. doi:10.2217/Cer.15.20.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/Cer.15.20</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelucci E, Li J, Greenberg P, et al. Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes: a randomized trial. Ann Intern Med. 2020;172:513&#x2013;522. doi:10.7326/M19-0916.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M19-0916</ArticleId></ArticleIdList></Reference><Reference><Citation>Killick S, Jackson A, Coulthard HC, et al. De-Iron: a phase 2 trial of the activity and safety of deferasirox administered at early iron loading in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol. 2020;189:e237&#x2013;e240. doi:10.1111/bjh.16669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.16669</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelucci E, Santini V, Di Tucci AA, et al. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 trial). Eur J Haematol. 2014;92:527&#x2013;536. doi:10.1111/ejh.12300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.12300</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheong J-W, Kim H-J, Lee K-H, et al. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia. Transfusion. 2014;54:1542&#x2013;1551. doi:10.1111/trf.12507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.12507</ArticleId></ArticleIdList></Reference><Reference><Citation>List AF, Baer MR, Steensma DP, et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion&#x2013;dependent patients with myelodysplastic syndrome. J Clin Oncol. 2012;30:2134&#x2013;2139. doi:10.1200/jco.2010.34.1222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2010.34.1222</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95:557&#x2013;566. doi:10.3324/haematol.2009.014696.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2009.014696</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80:168&#x2013;176. doi:10.1111/j.1600-0609.2007.00985.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0609.2007.00985.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Musto P, Maurillo L, Simeon V, et al. Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. Br J Haematol. 2017;177:741&#x2013;750. doi:10.1111/bjh.14621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.14621</ArticleId></ArticleIdList></Reference><Reference><Citation>Neukirchen J, Fox F, Kundgen A, et al. Improved survival in MDS patients receiving iron chelation therapy&#x2014;a matched pair analysis of 188 patients from the Dusseldorf MDS Registry. Leuk Res. 2012;36:1067&#x2013;1070. doi:10.1016/j.leukres.2012.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.leukres.2012.04.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeidan AM, Fradette C, Rozova A, et al. Safety of deferiprone in patients with myelodysplastic syndromes: results from the Deferiprone US Safety Registry and a compassionate use program. Blood. 2022;140(Supplement 1):1115&#x2013;1117. doi:doi.org/10.1182/blood-2022-169074.</Citation><ArticleIdList><ArticleId IdType="doi">doi:doi.org/10.1182/blood-2022-169074</ArticleId></ArticleIdList></Reference><Reference><Citation>Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol. 2008;88:24&#x2013;29. doi:10.1007/s12185-008-0118-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-008-0118-z</ArticleId></ArticleIdList></Reference><Reference><Citation>National Comprehensive Cancer Network practice guidelines in oncology. Myelodysplastic syndromes. Version 1.2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. Accessed March 19, 2023.</Citation></Reference><Reference><Citation>Yang Y, Tang Z, An T, et al. The impact of iron chelation therapy on patients with lower/intermediate IPSS MDS and the prognostic role of elevated serum ferritin in patients with MDS and AML: a meta-analysis. Medicine (Baltimore). 2019;98:e17406. doi:10.1097/MD.0000000000017406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000017406</ArticleId></ArticleIdList></Reference><Reference><Citation>Nachtkamp K, Stark R, Strupp C, et al. Causes of death in 2877 patients with myelodysplastic syndromes. Ann Hematol. 2016;95:937&#x2013;944. doi:10.1007/s00277-016-2649-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-016-2649-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Leone G, Pagano L. Infections in myelodysplastic syndrome in relation to stage and therapy. Mediterr J Hematol Infect Dis. 2018;10:e2018039. doi:10.4084/mjhid.2018.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.4084/mjhid.2018.039</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan LR, Sekeres MA, Shrestha NK, et al. Epidemiology and risk factors for infections in myelodysplastic syndromes. Transpl Infect Dis. 2013;15:652&#x2013;657. doi:10.1111/tid.12130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tid.12130</ArticleId></ArticleIdList></Reference><Reference><Citation>Caira M, Latagliata R, Girmenia C. The risk of infections in patients with myelodysplastic syndromes in 2016. Expert Rev Hematol. 2016;9:607&#x2013;614. doi:10.1080/17474086.2016.1181540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474086.2016.1181540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzana N, Avila LF, Alonso S, et al. The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment. Ann Hematol. 2017;96:1833&#x2013;1840. doi:10.1007/s00277-017-3091-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-017-3091-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Taplitz RA, Kennedy EB, Flowers CR. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update summary. J Oncol Pract. 2018;14:692&#x2013;695. doi:10.1200/jop.18.00366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jop.18.00366</ArticleId></ArticleIdList></Reference><Reference><Citation>Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1:CD004386. doi:10.1002/14651858.CD004386.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004386.pub3</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977&#x2013;987. doi:10.1056/NEJMoa044097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa044097</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen MH, Billingham LJ, Gaunt CH, et al. Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol. 2007;25:4821&#x2013;4828. doi:10.1200/jco.2006.08.7395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2006.08.7395</ArticleId></ArticleIdList></Reference><Reference><Citation>Merkel D, Filanovsky K, Gafter-Gvili A, et al. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. Am J Hematol. 2013;88:130&#x2013;134. doi:10.1002/ajh.23368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.23368</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Lee KH, Lee JH, et al. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome. Leuk Res. 2011;35:499&#x2013;503. doi:10.1016/j.leukres.2010.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.leukres.2010.07.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong SH, Kim YJ, Lee JH, et al. A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome. Oncotarget. 2015;6:44985&#x2013;44994. doi:10.18632/oncotarget.6242.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.6242</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali AM, Weisel D, Gao F, et al. Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. Cancer Med. 2017;6:2814&#x2013;2821. doi:10.1002/cam4.1231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.1231</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellinghoff SC, Panse J, Alakel N, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol. 2018;97:197&#x2013;207. doi:10.1007/s00277-017-3196-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-017-3196-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1&#x2013;e60. doi:10.1093/cid/ciw326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciw326</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348&#x2013;359. doi:10.1056/NEJMoa061094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa061094</ArticleId></ArticleIdList></Reference><Reference><Citation>Ananda-Rajah MR, Grigg A, Downey MT, et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica. 2012;97:459&#x2013;463. doi:10.3324/haematol.2011.051995.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2011.051995</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111&#x2013;5118. doi:10.1182/blood-2010-02-268151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-02-268151</ArticleId></ArticleIdList></Reference><Reference><Citation>Vehreschild JJ, B&#xf6;hme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect. 2007;55:445&#x2013;449. doi:10.1016/j.jinf.2007.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2007.07.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155:318&#x2013;327. doi:10.1111/j.1365-2141.2011.08838.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2011.08838.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsutsumi I, Kunisawa S, Yoshida C, et al. Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study. Int J Clin Oncol. 2019;24:1449&#x2013;1458. doi:10.1007/s10147-019-01506-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10147-019-01506-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Bose P, McCue D, Wurster S, et al. Isavuconazole as primary antifungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective, phase 2 study. Clin Infect Dis. 2021;72:1755&#x2013;1763. doi:10.1093/cid/ciaa358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa358</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronig I, Masouridi-Levrat S, Chalandon Y, et al. Clinical considerations of isavuconazole administration in high-risk hematological patients: a single-center 5-year, experience. Mycopathologia. 2021;186:775&#x2013;788. doi:10.1007/s11046-021-00583-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11046-021-00583-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiti A, Konopleva MY. How we incorporate venetoclax in treatment regimens for acute myeloid leukemia. Cancer J. 2022;28:2&#x2013;13. doi:10.1097/ppo.0000000000000567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ppo.0000000000000567</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutzschenreuter F, Monsef I, Kreuzer KA, et al. Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes. Cochrane Database Syst Rev. 2016;2:CD009310. doi:10.1002/14651858.CD009310.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009310.pub2</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele GJ, van der Holt B, Verhoef GE, et al; Dutch-Belgian Hemato-Oncology Cooperative Group. A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Leukemia. 1999;13:1207&#x2013;13. DOI: 10.1038/sj.leu.2401478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.leu.2401478</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881&#x2013;2892. doi:10.1182/blood.2020008824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020008824</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharafeldin N, Bates B, Song Q, et al. Outcomes of COVID-19 in patients with cancer: report from the National COVID Cohort Collaborative (N3C). J Clin Oncol. 2021;39:2232&#x2013;2246. doi:10.1200/jco.21.01074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.21.01074</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagano L, Salmanton-Garcia J, Marchesi F, et al. COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. Blood. 2022;139:1588&#x2013;1592. doi:10.1182/blood.2021014124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021014124</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603&#x2013;2615. doi:10.1056/nejmoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2034577</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 COVID-19, vaccine. N Engl J Med. 2021;385:1172&#x2013;1183. doi:10.1056/nejmoa2107659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2107659</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403&#x2013;416. doi:10.1056/nejmoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2035389</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahav G, Lustig Y, Lavee J, et al. BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: a prospective cohort study. eClinicalMedicine. 2021;41:101158. doi:10.1016/j.eclinm.2021.101158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101158</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury O, Bruguier H, Mallett G, et al. Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms. Br J Haematol. 2021;194:1010&#x2013;1015. doi:10.1111/bjh.17644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17644</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdul-Jawad S, Beatson R, Lechmere T, et al. BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes. Haematologica. 2022;107:1181&#x2013;1184. doi:10.3324/haematol.2021.280337.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2021.280337</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng C, Shao W, Chen X, et al. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022;114:252&#x2013;260. doi:10.1016/j.ijid.2021.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.11.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab&#x2013;cilgavimab) for prevention of COVID-19. N Engl J Med. 2022;386:2188&#x2013;2200. doi:10.1056/nejmoa2116620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2116620</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxlovid (Nirmatrelvir Tablets; and Ritonavir Tablets), Co-packaged for Oral Use [package insert]. New York, NY: Pfeizer Labs. Available at: https://labeling.pfizer.com/ShowLabeling.aspx?id=16474. Accessed March 19, 2023.</Citation></Reference><Reference><Citation>Veklury (Remdesivir) for Injection, for Intravenous Use [package insert]. Foster City, CA: Gilead Sciences, Inc. Available at: https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf. Accessed March 19, 2023.</Citation></Reference><Reference><Citation>Lagevrio (Molnupiravir) Capsules, for Oral Use [package insert]. Rahway, NJ: Merk Sharp &amp; Dohme LLC. Available at: https://www.fda.gov/media/155054/download. Accessed March 19, 2023.</Citation></Reference><Reference><Citation>Sotrovimab, Injection for Intravenous Use, Vials [fact sheet for healthcare providers]. Philadelphia, PA: GlaxoSmithKline, LLC. Available at: https://www.fda.gov/media/149534/download. Accessed March 19, 2023.</Citation></Reference><Reference><Citation>Bebtelovimab, Injection for Intravenous Use [package insert]. Indianapolis, IN: Eli Lilly and Company. Available at: https://www.fda.gov/media/156152/download. Accessed March 19, 2023.</Citation></Reference><Reference><Citation>Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 omicron sublineages. Nature. 2022;604:553&#x2013;556. doi:10.1038/s41586-022-04594-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04594-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesaro S, Ljungman P, Mikulska M, et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia. 2022;36:1467&#x2013;1480. doi:10.1038/s41375-022-01578-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-022-01578-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Titmarsh GJ, McMullin MF, McShane CM, et al. Community-acquired infections and their association with myeloid malignancies. Cancer Epidemiol. 2014;38:56&#x2013;61. doi:10.1016/j.canep.2013.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canep.2013.10.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices&#x2014;United States, 2022&#x2013;23 influenza season. MMWR Recomm Rep. 2022;71 (No. RR-1):1&#x2013;28. Available at: http://dx.doi.org/10.15585/mmwr.rr7101a1. Accessed March 19, 2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.rr7101a1.</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagnew AF, Ilhan O, Lee WS, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19:988&#x2013;1000. doi:10.1016/S1473-3099(19)30163-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(19)30163-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickolich MS, El-Jawahri A, Temel JS, et al. Discussing the evidence for upstream palliative care in improving outcomes in advanced cancer. Am Soc Clin Oncol Educ Book. 2016;35:e534&#x2013;e538. doi:10.1200/edbk_159224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/edbk_159224</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBlanc TW, El-Jawahri A. When and why should patients with hematologic malignancies see a palliative care specialist? Hematology Am Soc Hematol Educ Program. 2015;2015:471&#x2013;478. doi:10.1182/asheducation-2015.1.471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/asheducation-2015.1.471</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Zeidan AM, Halene S, et al. Health care use by older adults with acute myeloid leukemia at the end of life. J Clin Oncol. 2017;35:3417&#x2013;3424. doi:10.1200/jco.2017.72.7149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2017.72.7149</ArticleId></ArticleIdList></Reference><Reference><Citation>Manitta VJ, Philip JA, Cole-Sinclair MF. Palliative care and the hemato-oncological patient: can we live together? A review of the literature. J Palliat Med. 2010;13:1021&#x2013;1025. doi:10.1089/jpm.2009.0267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jpm.2009.0267</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein AS, Goldberg GR, Meier DE. Palliative care and hematologic oncology: the promise of collaboration. Blood Rev. 2012;26:233&#x2013;239. doi:10.1016/j.blre.2012.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2012.07.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Odejide OO, Cronin AM, Condron N, et al. Timeliness of end-of-life discussions for blood cancers: a national survey of hematologic oncologists. JAMA Intern Med. 2016;176:263&#x2013;265. doi:10.1001/jamainternmed.2015.6599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2015.6599</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher SA, Cronin AM, Zeidan AM, et al. Intensity of end-of-life care for patients with myelodysplastic syndromes: findings from a large national database. Cancer. 2016;122:1209&#x2013;1215. doi:10.1002/cncr.29913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.29913</ArticleId></ArticleIdList></Reference><Reference><Citation>Odejide OO, Coronado DYS, Watts CD, et al. End-of-life care for blood cancers: a series of focus groups with hematologic oncologists. J Oncol Pract. 2014;10:e396&#x2013;e403. doi:10.1200/jop.2014.001537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jop.2014.001537</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBlanc TW. Palliative care and hematologic malignancies: old dog, new tricks? J Oncol Pract. 2014;10:e404&#x2013;e407. doi:10.1200/jop.2014.000968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jop.2014.000968</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBlanc TW, Abernethy AP, Casarett DJ. What is different about patients with hematologic malignancies? A retrospective cohort study of cancer patients referred to a hospice research network. J Pain Symptom Manage. 2015;49:505&#x2013;512. doi:10.1016/j.jpainsymman.2014.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpainsymman.2014.07.003</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195772</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-336X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>3</Issue><PubDate><MedlineDate>2023 May-Jun 01</MedlineDate></PubDate></JournalIssue><Title>Cancer journal (Sudbury, Mass.)</Title><ISOAbbreviation>Cancer J</ISOAbbreviation></Journal><ArticleTitle>Overview of the Management of Higher-Risk Myelodysplastic Syndromes.</ArticleTitle><Pagination><StartPage>160</StartPage><EndPage>167</EndPage><MedlinePgn>160-167</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PPO.0000000000000664</ELocationID><Abstract><AbstractText>Myelodysplastic syndromes or myelodysplastic neoplasms (both abbreviated MDSs) (Leukemia 2022;36:1703-1719) have historically been challenging diseases to treat owing to their complex biology, molecular diversity, and a patient population that is elderly with comorbidities. As the patients are living longer, incidence of MDSs is rising, and challenges in selecting MDS treatments or lack thereof have been becoming more apparent. Fortunately, with better understanding of molecular underpinnings of this heterogeneous syndrome, numerous clinical trials reflecting the biology of disease and catering to the advanced age of MDS patients are in development to maximize the likelihood of identifying active drugs. Addressing this diverse nature of genetic abnormalities, novel agents, and combinations are in development to formulate personalized treatment approaches for MDS patients. Myelodysplastic syndrome is categorized into subtypes that are associated with lower or higher risk for leukemic evolution, and that knowledge helps with therapy selection. Currently, as it stands, for those with higher-risk MDSs, hypomethylating agents are the first-line therapy. Allogenic stem cell transplantation represents the only potential cure for our patients with MDSs and should be considered for all eligible patients with higher-risk MDSs at the time of diagnosis. This review discusses current MDS treatment landscape, as well as new approaches in development.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Abhay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Leukemia and Myeloid Disorder Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carraway</LastName><ForeName>Hetty E</ForeName><Initials>HE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer J</MedlineTA><NlmUniqueID>100931981</NlmUniqueID><ISSNLinking>1528-9117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>11</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195772</ArticleId><ArticleId IdType="doi">10.1097/PPO.0000000000000664</ArticleId><ArticleId IdType="pii">00130404-202305000-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ma X. Epidemiology of myelodysplastic syndromes. Am J Med. 2012;125:S2&#x2013;S5.</Citation></Reference><Reference><Citation>Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703&#x2013;1719.</Citation></Reference><Reference><Citation>Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200&#x2013;1228.</Citation></Reference><Reference><Citation>Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013;122:4021&#x2013;4034.</Citation></Reference><Reference><Citation>Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120:2454&#x2013;2465.</Citation></Reference><Reference><Citation>Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for myelodysplastic syndromes. 2022;1:EVIDoa2200008.</Citation></Reference><Reference><Citation>Bejar R, Stevenson KE, Stojanov P, et al. Detection of recurrent mutations by pooled targeted next-generation sequencing in MDS patients prior to treatment with hypomethylating agents or stem cell transplantation. Blood. 2012;120:311.</Citation></Reference><Reference><Citation>DeZern AE, Greenberg PL. Recent clinical and molecular advances for the classification of myelodysplastic neoplasms. J Natl Compr Canc Netw. 2022;20:1280&#x2013;1283.</Citation></Reference><Reference><Citation>Uy N, Singh A, Gore SD, et al. Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings. Expert Opin Pharmacother. 2017;18:1213&#x2013;1224.</Citation></Reference><Reference><Citation>Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Soci&#xe9;t&#xe9; Fran&#xe7;aise de Greffe de Moelle et de Th&#xe9;rapie-Cellulaire and the Groupe-francophone des My&#xe9;lodysplasies. J Clin Oncol. 2012;30:4533&#x2013;4540.</Citation></Reference><Reference><Citation>Garcia-Manero G. Myelodysplastic syndromes: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90:831&#x2013;841.</Citation></Reference><Reference><Citation>Duncavage EJ, Jacoby MA, Chang GS, et al. Mutation clearance after transplantation for myelodysplastic syndrome. N Engl J Med. 2018;379:1028&#x2013;1041.</Citation></Reference><Reference><Citation>Platzbecker U, Middeke JM, Sockel K, et al. Measurable residual disease&#x2013;guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19:1668&#x2013;1679.</Citation></Reference><Reference><Citation>Koenig KL, Borate U. New investigational combinations for higher-risk MDS. Hematology. 2022;2022:368&#x2013;374.</Citation></Reference><Reference><Citation>Dillon LW, Gui G, Logan BR, et al. Impact of conditioning intensity and genomics on relapse after allogeneic transplantation for patients with myelodysplastic syndrome. JCO Precis Oncol. 2021;5:265&#x2013;274.</Citation></Reference><Reference><Citation>Fathi AT, Kim HT, Soiffer RJ, et al. Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. Blood Adv. 2022;6:5857&#x2013;5865.</Citation></Reference><Reference><Citation>Mishra A, Tamari R, DeZern AE, et al. Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2022;40:3985&#x2013;3993.</Citation></Reference><Reference><Citation>Bewersdorf JP, Allen C, Mirza AS, et al. Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation&#x2014;a systematic review and meta-analysis. Transplant Cell Ther. 2021;27:997.e1&#x2013;997.e11.</Citation></Reference><Reference><Citation>Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223&#x2013;232.</Citation></Reference><Reference><Citation>Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794&#x2013;1803.</Citation></Reference><Reference><Citation>Zeidan AM, Stahl M, Hu X, et al. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood. 2018;131:818&#x2013;821.</Citation></Reference><Reference><Citation>Thota S, Oganesian A, Azab M, et al. Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia. Future Oncol. 2021;17:2077&#x2013;2087.</Citation></Reference><Reference><Citation>Zeidan AM, Hu X, Zhu W, et al. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leuk Lymphoma. 2020;61:397&#x2013;408.</Citation></Reference><Reference><Citation>Corman S, Joshi N, Wert T, et al. Under-use of hypomethylating agents in patients with higher-risk myelodysplastic syndrome in the United States: a large population-based analysis. Clin Lymphoma Myeloma Leuk. 2021;21:e206&#x2013;e211.</Citation></Reference><Reference><Citation>Stein EM, Bonifacio G, Latremouille-Viau D, et al. Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. Leuk Lymphoma. 2021;62:1411&#x2013;1421.</Citation></Reference><Reference><Citation>Zeidan AM, Salimi T, Epstein RS. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials? Future Oncol. 2021;17:5163&#x2013;5175.</Citation></Reference><Reference><Citation>Sekeres MA, Othus M, List AF, et al. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017;35:2745.</Citation></Reference><Reference><Citation>Ades L, Duployez N, Guerci-Bresler A, et al. A randomised phase II study of azacitidine (AZA) alone or with lenalidomide (LEN), valproic acid (VPA) or Idarubicin (IDA) in higher-risk MDS or low blast AML: GFM's &#x201c;Pick a Winner&#x201d; trial, with the impact of somatic mutations. Br J Haematol. 2018;132:467.</Citation></Reference><Reference><Citation>Pr&#xe9;bet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:3322&#x2013;3327.</Citation></Reference><Reference><Citation>DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617&#x2013;629.</Citation></Reference><Reference><Citation>Parker JE, Mufti GJ, Rasool F, et al. The role of apoptosis, proliferation, and the BCL-2&#x2013;related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 2000;96:3932&#x2013;3938.</Citation></Reference><Reference><Citation>Saygin C, Carraway HE. Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021;48:100791.</Citation></Reference><Reference><Citation>Yue X, Chen Q, He J. Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies. Cancer Cell Int. 2020;20:524.</Citation></Reference><Reference><Citation>Bogenberger JM, Kornblau SM, Pierceall WE, et al. BCL-2 family proteins as 5-azacytidine&#x2013;sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014;28:1657&#x2013;1665.</Citation></Reference><Reference><Citation>Wei AH, Garcia JS, Borate U, et al. A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine in treatment-na&#xef;ve patients with higher-risk myelodysplastic syndrome. Blood. 2019;134:568.</Citation></Reference><Reference><Citation>Garcia JS, Wei AH, Borate U, et al. Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study. Blood. 2020;136:55&#x2013;57.</Citation></Reference><Reference><Citation>Zeidan AM, Pollyea DA, Garcia JS, et al. A phase 1b study evaluating the safety and efficacy of venetoclax as monotherapy or in combination with azacitidine for the treatment of relapsed/refractory myelodysplastic syndrome. Blood. 2019;134:565.</Citation></Reference><Reference><Citation>Zeidan AM, Borate U, Pollyea DA, et al. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol. 2023;98:272&#x2013;281.</Citation></Reference><Reference><Citation>Garcia JS, Wei AH, Jacoby MA, et al. Molecular responses are observed across mutational spectrum in treatment-na&#xef;ve higher-risk myelodysplastic syndrome patients treated with venetoclax plus azacitidine. Blood. 2021;138:241.</Citation></Reference><Reference><Citation>Sallman DA, Malki MMA, Asch AS, et al. Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results. 2022;40:7017.</Citation></Reference><Reference><Citation>Sallman DA, Al Malki MM, Asch AS, et al. Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study. J Clin Oncol. 2023;JCO2201794.</Citation></Reference><Reference><Citation>Garcia-Manero G, Przespolewski A, Abaza Y, et al. Evorpacept (ALX148), a CD47-blocking myeloid checkpoint inhibitor, in combination with azacitidine and venetoclax in patients with acute myeloid leukemia (ASPEN-05): results from phase 1a dose escalation part. Blood. 2022;140:9046&#x2013;9047.</Citation></Reference><Reference><Citation>Garcia-Manero G, Erba HP, Sanikommu SR, et al. Evorpacept (ALX148), a CD47-blocking myeloid checkpoint inhibitor, in combination with azacitidine: a phase 1/2 study in patients with myelodysplastic syndrome (ASPEN-02). Blood. 2021;138:2601.</Citation></Reference><Reference><Citation>Garcia-Manero G, Wei AH, Porkka K, et al. MDS-420: sabatolimab plus hypomethylating agents (HMAs) in patients with high-/very high-risk myelodysplastic syndrome (HR/vHR-MDS) and newly diagnosed acute myeloid leukemia (ND-AML): subgroup analysis of a phase 1 study. Clin Lymphoma Myeloma Leuk. 2021;21:S350.</Citation></Reference><Reference><Citation>Ball BJ, Famulare CA, Stein EM, et al. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020;4:2866&#x2013;2870.</Citation></Reference><Reference><Citation>Ad&#xe8;s L, Girshova L, Doronin VA, et al. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Adv. 2022;6:5132&#x2013;5145.</Citation></Reference><Reference><Citation>Sekeres MA, Watts J, Radinoff A, et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia. 2021;35:2119&#x2013;2124.</Citation></Reference><Reference><Citation>Brunner AM, Esteve J, Porkka K, et al. Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): updated results from a phase 1b study. Blood. 2020;136:1&#x2013;2.</Citation></Reference><Reference><Citation>Sallman DA, DeZern AE, Garcia-Manero G, et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol. 2021;39:1584&#x2013;1594.</Citation></Reference><Reference><Citation>Zeidan AM, DeZern AE, Borate U, et al. Stimulus MDS-US trial in progress: evaluating sabatolimab in combination with hypomethylating agents (HMAs) in patients with intermediate-, high-, or very high-risk myelodysplastic syndrome (MDS). Blood. 2022;140:4069&#x2013;4070.</Citation></Reference><Reference><Citation>Zeidan AM, Ando K, Rauzy O, et al. Primary results of stimulus-MDS1: a randomized, double-blind, placebo-controlled phase II study of TIM-3 inhibition with sabatolimab added to hypomethylating agents (HMAs) in adult patients with higher-risk myelodysplastic syndromes (MDS). 2022;140:2063&#x2013;2065.</Citation></Reference><Reference><Citation>Swords RT, Coutre S, Maris MB, et al. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood. 2018;131:1415&#x2013;1424.</Citation></Reference><Reference><Citation>PANTHER: no significant benefit for pevonedistat plus azacitidine in higher-risk myelodysplastic syndrome. 2022. Available at: https://ascopost.com/issues/february-25-2022/no-significant-benefit-for-pevonedistat-plus-azacitidine-in-higher-risk-myelodysplastic-syndrome/. Accessed December 21, 2022.</Citation></Reference><Reference><Citation>Ogawa S. Genetics of MDS. Blood. 2019;133:1049&#x2013;1059.</Citation></Reference><Reference><Citation>Seiler M, Peng S, Agrawal AA, et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep. 2018;23:282&#x2013;96.e4.</Citation></Reference><Reference><Citation>Pellagatti A, Armstrong RN, Steeples V, et al. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. Blood. 2018;132:1225&#x2013;1240.</Citation></Reference><Reference><Citation>Shiozawa Y, Malcovati L, Gall&#xec; A, et al. Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. Nat Commun. 2018;9:3649.</Citation></Reference><Reference><Citation>Hershberger CE, Moyer DC, Adema V, et al. Complex landscape of alternative splicing in myeloid neoplasms. Leukemia. 2021;35:1108&#x2013;1120.</Citation></Reference><Reference><Citation>Seiler M, Yoshimi A, Darman R, et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018;24:497&#x2013;504.</Citation></Reference><Reference><Citation>Lee SC, Abdel-Wahab O. Therapeutic targeting of splicing in cancer. Nat Med. 2016;22:976&#x2013;986.</Citation></Reference><Reference><Citation>Steensma DP, Wermke M, Klimek VM, et al. Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021;35:3542&#x2013;3550.</Citation></Reference><Reference><Citation>Pellagatti A, Boultwood J. Splicing factor mutant myelodysplastic syndromes: recent advances. Adv Biol Regul. 2020;75:100655.</Citation></Reference><Reference><Citation>Flach J, Jann JC, Knaflic A, et al. Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations. Haematologica. 2021;106:2906&#x2013;2917.</Citation></Reference><Reference><Citation>Crews LA, Balaian L, Delos Santos NP, et al. RNA splicing modulation selectively impairs leukemia stem cell maintenance in secondary human AML. Cell Stem Cell. 2016;19:599&#x2013;612.</Citation></Reference><Reference><Citation>Schwartz LY, Choudhary GS, Ramachandra N, et al. Preclinical activity of the clinical stage protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in splicing mutant myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). 2021;138:2597.</Citation></Reference><Reference><Citation>DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386&#x2013;2398.</Citation></Reference><Reference><Citation>Cortes JE, Fenaux P, Yee K, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed/refractory mIDH1 acute myeloid leukemia. Results from a planned interim analysis of a phase 2 pivotal clinical trial. Blood. 2022;140:6193&#x2013;6196.</Citation></Reference><Reference><Citation>Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722&#x2013;731.</Citation></Reference><Reference><Citation>Daver N, Strati P, Jabbour E, et al. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013;88:56&#x2013;59.</Citation></Reference><Reference><Citation>Strati P, Kantarjian H, Ravandi F, et al. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015;90:276&#x2013;281.</Citation></Reference><Reference><Citation>Mohty R, Al Hamed R, Bazarbachi A, et al. Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease. J Hematol Oncol. 2022;15:124.</Citation></Reference><Reference><Citation>Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36:2684&#x2013;2692.</Citation></Reference><Reference><Citation>Peterlin P, Turlure P, Chevallier P, et al. CPX 351 as first line treatment in higher risk MDS a phase II trial by the GFM. 2021;138:243.</Citation></Reference><Reference><Citation>McKeown MR, Corces MR, Eaton ML, et al. Superenhancer analysis defines novel epigenomic subtypes of non-APL AML, including an RAR&#x3b1; dependency targetable by SY-1425, a potent and selective RAR&#x3b1; agonist. Cancer Discov. 2017;7:1136&#x2013;1153.</Citation></Reference><Reference><Citation>de Botton S, Cluzeau T, Vigil CE, et al. Targeting RARA overexpression with tamibarotene, a potent and selective RAR&#x3b1; agonist, is a novel approach in AML. Blood Adv. 2023;7:1858&#x2013;1870.</Citation></Reference><Reference><Citation>Sanford D, Lo-Coco F, Sanz MA, et al. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Br J Haematol. 2015;171:471&#x2013;477.</Citation></Reference><Reference><Citation>Jurcic JG, Raza A, Vlad G, et al. Early results from a biomarker-directed phase 2 trial of Sy-1425 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) demonstrate DHRS3 induction and myeloid differentiation following Sy-1425 treatment. Blood. 2017;130:2633.</Citation></Reference><Reference><Citation>Santini V. How I treat MDS after hypomethylating agent failure. Blood. 2019;133:521&#x2013;529.</Citation></Reference><Reference><Citation>Komrokji RS, Singh AM, Ali NA, et al. Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome. Blood Cancer J. 2022;12:148.</Citation></Reference><Reference><Citation>Pr&#xe9;bet T, Gore SD, Th&#xe9;pot S, et al. Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. Br J Haematol. 2012;157:764.</Citation></Reference><Reference><Citation>Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010;116:3830&#x2013;3834.</Citation></Reference><Reference><Citation>Sallman DA, DeZern AE, Gayle AA, et al. Phase 1 results of the first-in-class CXCR1/2 inhibitor SX-682 in patients with hypomethylating agent failure myelodysplastic syndromes. Blood. 2022;140:2070&#x2013;2072.</Citation></Reference><Reference><Citation>Senapati J, Almanza EH, Kadia TM, et al. Updated results of CPX-351 in combination with gemtuzumab ozogamicin (GO) in relapsed refractory (R/R) acute myeloid leukemia (AML) and post&#x2013;hypomethylating agent (post-HMA) failure high-risk myelodysplastic syndrome (HR-MDS). 2022;140:9050&#x2013;9053.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195771</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-336X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>3</Issue><PubDate><MedlineDate>2023 May-Jun 01</MedlineDate></PubDate></JournalIssue><Title>Cancer journal (Sudbury, Mass.)</Title><ISOAbbreviation>Cancer J</ISOAbbreviation></Journal><ArticleTitle>The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances.</ArticleTitle><Pagination><StartPage>152</StartPage><EndPage>159</EndPage><MedlinePgn>152-159</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PPO.0000000000000655</ELocationID><Abstract><AbstractText>The myelodysplastic syndromes (MDSs) are a heterogeneous group of hematologic neoplasms with varied natural histories and prognoses. Specific to this review, treatment of low-risk MDS most often focuses on improving quality of life by correcting cytopenias, as opposed to urgent disease modification to avoid acute myeloid leukemia. These treatments include transfusion support with iron chelation when necessary, growth factors including novel maturation agents such as luspatercept, lenalidomide for del(5q) disease, and, increasingly, low-dose hypomethylating agents. Recent advances in the understanding of the genetic lesions that drive MDS have prompted a reassessment of how low-risk disease is defined and helped to identify a subset of low-risk MDS patients who may benefit from a more aggressive treatment paradigm, including hematopoietic stem cell transplantation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Randall</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>From the Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeZern</LastName><ForeName>Amy E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Division of Hematologic Malignancies, The Johns Hopkins University School of Medicine, Baltimore, MD.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer J</MedlineTA><NlmUniqueID>100931981</NlmUniqueID><ISSNLinking>1528-9117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Conflicts of Interest and Source of Funding: A.E.D. disclosed that she has received consulting fees from Geron, Bristol-Myers Squibb, Novartis, CTI Biopharma, Sobi, and Gilead.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>11</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195771</ArticleId><ArticleId IdType="doi">10.1097/PPO.0000000000000655</ArticleId><ArticleId IdType="pii">00130404-202305000-00007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383:1358&#x2013;1374. doi:10.1056/NEJMra1904794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1904794</ArticleId></ArticleIdList></Reference><Reference><Citation>Nachtkamp K, Stark R, Strupp C, et al. Causes of death in 2877 patients with myelodysplastic syndromes. Ann Hematol. 2016;95:937&#x2013;944. doi:10.1007/s00277-016-2649-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-016-2649-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200&#x2013;1228. doi:10.1182/blood.2022015850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022015850</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson CJ, Papula AL, Poon GYP, et al. The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science. 2020;367:1449&#x2013;1454. doi:10.1126/science.aay9333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aay9333</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703&#x2013;1719. doi:10.1038/s41375-022-01613-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-022-01613-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Galli A, Todisco G, Catamo E, et al. Relationship between clone metrics and clinical outcome in clonal cytopenia. Blood. 2021;138:965&#x2013;976. doi:10.1182/blood.2021011323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021011323</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079&#x2013;2088.</Citation></Reference><Reference><Citation>Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120:2454&#x2013;2465. doi:10.1182/blood-2012-03-420489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-03-420489</ArticleId></ArticleIdList></Reference><Reference><Citation>Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503&#x2013;3510. doi:10.1200/jco.2006.08.5696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2006.08.5696</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113:1351&#x2013;1361. doi:10.1002/cncr.23697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.23697</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22:538&#x2013;543. doi:10.1038/sj.leu.2405070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.leu.2405070</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalton WB, Helmenstine E, Pieterse L, et al. The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing. Blood Adv. 2020;4:1192&#x2013;1196. doi:10.1182/bloodadvances.2019001127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2019001127</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549&#x2013;1556. doi:10.1038/s41591-020-1008-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1008-z</ArticleId></ArticleIdList></Reference><Reference><Citation>DeZern AE. Lower risk but high risk. Hematology Am Soc Hematol Educ Program. 2021;2021:428&#x2013;434. doi:10.1182/hematology.2021000277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/hematology.2021000277</ArticleId></ArticleIdList></Reference><Reference><Citation>DeZern AE, Dalton WB. How low risk are low risk myelodysplastic syndromes? Expert Rev Hematol. 2022;15:15&#x2013;24. doi:10.1080/17474086.2022.2029698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474086.2022.2029698</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008;100:1542&#x2013;1551. doi:10.1093/jnci/djn349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djn349</ArticleId></ArticleIdList></Reference><Reference><Citation>De Swart L, Smith A, Johnston TW, et al. Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol. 2015;170:372&#x2013;383. doi:10.1111/bjh.13450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.13450</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson-Ehle H, Birgeg&#xe5;rd G, Samuelsson J, et al. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of &#x2265;120 g/L with darbepoetin alfa &#xb1; filgrastim or erythrocyte transfusions. Eur J Haematol. 2011;87:244&#x2013;252. doi:10.1111/j.1600-0609.2011.01654.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0609.2011.01654.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstr&#xf6;m-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120:1037&#x2013;1046. doi:10.1046/j.1365-2141.2003.04153.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2141.2003.04153.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Westers TM, Alhan C, Chamuleau MED, et al. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood. 2010;115:1779&#x2013;1784. doi:10.1182/blood-2009-08-239749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-08-239749</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S, Kosmider O, Maloisel F, et al. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. Haematologica. 2019;104:497&#x2013;504. doi:10.3324/haematol.2018.203158.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2018.203158</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosmider O, Passet M, Santini V, et al. Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes? Haematologica. 2016;101:e280&#x2013;e283. doi:10.3324/haematol.2016.142695.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2016.142695</ArticleId></ArticleIdList></Reference><Reference><Citation>Platzbecker U, Symeonidis A, Oliva EN, et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia. 2017;31:1944&#x2013;1950. doi:10.1038/leu.2017.192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2017.192</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenaux P, Santini V, Spiriti MAA, et al. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-&#x3b1; in anemic patients with low-risk MDS. Leukemia. 2018;32:2648&#x2013;2658. doi:10.1038/s41375-018-0118-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-018-0118-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S, Greenberg P, Yucel A, et al. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. Br J Haematol. 2019;184:134&#x2013;160. doi:10.1111/bjh.15707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.15707</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;dersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26:3607&#x2013;3613. doi:10.1200/jco.2007.15.4906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2007.15.4906</ArticleId></ArticleIdList></Reference><Reference><Citation>Affentranger L, Bohlius J, Hallal M, et al. Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: a systematic review. Crit Rev Oncol Hematol. 2019;136:37&#x2013;47. doi:10.1016/j.critrevonc.2019.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2019.01.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S, Hamel JF, Toma A, et al. Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents. J Clin Oncol. 2017;35:1591&#x2013;1597. doi:10.1200/JCO.2016.71.3271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2016.71.3271</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382:140&#x2013;151. doi:10.1056/NEJMoa1908892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1908892</ArticleId></ArticleIdList></Reference><Reference><Citation>Bewersdorf JP, Zeidan AM. Transforming growth factor (TGF)-&#x3b2; pathway as a therapeutic target in lower risk myelodysplastic syndromes. Leukemia. 2019;33:1303&#x2013;1312. doi:10.1038/s41375-019-0448-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-019-0448-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Platzbecker U, Germing U, G&#xf6;tze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017;18:1338&#x2013;1347. doi:10.1016/s1470-2045(17)30615-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1470-2045(17)30615-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki K, Jabbour E, Montalban-Bravo G, et al. Low-dose decitabine versus low-dose azacitidine in lower-risk MDS. NEJM Evid. 2022;1:EVIDoa2200034. doi:10.1056/EVIDoa2200034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/EVIDoa2200034</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliva EN, Alati C, Santini V, et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017;4:e127&#x2013;e136. doi:10.1016/S2352-3026(17)30012-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(17)30012-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliva EN, Alati C, Santini V, et al. Long term effects of eltrombopag treatment versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): interim results of a single-blind, randomised, controlled, phase 2 superiority trial. Blood. 2019;134(Supplement_1):3000&#x2013;3000. doi:10.1182/blood-2019-126744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2019-126744</ArticleId></ArticleIdList></Reference><Reference><Citation>Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer. 2014;120:1838&#x2013;1846. doi:10.1002/cncr.28663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.28663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarjian HM, Fenaux P, Sekeres MA, et al. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematol. 2018;5:e117&#x2013;e126. doi:10.1016/S2352-3026(18)30016-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(18)30016-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO Classification-Based Prognostic Scoring System (WPSS). Haematologica. 2011;96:1433&#x2013;1440. doi:10.3324/haematol.2011.044602.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2011.044602</ArticleId></ArticleIdList></Reference><Reference><Citation>De Swart L, Crouch S, Hoeks M, et al. Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes. Haematologica. 2020;105:632&#x2013;639. doi:10.3324/haematol.2018.212217.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2018.212217</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin X, He X, Cao X, et al. Iron overload impairs normal hematopoietic stem and progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice. Haematologica. 2018;103:1627&#x2013;1634. doi:10.3324/haematol.2018.193128.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2018.193128</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenoy N, Vallumsetla N, Rachmilewitz E, et al. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124:873&#x2013;881. doi:10.1182/blood-2014-03-563221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-03-563221</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelucci E, Li J, Greenberg P, et al. Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes: a randomized trial. Ann Intern Med. 2020;172:513&#x2013;522. doi:10.7326/m19-0916.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/m19-0916</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeks M, Yu G, Langemeijer S, et al. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. Haematologica. 2020;105:640&#x2013;651. doi:10.3324/haematol.2018.212332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2018.212332</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitch HA, Parmar A, Wells RA, et al. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. Br J Haematol. 2017;179:83&#x2013;97. doi:10.1111/bjh.14825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.14825</ArticleId></ArticleIdList></Reference><Reference><Citation>Delforge M, Selleslag D, Beguin Y, et al. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. Leuk Res. 2014;38:557&#x2013;563. doi:10.1016/j.leukres.2014.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.leukres.2014.02.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink EC, Ebert BL. The novel mechanism of lenalidomide activity. Blood. 2015;126:2366&#x2013;2369. doi:10.1182/blood-2015-07-567958.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-07-567958</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion&#x2013;dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118:3765&#x2013;3776. doi:10.1182/blood-2011-01-330126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-01-330126</ArticleId></ArticleIdList></Reference><Reference><Citation>Santini V, Almeida A, Giagounidis A, et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion&#x2013;dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol. 2016;34:2988&#x2013;2996. doi:10.1200/JCO.2015.66.0118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2015.66.0118</ArticleId></ArticleIdList></Reference><Reference><Citation>List AF, Sun Z, Verma A, et al. Lenalidomide-epoetin alfa versus lenalidomide monotherapy in myelodysplastic syndromes refractory to recombinant erythropoietin. J Clin Oncol. 2021;39:1001&#x2013;1009. doi:10.1200/jco.20.01691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.20.01691</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling AS, Guerra VA, Kennedy JA, et al. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022;140:1753&#x2013;1763. doi:10.1182/blood.2021014956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021014956</ArticleId></ArticleIdList></Reference><Reference><Citation>Jabbour E, Short NJ, Montalban-Bravo G, et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017;130:1514&#x2013;1522. doi:10.1182/blood-2017-06-788497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2017-06-788497</ArticleId></ArticleIdList></Reference><Reference><Citation>Savona MR, Odenike O, Amrein PC, et al. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 2019;6:e194&#x2013;e203. doi:10.1016/s2352-3026(19)30030-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2352-3026(19)30030-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Manero G, Santini V, Almeida A, et al. Phase III, randomized, placebo-controlled trial of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2021;39:1426&#x2013;1436. doi:10.1200/jco.20.02619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.20.02619</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochman MJ, DeZern AE. Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin? Lancet Haematol. 2022;9:e523&#x2013;e534. doi:10.1016/s2352-3026(22)00138-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2352-3026(22)00138-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Fattizzo B, Ireland R, Dunlop A, et al. Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia. Leukemia. 2021;35:3223&#x2013;3231. doi:10.1038/s41375-021-01190-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-021-01190-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl M, DeVeaux M, de Witte T, et al. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv. 2018;2:1765&#x2013;1772. doi:10.1182/bloodadvances.2018019414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2018019414</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579&#x2013;585. doi:10.1182/blood-2004-01-0338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2004-01-0338</ArticleId></ArticleIdList></Reference><Reference><Citation>Koreth J, Pidala J, Perez WS, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013;31:2662&#x2013;2670. doi:10.1200/jco.2012.46.8652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2012.46.8652</ArticleId></ArticleIdList></Reference><Reference><Citation>de Witte T, Bowen D, Robin M, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129:1753&#x2013;1762. doi:10.1182/blood-2016-06-724500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-06-724500</ArticleId></ArticleIdList></Reference><Reference><Citation>Steensma DP, Fenaux P, van Eygen K, et al. Imetelstat achieves meaningful and durable transfusion Independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study. J Clin Oncol. 2021;39:48&#x2013;56. doi:10.1200/JCO.20.01895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.20.01895</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry DH, Glaspy J, Harrup R, et al. Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: open-label, dose-selection, lead-in stage of a phase 3 study. Am J Hematol. 2022;97:174&#x2013;184. doi:10.1002/ajh.26397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26397</ArticleId></ArticleIdList></Reference><Reference><Citation>Steensma DP, Wermke M, Klimek VM, et al. Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021;35:3542&#x2013;3550. doi:10.1038/s41375-021-01328-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-021-01328-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Steensma DP, Wermke M, Klimek VM, et al. Results of a clinical trial of H3B-8800, a splicing modulator, in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML). Blood. 2019;134(Supplement_1):673&#x2013;673. doi:10.1182/blood-2019-123854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2019-123854</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein EM, Fathi AT, DiNardo CD, et al. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020;7:e309&#x2013;e319. doi:10.1016/s2352-3026(19)30284-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2352-3026(19)30284-4</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195770</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-336X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>3</Issue><PubDate><MedlineDate>2023 May-Jun 01</MedlineDate></PubDate></JournalIssue><Title>Cancer journal (Sudbury, Mass.)</Title><ISOAbbreviation>Cancer J</ISOAbbreviation></Journal><ArticleTitle>Germline Predisposition to Myelodysplastic Syndromes.</ArticleTitle><Pagination><StartPage>143</StartPage><EndPage>151</EndPage><MedlinePgn>143-151</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PPO.0000000000000660</ELocationID><Abstract><AbstractText>While germline predisposition to myelodysplastic syndromes is well-established, knowledge has advanced rapidly resulting in more cases of inherited hematologic malignancies being identified. Understanding the biological features and main clinical manifestations of hereditary hematologic malignancies is essential to recognizing and referring patients with myelodysplastic syndrome, who may underlie inherited predisposition, for appropriate genetic evaluation. Importance lies in individualized genetic counseling along with informed treatment decisions, especially with regard to hematopoietic stem cell transplant-related donor selection. Future studies will improve comprehension of these disorders, enabling better management of affected patients and their families.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gener-Ricos</LastName><ForeName>Georgina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>From the Department of Leukemia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerstein</LastName><ForeName>Yoheved S</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Clinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammond</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Department of Leukemia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiNardo</LastName><ForeName>Courtney D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>From the Department of Leukemia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer J</MedlineTA><NlmUniqueID>100931981</NlmUniqueID><ISSNLinking>1528-9117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Conflicts of Interest and Source of Funding: C.D.D. declares research support (to institution): Abbvie, Astex, Beigene, Calithera, BMS, Cleave, ImmuneOnc, and Loxo; consultant/advisory boards: Abbvie, Astellas, BMS, Daiichi-Sankyo, GenMab, GSK, Immunogen, Notable Labs, Servier, and Stemline. For the remaining authors, none were declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>11</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195770</ArticleId><ArticleId IdType="doi">10.1097/PPO.0000000000000660</ArticleId><ArticleId IdType="pii">00130404-202305000-00006</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703&#x2013;1719. doi:10.1038/s41375-022-01613-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-022-01613-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200&#x2013;1228. doi:10.1182/blood.2022015850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022015850</ArticleId></ArticleIdList></Reference><Reference><Citation>Polprasert C, Schulze I, Sekeres MA, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015;27:658&#x2013;670. doi:10.1016/j.ccell.2015.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2015.03.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Chlon TM, Stepanchick E, Hershberger CE, et al. Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell. 2021;28:1966&#x2013;1981.e6. doi:10.1016/j.stem.2021.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2021.08.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Makishima H, Saiki R, Nannya Y, et al. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. 2023;141:534&#x2013;549. doi:10.1182/blood.2022018221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022018221</ArticleId></ArticleIdList></Reference><Reference><Citation>Quesada AE, Routbort MJ, DiNardo CD, et al. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019;94:757&#x2013;766. doi:10.1002/ajh.25486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.25486</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannon SA, Routbort MJ, Montalban-Bravo G, et al. Next-generation sequencing of DDX41 in myeloid neoplasms leads to increased detection of germline alterations. Front Oncol. 2021;10:582213. doi:10.3389/fonc.2020.582213.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.582213</ArticleId></ArticleIdList></Reference><Reference><Citation>Feurstein S, Churpek JE, Walsh T, et al. Germline variants drive myelodysplastic syndrome in young adults. Leukemia. 2021;35:2439&#x2013;2444. doi:10.1038/s41375-021-01137-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-021-01137-0</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe9;bert M, Passet M, Raimbault A, et al. Germline DDX41 mutations define a significant entity within adult MDS/AML patients. Blood. 2019;134:1441&#x2013;1444. doi:10.1182/blood.2019000909.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2019000909</ArticleId></ArticleIdList></Reference><Reference><Citation>Duployez N, Largeaud L, Duchmann M, et al. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. Blood. 2022;140:756&#x2013;768. doi:10.1182/blood.2021015328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021015328</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou Dalle I, Kantarjian H, Bannon SA, et al. Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol. 2020;95:227&#x2013;229. doi:10.1002/ajh.25610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.25610</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhardt HC, Schumacher B. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet. 2012;28:128&#x2013;136. doi:10.1016/j.tig.2011.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2011.12.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Chompret A, Brugi&#xe8;res L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000;82:1932&#x2013;1937. doi:10.1054/bjoc.2000.1167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1054/bjoc.2000.1167</ArticleId></ArticleIdList></Reference><Reference><Citation>Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969;71:747&#x2013;752. doi:10.7326/0003-4819-71-4-747.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-71-4-747</ArticleId></ArticleIdList></Reference><Reference><Citation>Bougeard G, Renaux-Petel M, Flaman JM, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33:2345&#x2013;2352. doi:10.1200/JCO.2014.59.5728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2014.59.5728</ArticleId></ArticleIdList></Reference><Reference><Citation>Mai PL, Best AF, Peters JA, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016;122:3673&#x2013;3681. doi:10.1002/cncr.30248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.30248</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerdoumi Y, Aury-Landas J, Bona&#xef;ti-Pelli&#xe9; C, et al. Drastic effect of germline TP53 missense mutations in Li-Fraumeni patients. Hum Mutat. 2013;34:453&#x2013;461. doi:10.1002/humu.22254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22254</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen RJ, Curtis RE, Inskip PD, et al. The risk of developing second cancers among survivors of childhood soft tissue sarcoma. Cancer. 2005;103:2391&#x2013;2396. doi:10.1002/cncr.21040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.21040</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan M, Bannon SA, Routbort M, et al. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud. 2019;5:a003210. doi:10.1101/mcs.a003210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/mcs.a003210</ArticleId></ArticleIdList></Reference><Reference><Citation>Talwalkar SS, Yin CC, Naeem RC, et al. Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome. Arch Pathol Lab Med. 2010;134:1010&#x2013;1015. doi:10.5858/2009-0015-OA.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.5858/2009-0015-OA.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23:166&#x2013;175. doi:10.1038/13793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/13793</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen CJ, Toze CL, Koochin A, et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood. 2008;112:4639&#x2013;4645. doi:10.1182/blood-2008-05-156745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-05-156745</ArticleId></ArticleIdList></Reference><Reference><Citation>Churpek JE, Pyrtel K, Kanchi KL, et al. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood. 2015;126:2484&#x2013;2490. doi:10.1182/blood-2015-04-641100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-04-641100</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y. Oncogenic potential of the RUNX gene family: &#x2018;overview&#x2019;. Oncogene. 2004;23:4198&#x2013;4208. doi:10.1038/sj.onc.1207755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1207755</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakurai M, Kunimoto H, Watanabe N, et al. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients. Leukemia. 2014;28:2344&#x2013;2354. doi:10.1038/leu.2014.136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2014.136</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99:1364&#x2013;1372. doi:10.1182/blood.v99.4.1364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.v99.4.1364</ArticleId></ArticleIdList></Reference><Reference><Citation>Preudhomme C, Renneville A, Bourdon V, et al. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood. 2009;113:5583&#x2013;5587. doi:10.1182/blood-2008-07-168260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-07-168260</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AL, Arts P, Carmichael CL, et al. RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Adv. 2020;4:1131&#x2013;1144. doi:10.1182/bloodadvances.2019000901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2019000901</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rocco D, Melazzini F, Marconi C, et al. Mutations of RUNX1 in families with inherited thrombocytopenia. Am J Hematol. 2017;92:E86&#x2013;E88. doi:10.1002/ajh.24703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.24703</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez Botero J, Chen D, Cousin MA, et al. Clinical characteristics and platelet phenotype in a family with RUNX1 mutated thrombocytopenia. Leuk Lymphoma. 2017;58:1963&#x2013;1967. doi:10.1080/10428194.2016.1265118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10428194.2016.1265118</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanagal-Shamanna R, Loghavi S, DiNardo CD, et al. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica. 2017;102:1661&#x2013;1670. doi:10.3324/haematol.2017.167726.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2017.167726</ArticleId></ArticleIdList></Reference><Reference><Citation>Chisholm KM, Denton C, Keel S, et al. Bone marrow morphology associated with germline RUNX1 mutations in patients with familial platelet disorder with associated myeloid malignancy. Pediatr Dev Pathol. 2019;22:315&#x2013;328. doi:10.1177/1093526618822108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1093526618822108</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew E, Owen C. Familial myelodysplastic syndromes: a review of the literature. Haematologica. 2011;96:1536&#x2013;1542. doi:10.3324/haematol.2011.043422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2011.043422</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimi A, Toya T, Nannya Y, et al. Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan. Ann Oncol. 2016;27:887&#x2013;895. doi:10.1093/annonc/mdw066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdw066</ArticleId></ArticleIdList></Reference><Reference><Citation>Pippucci T, Savoia A, Perrotta S, et al. Mutations in the 5&#x2032; UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2. Am J Hum Genet. 2011;88:115&#x2013;120. doi:10.1016/j.ajhg.2010.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2010.12.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kewan T, Noss R, Godley LA, et al. Inherited thrombocytopenia caused by germline ANKRD26 mutation should be considered in young patients with suspected myelodysplastic syndrome. J Investig Med High Impact Case Rep. 2020;8:2324709620938941. doi:10.1177/2324709620938941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2324709620938941</ArticleId></ArticleIdList></Reference><Reference><Citation>Noris P, Perrotta S, Seri M, et al. Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood. 2011;117:6673&#x2013;6680. doi:10.1182/blood-2011-02-336537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-02-336537</ArticleId></ArticleIdList></Reference><Reference><Citation>Noris P, Favier R, Alessi MC, et al. ANKRD26-related thrombocytopenia and myeloid malignancies. Blood. 2013;122:1987&#x2013;1989. doi:10.1182/blood-2013-04-499319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-04-499319</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez Botero J, Oliveira JL, Chen D, et al. ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26. Blood Cancer J. 2015;5:e315. doi:10.1038/bcj.2015.41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bcj.2015.41</ArticleId></ArticleIdList></Reference><Reference><Citation>Macaulay IC, Tijssen MR, Thijssen-Timmer DC, et al. Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins. Blood. 2007;109:3260&#x2013;3269. doi:10.1182/blood-2006-07-036269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-07-036269</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Daama SA, Housawi YH, Dridi W, et al. A missense mutation in ANKRD26 segregates with thrombocytopenia. Blood. 2013;122:461&#x2013;462. doi:10.1182/blood-2013-03-489344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-03-489344</ArticleId></ArticleIdList></Reference><Reference><Citation>Bluteau D, Balduini A, Balayn N, et al. Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. J Clin Invest. 2014;124:580&#x2013;591. doi:10.1172/JCI71861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI71861</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier E, Debord C, Soenen V, et al. Baseline dysmegakaryopoiesis in inherited thrombocytopenia/platelet disorder with predisposition to haematological malignancies. Br J Haematol. 2020;189:e119&#x2013;e122. doi:10.1111/bjh.16543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.16543</ArticleId></ArticleIdList></Reference><Reference><Citation>Drazer MW, Homan CC, Yu K, et al. Clonal hematopoiesis in patients with ANKRD26 or ETV6 germline mutations. Blood Adv. 2022;6:4357&#x2013;4359. doi:10.1182/bloodadvances.2022007211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2022007211</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Paola J, Porter CC. ETV6-related thrombocytopenia and leukemia predisposition. Blood. 2019;134:663&#x2013;667. doi:10.1182/blood.2019852418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2019852418</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Paola J, Fisher MH. ETV6-related thrombocytopenia and platelet dysfunction. Platelets. 2021;32:141&#x2013;143. doi:10.1080/09537104.2020.1760229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09537104.2020.1760229</ArticleId></ArticleIdList></Reference><Reference><Citation>Faleschini M, Ammeti D, Papa N, et al. ETV6-related thrombocytopenia: dominant negative effect of mutations as common pathogenic mechanism. Haematologica. 2022;107:2249&#x2013;2254. doi:10.3324/haematol.2022.280729.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2022.280729</ArticleId></ArticleIdList></Reference><Reference><Citation>Topka S, Vijai J, Walsh MF, et al. Germline ETV6 mutations confer susceptibility to acute lymphoblastic leukemia and thrombocytopenia. PLoS Genet. 2015;11:e1005262. doi:10.1371/journal.pgen.1005262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1005262</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang MY, Churpek JE, Keel SB, et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet. 2015;47:180&#x2013;185. doi:10.1038/ng.3177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3177</ArticleId></ArticleIdList></Reference><Reference><Citation>Noetzli L, Lo RW, Lee-Sherick AB, et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet. 2015;47:535&#x2013;538. doi:10.1038/ng.3253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3253</ArticleId></ArticleIdList></Reference><Reference><Citation>Feurstein S, Godley LA. Germline ETV6 mutations and predisposition to hematological malignancies. Int J Hematol. 2017;106:189&#x2013;195. doi:10.1007/s12185-017-2259-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-017-2259-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishii R, Baskin-Doerfler R, Yang W, et al. Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia. Blood. 2021;137:364&#x2013;373. doi:10.1182/blood.2020006164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020006164</ArticleId></ArticleIdList></Reference><Reference><Citation>Churpek JE, Marquez R, Neistadt B, et al. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2016;122:304&#x2013;311. doi:10.1002/cncr.29615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.29615</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Walsh MF, Wu G, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373:2336&#x2013;2346. doi:10.1056/NEJMoa1508054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1508054</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood. 2011;118:2653&#x2013;2655. doi:10.1182/blood-2011-05-356352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-05-356352</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostergaard P, Simpson MA, Connell FC, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet. 2011;43:929&#x2013;931. doi:10.1038/ng.923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.923</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn CN, Chong CE, Carmichael CL, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet. 2011;43:1012&#x2013;1019. doi:10.1038/ng.913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.913</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickinson RE, Griffin H, Bigley V, et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood. 2011;118:2656&#x2013;2658. doi:10.1182/blood-2011-06-360313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-06-360313</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquet M, Bellann&#xe9;-Chantelot C, Tavitian S, et al. High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMAC syndrome, myelodysplasia, and acute myeloid leukemia. Blood. 2013;121:822&#x2013;829. doi:10.1182/blood-2012-08-447367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-08-447367</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsley DM, Hsu A, Dumitriu B, et al. Regulatory mutations in GATA2 associated with aplastic anemia. Blood. 2012;120:3488&#x2013;3488. doi:10.1182/blood.V120.21.3488.3488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V120.21.3488.3488</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai FY, Keller G, Kuo FC, et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature. 1994;371:221&#x2013;226. doi:10.1038/371221a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/371221a0</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinner MA, Sanchez LA, Hsu AP, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2014;123:809&#x2013;821. doi:10.1182/blood-2013-07-515528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-07-515528</ArticleId></ArticleIdList></Reference><Reference><Citation>Wlodarski MW, Hirabayashi S, Pastor V, et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood. 2016;127:1387&#x2013;1397. quiz 1518. doi:10.1182/blood-2015-09-669937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-09-669937</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozyra EJ, Pastor VB, Lefkopoulos S, et al. Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency. Leukemia. 2020;34:2673&#x2013;2687. doi:10.1038/s41375-020-0899-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-020-0899-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganapathi KA, Townsley DM, Hsu AP, et al. GATA2 deficiency&#x2013;associated bone marrow disorder differs from idiopathic aplastic anemia. Blood. 2015;125:56&#x2013;70. doi:10.1182/blood-2014-06-580340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-06-580340</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M, Tanase-Nakao K, Shima H, et al. Prevalence of germline GATA2 and SAMD9/9L variants in paediatric haematological disorders with monosomy 7. Br J Haematol. 2020;191:835&#x2013;843. doi:10.1111/bjh.17006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17006</ArticleId></ArticleIdList></Reference><Reference><Citation>West RR, Hsu AP, Holland SM, et al. Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation. Haematologica. 2014;99:276&#x2013;281. doi:10.3324/haematol.2013.090217.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2013.090217</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;d&#xf6;r C, Renneville A, Smith M, et al. Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival. Haematologica. 2012;97:890&#x2013;894. doi:10.3324/haematol.2011.054361.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2011.054361</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahoo SS, Kozyra EJ, Wlodarski MW. Germline predisposition in myeloid neoplasms: unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes. Best Pract Res Clin Haematol. 2020;33:101197. doi:10.1016/j.beha.2020.101197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beha.2020.101197</ArticleId></ArticleIdList></Reference><Reference><Citation>Tholouli E, Sturgess K, Dickinson RE, et al. In vivo T-depleted reduced-intensity transplantation for GATA2-related immune dysfunction. Blood. 2018;131:1383&#x2013;1387. doi:10.1182/blood-2017-10-811489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2017-10-811489</ArticleId></ArticleIdList></Reference><Reference><Citation>Parta M, Shah NN, Baird K, et al. Allogeneic hematopoietic stem cell transplantation for GATA2 deficiency using a busulfan-based regimen. Biol Blood Marrow Transplant. 2018;24:1250&#x2013;1259. doi:10.1016/J.BBMT.2018.01.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.BBMT.2018.01.030</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilad O, Dgany O, Noy-Lotan S, et al. Syndromes predisposing to leukemia are a major cause of inherited cytopenias in children. Haematologica. 2022;107:2081&#x2013;2095. doi:10.3324/haematol.2021.280116.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2021.280116</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas ME 3rd, Abdelhamed S, Hiltenbrand R, et al. Pediatric MDS and bone marrow failure&#x2013;associated germline mutations in SAMD9 and SAMD9L impair multiple pathways in primary hematopoietic cells. Leukemia. 2021;35:3232&#x2013;3244. doi:10.1038/s41375-021-01212-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-021-01212-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesi B, Davidsson J, Voss M, et al. Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms. Blood. 2017;129:2266&#x2013;2279. doi:10.1182/blood-2016-10-743302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-10-743302</ArticleId></ArticleIdList></Reference><Reference><Citation>Narumi S, Amano N, Ishii T, et al. SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7. Nat Genet. 2016;48:792&#x2013;797. doi:10.1038/ng.3569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3569</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen DH, Below JE, Shimamura A, et al. Ataxia-pancytopenia syndrome is caused by missense mutations in SAMD9L. Am J Hum Genet. 2016;98:1146&#x2013;1158. doi:10.1016/j.ajhg.2016.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2016.04.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz JR, Wang S, Ma J, et al. Germline SAMD9 mutation in siblings with monosomy 7 and myelodysplastic syndrome. Leukemia. 2017;31:1827&#x2013;1830. doi:10.1038/leu.2017.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2017.142</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonocore F, K&#xfc;hnen P, Suntharalingham JP, et al. Somatic mutations and progressive monosomy modify SAMD9-related phenotypes in humans. J Clin Invest. 2017;127:1700&#x2013;1713. doi:10.1172/JCI91913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI91913</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahoo SS, Pastor VB, Goodings C, et al. Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. Nat Med. 2021;27:1806&#x2013;1817. doi:10.1038/s41591-021-01511-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01511-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed IA, Farooqi MS, Vander Lugt MT, et al. Outcomes of hematopoietic cell transplantation in patients with germline SAMD9/SAMD9L mutations. Biol Blood Marrow Transplant. 2019;25:2186&#x2013;2196. doi:10.1016/j.bbmt.2019.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2019.07.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter BP, Giri N, Savage SA, et al. Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up. Haematologica. 2018;103:30&#x2013;39. doi:10.3324/haematol.2017.178111.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2017.178111</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagby G. Recent advances in understanding hematopoiesis in Fanconi anemia. F1000Res. 2018;7:105. doi:10.12688/f1000research.13213.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.13213.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez A, D&#x2019;Andrea A. Fanconi anemia pathway. Curr Biol. 2017;27:R986&#x2013;R988. doi:10.1016/j.cub.2017.07.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2017.07.043</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogliolo M, Surrall&#xe9;s J. Fanconi anemia: a model disease for studies on human genetics and advanced therapeutics. Curr Opin Genet Dev. 2015;33:32&#x2013;40. doi:10.1016/j.gde.2015.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gde.2015.07.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Auerbach AD, Adler B, Chaganti RS. Prenatal and postnatal diagnosis and carrier detection of Fanconi anemia by a cytogenetic method. Pediatrics. 1981;67:128&#x2013;135.</Citation></Reference><Reference><Citation>Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev. 2010;24:101&#x2013;122. doi:10.1016/j.blre.2010.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2010.03.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebens CL, MacMillan ML, Wagner JE. Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations. Expert Rev Hematol. 2017;10:81&#x2013;97. doi:10.1080/17474086.2016.1268048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474086.2016.1268048</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xed;o P, Navarro S, Wang W, et al. Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia. Nat Med. 2019;25:1396&#x2013;1401. doi:10.1038/s41591-019-0550-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0550-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawyer SL, Tian L, K&#xe4;hk&#xf6;nen M, et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discov. 2015;5:135&#x2013;142. doi:10.1158/2159-8290.CD-14-1156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-14-1156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganapathi KA, Austin KM, Lee CS, et al. The human Shwachman-Diamond syndrome protein, SBDS, associates with ribosomal RNA. Blood. 2007;110:1458&#x2013;1465. doi:10.1182/blood-2007-02-075184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2007-02-075184</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers KC, Bolyard AA, Otto B, et al. Variable clinical presentation of Shwachman-Diamond syndrome: update from the North American Shwachman-Diamond Syndrome Registry. J Pediatr. 2014;164:866&#x2013;870. doi:10.1016/j.jpeds.2013.11.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2013.11.039</ArticleId></ArticleIdList></Reference><Reference><Citation>Dror Y, Freedman MH. Shwachman-Diamond syndrome. Br J Haematol. 2002;118:701&#x2013;713. doi:10.1046/j.1365-2141.2002.03585.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2141.2002.03585.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy AL, Myers KC, Bowman J, et al. Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. Nat Commun. 2021;12:1334. doi:10.1038/s41467-021-21588-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21588-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton JM, Ellis SR. Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis. Hematol Oncol Clin North Am. 2009;23:261&#x2013;282. doi:10.1016/j.hoc.2009.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hoc.2009.01.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers KC, Furutani E, Weller E, et al. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study. Lancet Haematol. 2020;7:e238&#x2013;e246. doi:10.1016/S2352-3026(19)30206-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(19)30206-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Simkins A, Bannon SA, Khoury JD, et al. Diamond-Blackfan anemia predisposing to myelodysplastic syndrome in early adulthood. JCO Precis Oncol. 2017;1:1&#x2013;5. doi:10.1200/PO.17.00112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/PO.17.00112</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachos A, Ball S, Dahl N, et al. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008;142:859&#x2013;876. doi:10.1111/j.1365-2141.2008.07269.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2008.07269.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature. 1999;402:551&#x2013;555. doi:10.1038/990141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/990141</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewisch MR, Savage SA. An update on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev Hematol. 2019;12:1037&#x2013;1052. doi:10.1080/17474086.2019.1662720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474086.2019.1662720</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma R, Sahoo SS, Honda M, et al. Gain-of-function mutations in RPA1 cause a syndrome with short telomeres and somatic genetic rescue. Blood. 2022;139:1039&#x2013;1051. doi:10.1182/blood.2021011980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021011980</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter BP, Baerlocher GM, Savage SA, et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood. 2007;110:1439&#x2013;1447. doi:10.1182/blood-2007-02-075598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2007-02-075598</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage SA, Bertuch AA. The genetics and clinical manifestations of telomere biology disorders. Genet Med. 2010;12:753&#x2013;764. doi:10.1097/GIM.0b013e3181f415b5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GIM.0b013e3181f415b5</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med. 2005;352:1413&#x2013;1424. doi:10.1056/NEJMoa042980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa042980</ArticleId></ArticleIdList></Reference><Reference><Citation>De la Fuente J, Dokal I. Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatr Transplant. 2007;11:584&#x2013;594. doi:10.1111/j.1399-3046.2007.00721.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-3046.2007.00721.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Khincha PP, Wentzensen IM, Giri N, et al. Response to androgen therapy in patients with dyskeratosis congenita. Br J Haematol. 2014;165:349&#x2013;357. doi:10.1111/bjh.12748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.12748</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz MS, Corey SJ, Grimes HL, et al. ELANE mutations in cyclic and severe congenital neutropenia: genetics and pathophysiology. Hematol Oncol Clin North Am. 2013;27:19&#x2013;41. doi:10.1016/j.hoc.2012.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hoc.2012.10.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Welte K, Zeidler C, Dale DC. Severe congenital neutropenia. Semin Hematol. 2006;43:189&#x2013;195. doi:10.1053/j.seminhematol.2006.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminhematol.2006.04.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlsson G, Fasth A, Bergl&#xf6;f E, et al. Incidence of severe congenital neutropenia in Sweden and risk of evolution to myelodysplastic syndrome/leukaemia. Br J Haematol. 2012;158:363&#x2013;369. doi:10.1111/j.1365-2141.2012.09171.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2012.09171.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg PS, Zeidler C, Bolyard AA, et al. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol. 2010;150:196&#x2013;199. doi:10.1111/j.1365-2141.2010.08216.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2010.08216.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Skokowa J, Steinemann D, Katsman-Kuipers JE, et al. Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. Blood. 2014;123:2229&#x2013;2237. doi:10.1182/blood-2013-11-538025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-11-538025</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekman R, Valkhof MG, Sanders MA, et al. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood. 2012;119:5071&#x2013;5077. doi:10.1182/blood-2012-01-406116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-01-406116</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla MA, Gillio AP, Ruggeiro M, et al. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med. 1989;320:1574&#x2013;1580. doi:10.1056/NEJM198906153202402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198906153202402</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotulo GA, Beaupain B, Rialland F, et al. HSCT may lower leukemia risk in ELANE neutropenia: a before-after study from the French Severe Congenital Neutropenia Registry. Bone Marrow Transplant. 2020;55:1614&#x2013;1622. doi:10.1038/s41409-020-0800-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41409-020-0800-1</ArticleId></ArticleIdList></Reference><Reference><Citation>DeRoin L, Cavalcante de Andrade Silva M, Petras K, et al. Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders. Hum Mutat. 2022;43:950&#x2013;962. doi:10.1002/humu.24374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.24374</ArticleId></ArticleIdList></Reference><Reference><Citation>DiNardo CD, Bannon SA, Routbort M, et al. Evaluation of patients and families with concern for predispositions to hematologic malignancies within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk. 2016;16:417&#x2013;428.e2. doi:10.1016/j.clml.2016.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clml.2016.04.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Feurstein S, Trottier AM, Estrada-Merly N, et al. Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages. Blood. 2022;140:2533&#x2013;2548. doi:10.1182/blood.2022015790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022015790</ArticleId></ArticleIdList></Reference><Reference><Citation>Churpek JE, Lorenz R, Nedumgottil S, et al. Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leuk Lymphoma. 2013;54:28&#x2013;35. doi:10.3109/10428194.2012.701738.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10428194.2012.701738</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;hner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345&#x2013;1377. doi:10.1182/blood.2022016867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022016867</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195769</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-336X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>3</Issue><PubDate><MedlineDate>2023 May-Jun 01</MedlineDate></PubDate></JournalIssue><Title>Cancer journal (Sudbury, Mass.)</Title><ISOAbbreviation>Cancer J</ISOAbbreviation></Journal><ArticleTitle>Updates in Risk Stratification in Myelodysplastic Syndromes.</ArticleTitle><Pagination><StartPage>138</StartPage><EndPage>142</EndPage><MedlinePgn>138-142</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PPO.0000000000000654</ELocationID><Abstract><AbstractText>Risk stratification plays an essential role in treatment planning in myelodysplastic syndromes. For decades, the International Prognostic Scoring System and its revised version have provided unified consensus for clinical trial enrollment and design. These models relied on laboratory and cytogenetic data to estimate prognosis and dictate treatment paradigms. Critical developments in DNA sequencing techniques in recent years, as well as our growing understanding of the clonal dynamics of myelodysplastic syndromes and the role that specific mutations have in shaping disease-specific phenotypes and treatment susceptibilities, have made it possible to identify molecular markers that carry critical diagnostic and therapeutic relevance and remained unaccounted for in the older models. The Molecular International Prognostic Scoring System is a novel risk stratification model that integrates clinical, cytogenetic, and molecular data to devise a more refined prognostic tool that builds on the accuracy of the traditional models.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aguirre</LastName><ForeName>Luis E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>From the H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sallman</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Komrokji</LastName><ForeName>Rami S</ForeName><Initials>RS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer J</MedlineTA><NlmUniqueID>100931981</NlmUniqueID><ISSNLinking>1528-9117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>11</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195769</ArticleId><ArticleId IdType="doi">10.1097/PPO.0000000000000654</ArticleId><ArticleId IdType="pii">00130404-202305000-00005</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguirre LE, Komrokji R, Padron E. It is time to shift the treatment paradigm in myelodysplastic syndromes: a focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS. Best Pract Res Clin Haematol. 2021 Dec;34:101325.</Citation></Reference><Reference><Citation>Ades L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383:2239&#x2013;2252.</Citation></Reference><Reference><Citation>Mishra A, Corrales-Yepez M, Ali NA, et al. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol. 2013;88:566&#x2013;570.</Citation></Reference><Reference><Citation>Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079&#x2013;2088.</Citation></Reference><Reference><Citation>Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120:2454&#x2013;2465.</Citation></Reference><Reference><Citation>Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503&#x2013;3510.</Citation></Reference><Reference><Citation>Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113:1351&#x2013;1361.</Citation></Reference><Reference><Citation>Komrokji RS, Corrales-Yepez M, Al Ali N, et al. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer. 2012;118:2659&#x2013;2664.</Citation></Reference><Reference><Citation>Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22:538&#x2013;543.</Citation></Reference><Reference><Citation>Ogawa S. Genetics of MDS. Blood. 2019;133:1049&#x2013;1059.</Citation></Reference><Reference><Citation>Itzykson R, Solary E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia. 2013;27:1441&#x2013;1450.</Citation></Reference><Reference><Citation>Kennedy JA, Ebert BL. Clinical implications of genetic mutations in myelodysplastic syndrome. J Clin Oncol. 2017;35:968&#x2013;974.</Citation></Reference><Reference><Citation>Van den Berghe H, Cassiman JJ, David G, et al. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature. 1974;251:437&#x2013;438.</Citation></Reference><Reference><Citation>Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013;122:4021&#x2013;4034.</Citation></Reference><Reference><Citation>Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365:1384&#x2013;1395.</Citation></Reference><Reference><Citation>Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616&#x2013;3627.</Citation></Reference><Reference><Citation>Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382:140&#x2013;151.</Citation></Reference><Reference><Citation>Yoshizato T, Nannya Y, Atsuta Y, et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood. 2017;129:2347&#x2013;2358.</Citation></Reference><Reference><Citation>Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014;32:2691&#x2013;2698.</Citation></Reference><Reference><Citation>Della Porta MG, Gall&#xec; A, Bacigalupo A, et al. Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2016;34:3627&#x2013;3637.</Citation></Reference><Reference><Citation>Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376:536&#x2013;547.</Citation></Reference><Reference><Citation>Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703&#x2013;1719.</Citation></Reference><Reference><Citation>Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200&#x2013;1228.</Citation></Reference><Reference><Citation>Bersanelli M, Travaglino E, Meggendorfer M, et al. Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes. J Clin Oncol. 2021;39:1223&#x2013;1233.</Citation></Reference><Reference><Citation>Nazha A, Komrokji R, Meggendorfer M, et al. Personalized prediction model to risk stratify patients with myelodysplastic syndromes. J Clin Oncol. 2021;39:3737&#x2013;3746.</Citation></Reference><Reference><Citation>Bernard E, Tuechler H, Greenberg P, et al. Molecular International Prognostic Scoring System for myelodysplastic syndromes. NEJM Evid. 2022;1:EVIDoa2200008.</Citation></Reference><Reference><Citation>Tay K. (2019) Statistical odds &amp; ends: what is Harrell's C-index? Available at: https://statisticaloddsandends.wordpress.com/ 2019/ 10/26/what-is-Harrells-c-index/. Accessed December 1, 2022.</Citation></Reference><Reference><Citation>Aguirre LE, Al-Ali N, Ball S, et al. Validation of the Molecular International Prognostic Scoring System (IPSS-M) risk stratification model for myelodysplastic syndromes. Blood. 2022;140(Supplement 1):1125&#x2013;1127.</Citation></Reference><Reference><Citation>Sauta E, Robin M, Bersanelli M, et al. Real-world validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes. Blood. 2022;140(Supplement 1):1121&#x2013;1124.</Citation></Reference><Reference><Citation>Aguirre LE, Al-Ali N, Ball S, et al. Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Therapy-Related Myelodysplastic Syndromes. Blood. 2022;140(Supplement 1):9813&#x2013;9815.</Citation></Reference><Reference><Citation>Aguirre LE, Al-Ali N, Ball S, et al. Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes. Blood. 2022;140(Supplement 1):6909&#x2013;6911.</Citation></Reference><Reference><Citation>McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017;17:513&#x2013;527.</Citation></Reference><Reference><Citation>Kuendgen A, Nomdedeu M, Tuechler H, et al. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia. 2021;35:835&#x2013;849.</Citation></Reference><Reference><Citation>Kayser S, D&#xf6;hner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117:2137&#x2013;2145.</Citation></Reference><Reference><Citation>Bono E, McLornan D, Travaglino E, et al. Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. Leukemia. 2019;33:2495&#x2013;2505.</Citation></Reference><Reference><Citation>Fattizzo B, Serpenti F, Barcellini W, et al. Hypoplastic myelodysplastic syndromes: just an overlap syndrome? Cancers (Basel). 2021;13:132.</Citation></Reference><Reference><Citation>Estey E, Hasserjian RP, D&#xf6;hner H. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. Blood. 2022;139:323&#x2013;332.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195768</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-336X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>3</Issue><PubDate><MedlineDate>2023 May-Jun 01</MedlineDate></PubDate></JournalIssue><Title>Cancer journal (Sudbury, Mass.)</Title><ISOAbbreviation>Cancer J</ISOAbbreviation></Journal><ArticleTitle>Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms.</ArticleTitle><Pagination><StartPage>130</StartPage><EndPage>137</EndPage><MedlinePgn>130-137</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PPO.0000000000000656</ELocationID><Abstract><AbstractText>Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH management and research.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Zhuoer</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>From the Malignant Hematology Department, H. Lee Moffitt Cancer Center &amp; Research Institute, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Evan C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Adult Leukemia Program, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendez</LastName><ForeName>Lourdes M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Section of Hematology, Department of Internal Medicine, Yale Cancer Center and Smilow Cancer Hospital, Yale University School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komrokji</LastName><ForeName>Rami</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Malignant Hematology Department, H. Lee Moffitt Cancer Center &amp; Research Institute, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeidan</LastName><ForeName>Amer M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Section of Hematology, Department of Internal Medicine, Yale Cancer Center and Smilow Cancer Hospital, Yale University School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer J</MedlineTA><NlmUniqueID>100931981</NlmUniqueID><ISSNLinking>1528-9117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Conflicts of Interest and Source of Funding: Z.X., E.C.C., and L.M.M. declare no conflict of interest. A.M.Z. received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Trovagene/Cardiff Oncology, Incyte, Takeda, Novartis, Aprea, and ADC Therapeutics; participated in advisory boards and/or had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Cardiff Oncology, Takeda, Ionis, Amgen, Janssen, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, and Tyme; and served on clinical trial committees for Novartis, Abbvie, Geron, and Celgene/BMS. None of these relationships were related to this work. A.M.Z. is a Leukemia and Lymphoma Society Scholar in Clinical Research. R.K. consulted for Abbvie: speaker's bureau, advisory board; BMS: research grant, advisory board; CTI Biopharma: speaker's bureau, advisory board; Geron: consultancy; Jazz: speaker's bureau, advisory board; Novartis: advisory board; Pharma Essentia: speaker's bureau, advisory board; Servio: speaker's bureau, advisory board; Taiho: advisory board. All figures were created with BioRender.com.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>11</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195768</ArticleId><ArticleId IdType="doi">10.1097/PPO.0000000000000656</ArticleId><ArticleId IdType="pii">00130404-202305000-00004</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703&#x2013;1719.</Citation></Reference><Reference><Citation>Saiki R, Momozawa Y, Nannya Y, et al. Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis. Nat Med. 2021;27:1239&#x2013;1249.</Citation></Reference><Reference><Citation>Jacobs KB, Yeager M, Zhou W, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet. 2012;44:651&#x2013;658.</Citation></Reference><Reference><Citation>Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;26:2488&#x2013;2498.</Citation></Reference><Reference><Citation>Genovese G, K&#xe4;hler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477&#x2013;2487.</Citation></Reference><Reference><Citation>Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20:1472&#x2013;1478.</Citation></Reference><Reference><Citation>Jaiswal S. Clonal hematopoiesis and non-hematologic disorders. Blood. 2020;136:1606&#x2013;1614.</Citation></Reference><Reference><Citation>DeZern AE, Malcovati L, Ebert BL. CHIP, CCUS, and other acronyms: definition, implications, and impact on practice. Am Soc Clin Oncol Educ Book. 2019;39:400&#x2013;410.</Citation></Reference><Reference><Citation>Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9&#x2013;16.</Citation></Reference><Reference><Citation>Malcovati L, Gall&#xec; A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017;129:3371&#x2013;3378.</Citation></Reference><Reference><Citation>Gall&#xec; A, Todisco G, Catamo E, et al. Relationship between clone metrics and clinical outcome in clonal cytopenia. Blood. 2021;138:965&#x2013;976.</Citation></Reference><Reference><Citation>Cargo CA, Rowbotham N, Evans PA, et al. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood. 2015;126:2362&#x2013;2365.</Citation></Reference><Reference><Citation>Gibson CJ, Steensma DP. New insights from studies of clonal hematopoiesis. Clin Cancer Res. 2018;24:4633&#x2013;4642.</Citation></Reference><Reference><Citation>Zink F, Stacey SN, Norddahl GL, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017;130:742&#x2013;752.</Citation></Reference><Reference><Citation>Bhattacharya R, Zekavat SM, Haessler J, et al. Clonal hematopoiesis is associated with higher risk of stroke. Stroke. 2022;53:788&#x2013;797.</Citation></Reference><Reference><Citation>McKerrell T, Park N, Moreno T, et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep. 2015;10:1239&#x2013;1245.</Citation></Reference><Reference><Citation>Van Zeventer IA, de Graaf AO, Wouters HJCM, et al. Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals. Blood. 2020;135:1161&#x2013;1170.</Citation></Reference><Reference><Citation>Acuna-Hidalgo R, Sengul H, Steehouwer M, et al. Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life. Am J Hum Genet. 2017;101:50&#x2013;64.</Citation></Reference><Reference><Citation>Buscarlet M, Provost S, Zada YF, et al. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood. 2017;130:753&#x2013;762.</Citation></Reference><Reference><Citation>Arends CM, Galan-Sousa J, Hoyer K, et al. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia. 2018;32:1908&#x2013;1919.</Citation></Reference><Reference><Citation>Young AL, Wong TN, Hughes AE, et al. Quantifying ultra-rare pre-leukemic clones via targeted error-corrected sequencing. Leukemia. 2015;29:1608&#x2013;1611.</Citation></Reference><Reference><Citation>Abelson S, Collord G, Ng SWK, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559:400&#x2013;404.</Citation></Reference><Reference><Citation>Young AL, Challen GA, Birmann BM, et al. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016;7:12484.</Citation></Reference><Reference><Citation>Rossi DJ, Jamieson CH, Weissman IL. Stems cells and the pathways to aging and cancer. Cell. 2008;132:681&#x2013;696.</Citation></Reference><Reference><Citation>Feusier JE, Arunachalam S, Tashi T, et al. Large-scale identification of clonal hematopoiesis and mutations recurrent in blood cancers. Blood Cancer Discov. 2021;2:226&#x2013;237.</Citation></Reference><Reference><Citation>Bailey MH, Tokheim C, Porta-Pardo E, et al. Comprehensive characterization of cancer driver genes and mutations. Cell. 2018;173:371&#x2013;385.e18.</Citation></Reference><Reference><Citation>Watson CJ, Papula AL, Poon GYP, et al. The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science (1979). 2020;367:1449&#x2013;1454.</Citation></Reference><Reference><Citation>Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69:S4&#x2013;S9.</Citation></Reference><Reference><Citation>Franceschi C, Zaikin A, Gordleeva S, et al. Inflammaging 2018: an update and a model. Semin Immunol. 2018;40:1&#x2013;5.</Citation></Reference><Reference><Citation>Xie Z, Zeidan AM. CHIPing away the progression potential of CHIP: a new reality in the making. Blood Rev. 2023;58:101001. doi:10.1016/j.blre.2022.101001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2022.101001</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell E, Spencer Chapman M, Williams N, et al. Clonal dynamics of haematopoiesis across the human lifespan. Nature. 2022;606:343&#x2013;350. doi:10.1038/s41586-022-04786-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04786-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabre MA, de Almeida JG, Fiorillo E, et al. The longitudinal dynamics and natural history of clonal haematopoiesis. Nature. 2022;606:335&#x2013;342.</Citation></Reference><Reference><Citation>Young AL, Tong RS, Birmann BM, et al. Clonal hematopoiesis and risk of acute myeloid leukemia. Haematologica. 2019;104:2410&#x2013;2417.</Citation></Reference><Reference><Citation>Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111&#x2013;121.</Citation></Reference><Reference><Citation>Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378:241&#x2013;249.</Citation></Reference><Reference><Citation>Landgren O, Albitar M, Ma W, et al. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med. 2009;360:659&#x2013;667.</Citation></Reference><Reference><Citation>Niroula A, Sekar A, Murakami MA, et al. Distinction of lymphoid and myeloid clonal hematopoiesis. Nat Med. 2021;27:1921&#x2013;1927.</Citation></Reference><Reference><Citation>Kwok B, Hall JM, Witte JS, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015;126:2355&#x2013;2361.</Citation></Reference><Reference><Citation>Baer C, Pohlkamp C, Haferlach C, et al. Molecular patterns in cytopenia patients with or without evidence of myeloid neoplasm-a comparison of 756 cases. Leukemia. 2018;32:2295&#x2013;2298.</Citation></Reference><Reference><Citation>Van Zeventer IA, de Graaf AO, Koorenhof-Scheele TN, et al. Monocytosis and its association with clonal hematopoiesis in community-dwelling individuals. Blood Adv. 2022;6:4174&#x2013;4184.</Citation></Reference><Reference><Citation>Cargo C, Cullen M, Taylor J, et al. The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis. Blood. 2019;133:1325&#x2013;1334.</Citation></Reference><Reference><Citation>Gillis NK, Ball M, Zhang Q, et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017;18:112&#x2013;121.</Citation></Reference><Reference><Citation>Takahashi K, Wang F, Kantarjian H, et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017;18:100&#x2013;111.</Citation></Reference><Reference><Citation>Bolton KL, Ptashkin RN, Gao T, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020;52:1219&#x2013;1226.</Citation></Reference><Reference><Citation>Coombs CC, Zehir A, Devlin SM, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017;21:374&#x2013;382.e4.</Citation></Reference><Reference><Citation>Gibson CJ, Lindsley RC, Tchekmedyian V, et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol. 2017;35:1598&#x2013;1605.</Citation></Reference><Reference><Citation>Kwan TT, Oza AM, Tinker AV, et al. Preexisting TP53-variant clonal hematopoiesis and risk of secondary myeloid neoplasms in patients with high-grade ovarian cancer treated with rucaparib. JAMA Oncol. 2021;7:1772&#x2013;1781.</Citation></Reference><Reference><Citation>Sperling AS, Guerra VA, Kennedy JA, et al. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022;140:1753&#x2013;1763.</Citation></Reference><Reference><Citation>Husby S, Favero F, Nielsen C, et al. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study. Leukemia. 2020;34:3256&#x2013;3268. doi:10.1038/s41375-020-0795-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-020-0795-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong TN, Miller CA, Jotte MRM, et al. Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nat Commun. 2018;9:455.</Citation></Reference><Reference><Citation>Miller PG, Sperling AS, Brea EJ, et al. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021;5:2982&#x2013;2986.</Citation></Reference><Reference><Citation>Saini NY, Swoboda DM, Greenbaum U, et al. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov. 2022;3:385&#x2013;393.</Citation></Reference><Reference><Citation>Ortmann CA, Dorsheimer L, Abou-El-Ardat K, et al. Functional dominance of CHIP-mutated hematopoietic stem cells in patients undergoing autologous transplantation. Cell Rep. 2019;27:2022&#x2013;2028.e3.</Citation></Reference><Reference><Citation>Chitre S, St&#xf6;lzel F, Cuthill K, et al. Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation. Leukemia. 2018;32:2020&#x2013;2024.</Citation></Reference><Reference><Citation>Mouhieddine TH, Sperling AS, Redd R, et al. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020;11:2996.</Citation></Reference><Reference><Citation>Wudhikarn K, Padrnos L, Lasho T, et al. Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. Am J Hematol. 2021;96:E157&#x2013;E162.</Citation></Reference><Reference><Citation>Gibson CJ, Kim HT, Zhao L, et al. Donor clonal hematopoiesis and recipient outcomes after transplantation. J Clin Oncol. 2022;40:189&#x2013;201.</Citation></Reference><Reference><Citation>Teipel R, Kroschinsky F, Kramer M, et al. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Adv. 2022;6:1941&#x2013;1946.</Citation></Reference><Reference><Citation>Frick M, Chan W, Arends CM, et al. Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2019;37:375&#x2013;385.</Citation></Reference><Reference><Citation>Oran B, Champlin RE, Wang F, et al. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022;36:257&#x2013;262.</Citation></Reference><Reference><Citation>Kar SP, Quiros PM, Gu M, et al. Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis. Nat Genet. 2022;54:1155&#x2013;1166.</Citation></Reference><Reference><Citation>Kim PG, Niroula A, Shkolnik V, et al. Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis. J Exp Med. 2021;218:e20211872.</Citation></Reference><Reference><Citation>Miller PG, Qiao D, Rojas-Quintero J, et al. Association of clonal hematopoiesis with chronic obstructive pulmonary disease. Blood. 2022;139:357&#x2013;368.</Citation></Reference><Reference><Citation>Dawoud AAZ, Gilbert RD, Tapper WJ, et al. Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease. Leukemia. 2021;36:507&#x2013;515.</Citation></Reference><Reference><Citation>Savola P, Lundgren S, Ker&#xe4;nen MAI, et al. Clonal hematopoiesis in patients with rheumatoid arthritis. Blood Cancer J. 2018;8:69.</Citation></Reference><Reference><Citation>Arends CM, Weiss M, Christen F, et al. Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody&#x2013;associated vasculitis. Haematologica. 2020;105:E264&#x2013;E267.</Citation></Reference><Reference><Citation>Bouzid H, Belk JA, Jan M, et al. Clonal hematopoiesis is associated with protection from Alzheimer's disease. medRxiv. 2021. doi:10.1101/2021.12.10.21267552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.10.21267552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolton KL, Gillis NK, Coombs CC, et al. Managing clonal hematopoiesis in patients with solid tumors. J Clin Oncol. 2019;37:7&#x2013;11.</Citation></Reference><Reference><Citation>Bolton KL, Zehir A, Ptashkin RN, et al. The clinical management of clonal hematopoiesis: creation of a clonal hematopoiesis clinic. Hematol Oncol Clin North Am. 2020;34:357&#x2013;367. doi:10.1016/j.hoc.2019.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hoc.2019.11.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Steensma DP, Bolton KL. What to tell your patient with clonal hematopoiesis and why: insights from 2 specialized clinics. Blood. 2020;136:1623&#x2013;1631.</Citation></Reference><Reference><Citation>Uy GL, Duncavage EJ, Chang GS, et al. Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia. 2016;31:872&#x2013;881.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195767</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-336X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>3</Issue><PubDate><MedlineDate>2023 May-Jun 01</MedlineDate></PubDate></JournalIssue><Title>Cancer journal (Sudbury, Mass.)</Title><ISOAbbreviation>Cancer J</ISOAbbreviation></Journal><ArticleTitle>Updates in Classification of Myelodysplastic Syndrome.</ArticleTitle><Pagination><StartPage>122</StartPage><EndPage>129</EndPage><MedlinePgn>122-129</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PPO.0000000000000659</ELocationID><Abstract><AbstractText>Myelodysplastic syndrome includes a broad range of myeloid neoplasms characterized by cytopenia and morphologic dysplasia. Recently, 2 new classification systems emerged to further define how these diseases are diagnosed and risk stratified. This review compares these models, provides detailed approaches, and reveals practical ways to move forward in clinical practice of myelodysplastic syndrome diagnosis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Mina L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>From the Yale University, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasserjian</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer J</MedlineTA><NlmUniqueID>100931981</NlmUniqueID><ISSNLinking>1528-9117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>11</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195767</ArticleId><ArticleId IdType="doi">10.1097/PPO.0000000000000659</ArticleId><ArticleId IdType="pii">00130404-202305000-00003</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang SA, Ok CY, Kim AS, et al. Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. Am J Hematol. 2021;96:E420&#x2013;E423.</Citation></Reference><Reference><Citation>Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9&#x2013;16.</Citation></Reference><Reference><Citation>Valent P, Orazi A, Steensma DP, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017;8:73483&#x2013;73500.</Citation></Reference><Reference><Citation>Greenberg PL, Tuechler H, Schanz J, et al. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood. 2016;128:2096&#x2013;2097.</Citation></Reference><Reference><Citation>Steensma DP. Dysplasia has a differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. Curr Hematol Malig Rep. 2012;7:310&#x2013;320.</Citation></Reference><Reference><Citation>Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. IARC: Lyon, France; 2017.</Citation></Reference><Reference><Citation>Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200&#x2013;1228.</Citation></Reference><Reference><Citation>Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703&#x2013;1719.</Citation></Reference><Reference><Citation>Malcovati L, Galli A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017;129:3371&#x2013;3378.</Citation></Reference><Reference><Citation>Estey E, Hasserjian RP, Dohner H. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. Blood. 2022;139:323&#x2013;332.</Citation></Reference><Reference><Citation>DiNardo CD, Garcia-Manero G, Kantarjian HM. Time to blur the blast boundaries. Cancer. 2022;128:1568&#x2013;1570.</Citation></Reference><Reference><Citation>Calvo X, Garcia-Gisbert N, Parraga I, et al. Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features. Blood Adv. 2020;4:5285&#x2013;5296.</Citation></Reference><Reference><Citation>Cargo C, Cullen M, Taylor J, et al. The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis. Blood. 2019;133:1325&#x2013;1334.</Citation></Reference><Reference><Citation>Bersanelli M, Travaglino E, Meggendorfer M. Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes. J Clin Oncol. 2021;39:1223&#x2013;1233.</Citation></Reference><Reference><Citation>Nagata Y, Zhao R, Awada H, et al. Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes. Blood. 2020;136:2249&#x2013;2262.</Citation></Reference><Reference><Citation>Bernard E, Tuechler T, Greenberg PL, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1:1&#x2013;14.</Citation></Reference><Reference><Citation>Woll PS, Kjallquist U, Chowdhury O, et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell. 2014;25:794&#x2013;808.</Citation></Reference><Reference><Citation>Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020;136:157&#x2013;170.</Citation></Reference><Reference><Citation>Gerstung M, Pellagatti A, Malcovati L, et al. Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndrome. Nat Commun. 2015;6:5901.</Citation></Reference><Reference><Citation>Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376:536&#x2013;547.</Citation></Reference><Reference><Citation>Haase D, Stevenson KE, Neuberg D. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019;33:1747&#x2013;1758.</Citation></Reference><Reference><Citation>Weinberg OK, Siddon A, Madanat YF, et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022;6:2847&#x2013;2853.</Citation></Reference><Reference><Citation>Sallman DA, Komrokji R, Vaupel C, et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016;30:666&#x2013;673.</Citation></Reference><Reference><Citation>Shallis RM, Daver NG, Altman JK, et al. TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity. Cancer. 2023;129:175&#x2013;180.</Citation></Reference><Reference><Citation>Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549&#x2013;1556.</Citation></Reference><Reference><Citation>Grob T, Al Hinai ASA, Sanders MA, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022;139:2347&#x2013;2354. doi:10.1182/blood.2021014472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021014472</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia. 2007;21:1436&#x2013;1441.</Citation></Reference><Reference><Citation>Fattizzo B, Ireland R, Dunlop A, et al. Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia. Leukemia. 2021;35:3223&#x2013;3231.</Citation></Reference><Reference><Citation>Huang T-C, Ko B-S, Tang J-L, et al. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by international prognostic scoring system, cytogenetic and genetic studies. Leukemia. 2008;22:544&#x2013;550.</Citation></Reference><Reference><Citation>Yao C-Y, Hou H-A, Lin T-Y, et al. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS). Oncotarget. 2016;7:63177&#x2013;63188.</Citation></Reference><Reference><Citation>Nazha A, Seastone D, Radivoyevitch T, et al. Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes. Haematologica. 2015;100:e434&#x2013;e437.</Citation></Reference><Reference><Citation>Zhao Y, Guo J, Zhao S, et al. Bone marrow fibrosis at diagnosis and during the course of disease is associated with TP53 mutations and adverse prognosis in primary myelodysplastic syndrome. Cancers (Basel). 2022;14:2984.</Citation></Reference><Reference><Citation>Shahidi R, Mohamed M, Sharma A, et al. Bone marrow fibrosis impact on response to azacytidine in myelodysplastic syndromes. Pathology. 2022;54:763&#x2013;767.</Citation></Reference><Reference><Citation>Fu B, Jaso JM, Sargent RL. Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. Mod Pathol. 2014;27:681&#x2013;689.</Citation></Reference><Reference><Citation>Margolskee E, Hasserjian RP, Hassane D, et al. Myelodysplastic syndrome, unclassifiable (MDS-U) with 1% blasts is a distinct subgroup of MDS-U with a poor prognosis. Am J Clin Pathol. 2017;148:49&#x2013;57.</Citation></Reference><Reference><Citation>Takahashi K, Wang F, Kantarjian H, et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017;18:100&#x2013;111.</Citation></Reference><Reference><Citation>Kanagal-Shamanna R. The emerging role of hematopathologists and molecular pathologists in detection, monitoring and management of myeloid neoplasms with germline predisposition. Curr Hematol Malig Rep. 2021;16:336&#x2013;344.</Citation></Reference><Reference><Citation>Babushok DV, Bessler M. Genetic predisposition syndromes; when should they be considered in the work-up of MDS? Best Pract Res Clin Haematol. 2015;28:55&#x2013;68.</Citation></Reference><Reference><Citation>Wintering A, Dvorak CC, Stieglitz E, et al. Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment. Blood Adv. 2021;5:4783&#x2013;4793.</Citation></Reference><Reference><Citation>Baumann I, Fuhrer M, Behrendt S, et al. Morphological differentiation of severe aplastic anaemia from hypocellular refractory cytopenia of childhood: reproducibility of histopathological diagnostic criteria. Histopathology. 2012;61:10&#x2013;17.</Citation></Reference><Reference><Citation>Hasegawa D. The current perspective of low-grade myelodysplastic syndrome in children. Int J Hematol. 2016;103:360&#x2013;364.</Citation></Reference><Reference><Citation>Dolan MM, Singleton TP, Neglia J, et al. Aplastic anemia and monosomy 7&#x2013;associated dysmegakaryocytopoiesis. Am J Clin Pathol. 2006;126:925&#x2013;930.</Citation></Reference><Reference><Citation>Locatelli F, Strahm B. How I treat myelodysplastic syndromes of childhood. Blood. 2018;131:1406&#x2013;1414.</Citation></Reference><Reference><Citation>Sahoo SS, Pastor VB, Goodings C, et al. Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. Nat Med. 2021;27:1806&#x2013;1817.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195766</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-336X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>3</Issue><PubDate><MedlineDate>2023 May-Jun 01</MedlineDate></PubDate></JournalIssue><Title>Cancer journal (Sudbury, Mass.)</Title><ISOAbbreviation>Cancer J</ISOAbbreviation></Journal><ArticleTitle>Epidemiology and Pathogenesis of Myelodysplastic Syndrome.</ArticleTitle><Pagination><StartPage>111</StartPage><EndPage>121</EndPage><MedlinePgn>111-121</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PPO.0000000000000665</ELocationID><Abstract><AbstractText>Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal hematopoiesis (CH) to CH of indeterminate potential, clonal cytopenia of unknown significance, to frank MDS. The molecular heterogeneity seen in MDS is highly complex and includes mutations of genes involved in splicing machinery, epigenetic regulation, differentiation, and cell signaling. Recent advances in the understanding of the molecular landscape of MDS have led to the development of improved risk assessment tools and novel therapies. Therapies targeting the underlying pathophysiology will hopefully further expand the armamentarium of MDS therapeutics, bringing us closer to a more individualized therapeutic approach based on the unique molecular profile of each patient and eventually improving the outcomes of patients with MDS. We review the epidemiology of MDS and the newly described MDS precursor conditions CH, CH of indeterminate potential, and CCUS. We then discuss central aspects of MDS pathophysiology and outline specific strategies targeting hallmarks of MDS pathophysiology, including ongoing clinical trials examining the efficacy of these therapeutic modalities.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rotter</LastName><ForeName>Lara K</ForeName><Initials>LK</Initials></Author><Author ValidYN="Y"><LastName>Shimony</LastName><ForeName>Shai</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shallis</LastName><ForeName>Rory M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Zeidan</LastName><ForeName>Amer M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Stahl</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer J</MedlineTA><NlmUniqueID>100931981</NlmUniqueID><ISSNLinking>1528-9117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Conflicts of Interest and Source of Funding: M.S. served on the advisory board for Novartis, Kymera, Sierra Oncology, GSK, and Rigel; consulted for Boston Consulting and Dedham group and participated in GME activity for Novartis, Curis Oncology, Haymarket Media, and Clinical Care Options. A.M.Z. is a Leukemia and Lymphoma Society Scholar in Clinical Research. A.M.Z. received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Cardiff Oncology, Incyte, Takeda, Novartis, Shattuck Labs, Geron, Aprea, and ADC Therapeutics. A.M.Z. participated in advisory boards and/or had a consultancy with and received honoraria from AbbVie, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Servier, Boehringer-Ingelheim, Novartis, Astellas, Daiichi Sankyo, Geron, Taiho, Seattle Genetics, BeyondSpring, Takeda, Ionis, Amgen, Janssen, Genentech, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, Notable, Orum, Mendus, Foran, Syros, and Tyme. A.M.Z. served on clinical trial committees for Novartis, Abbvie, Gilead, Syros, BioCryst, Abbvie, ALX Oncology, Geron, and Celgene/BMS. A.M.Z. received travel support for meetings from Pfizer, Novartis, and Cardiff Oncology. For the remaining authors, none were declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>11</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195766</ArticleId><ArticleId IdType="doi">10.1097/PPO.0000000000000665</ArticleId><ArticleId IdType="pii">00130404-202305000-00002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361:1872&#x2013;1885.</Citation></Reference><Reference><Citation>Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383:1358&#x2013;1374.</Citation></Reference><Reference><Citation>Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241&#x2013;247.</Citation></Reference><Reference><Citation>Bera R, Chiu MC, Huang YJ, et al. DNMT3A mutants provide proliferating advantage with augmentation of self-renewal activity in the pathogenesis of AML in KMT2A-PTD&#x2013;positive leukemic cells. Oncogene. 2020;9:7.</Citation></Reference><Reference><Citation>Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, et al. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer. 2020;126:765&#x2013;774.</Citation></Reference><Reference><Citation>Wang L, Ozark PA, Smith ER, et al. TET2 coactivates gene expression through demethylation of enhancers. Sci Adv. 2018;4:eaau6986.</Citation></Reference><Reference><Citation>Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20:11&#x2013;24.</Citation></Reference><Reference><Citation>Kosmider O, Gelsi-Boyer V, Cheok M, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009;114:3285&#x2013;3291.</Citation></Reference><Reference><Citation>Sulkowski PL, Oeck S, Dow J, et al. Oncometabolites suppress DNA repair by disrupting local chromatin signalling. Nature. 2020;582:586&#x2013;591.</Citation></Reference><Reference><Citation>DiNardo CD, Jabbour E, Ravandi F, et al. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. 2016;30:980&#x2013;984.</Citation></Reference><Reference><Citation>Ye D, Ma S, Xiong Y, et al. R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. Cancer Cell. 2013;23:274&#x2013;276.</Citation></Reference><Reference><Citation>Yamamoto K, Goyama S, Asada S, et al. A histone modifier, ASXL1, interacts with NONO and is involved in paraspeckle formation in hematopoietic cells. Cell Rep. 2021;36:109576.</Citation></Reference><Reference><Citation>Yannakou CK, Jones K, McBean M, et al. ASXL1 c.1934dup;p.Gly646Trpfs*12-a true somatic alteration requiring a new approach. Blood. Cancer J. 2017;7:656.</Citation></Reference><Reference><Citation>Della Porta MG, Gall&#xec; A, Bacigalupo A, et al. Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2016;34:3627&#x2013;3637.</Citation></Reference><Reference><Citation>Abdel-Wahab O, Adli M, LaFave LM, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 2012;22:180&#x2013;193.</Citation></Reference><Reference><Citation>Boultwood J, Perry J, Pellagatti A, et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia. 2010;24:1062&#x2013;1065.</Citation></Reference><Reference><Citation>Fisher CL, Randazzo F, Humphries RK, et al. Characterization of Asxl1, a murine homolog of additional sex combs, and analysis of the Asx-like gene family. Gene. 2006;369:109&#x2013;118.</Citation></Reference><Reference><Citation>Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the international working Group for the prognosis of MDS. Blood. 2020;136:157&#x2013;170.</Citation></Reference><Reference><Citation>Singh S, Ahmed D, Dolatshad H, et al. SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications. Leukemia. 2020;34:2525&#x2013;2530.</Citation></Reference><Reference><Citation>Malcovati L, Karimi M, Papaemmanuil E, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015;126:233&#x2013;241.</Citation></Reference><Reference><Citation>Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011;118:6239&#x2013;6246.</Citation></Reference><Reference><Citation>Hosono N. Genetic abnormalities and pathophysiology of MDS. Int J Clin Oncol. 2019;24:885&#x2013;892.</Citation></Reference><Reference><Citation>Zhao X, Tian X, Kajigaya S, et al. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS. Br J Haematol. 2016;175:427&#x2013;439.</Citation></Reference><Reference><Citation>Davis RE, Greenberg PL. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. Leuk Res. 1998;22:767&#x2013;777.</Citation></Reference><Reference><Citation>Cull AH, Snetsinger B, Buckstein R, et al. Tet2 restrains inflammatory gene expression in macrophages. Exp Hematol. 2017;55:56&#x2013;70.e13.</Citation></Reference><Reference><Citation>Smith MA, Choudhary GS, Pellagatti A, et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nat Cell Biol. 2019;21:640&#x2013;650.</Citation></Reference><Reference><Citation>Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391&#x2013;2405.</Citation></Reference><Reference><Citation>Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292&#x2013;2302.</Citation></Reference><Reference><Citation>Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937&#x2013;951.</Citation></Reference><Reference><Citation>Myelodysplastic syndromes (MDS) people alive with cancer (U.S. prevalence) on January 1, 2019.</Citation></Reference><Reference><Citation>Cogle CR, Craig BM, Rollison DE, et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011;117:7121&#x2013;7125.</Citation></Reference><Reference><Citation>Myelodysplastic syndromes (MDS), SEER incidence rates by age at diagnosis, 2015&#x2013;2019. Available at: https://seer.cancer.gov/statistics-network/explorer/application.html?site=409&amp;data_type=1&amp;graph_type=3&amp;compareBy=sex&amp;chk_sex_1=1&amp;hdn_rate_type=1&amp;race=1&amp;advopt_precision=1&amp;advopt_show_ci=on&amp;advopt_show_count=on&amp;hdn_view=0&amp;advopt_show_apc=on&amp;advopt_display=2#graphArea. Accessed March 5, 2023.</Citation></Reference><Reference><Citation>Myelodysplastic syndromes (MDS), recent trends in SEER age-adjusted incidence rates, 2001&#x2013;2019. Available at: https://seer.cancer.gov/statistics-network/explorer/application.html?site=409&amp;data_type=1&amp;graph_type=2&amp;compareBy=sex&amp;chk_sex_3=3&amp;chk_sex_2=2&amp;hdn_rate_type=1&amp;race=1&amp;age_range=1&amp;hdn_stage=101&amp;advopt_precision=1&amp;advopt_show_ci=on&amp;hdn_view=0&amp;advopt_show_apc=on&amp;advopt_display=2#graphArea. Accessed March 5, 2023.</Citation></Reference><Reference><Citation>Ohgami RS, Shahmarvand N. del (5q) solely in myelodysplastic syndrome. Atlas Genet Cytogenet Oncol Haematol. 2016. Available at: http://atlasgeneticsoncology.org/haematological/1134/del-(5q)-solely-in-myelodysplastic-syndrome. Accessed March 5, 2023.</Citation></Reference><Reference><Citation>Myelodysplastic syndromes (MDS), SEER 5-year age-adjusted incidence rates, 2015&#x2013;2019. Available at: https://seer.cancer.gov/statistics-network/explorer/application.html?site=409&amp;data_type=1&amp;graph_type=10&amp;compareBy=race&amp;chk_race_1=1&amp;chk_race_5=5&amp;chk_race_4=4&amp;chk_race_3=3&amp;chk_race_2=2&amp;series=9&amp;sex=1&amp;age_range=1&amp;hdn_stage=101&amp;advopt_precision=1&amp;advopt_show_ci=on&amp;advopt_show_count=on&amp;hdn_view=0&amp;advopt_show_apc=on&amp;advopt_display=2#graphArea. Accessed March 5, 2023.</Citation></Reference><Reference><Citation>Bhatia S, Krailo MD, Chen Z, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the Children's Oncology Group. Blood. 2007;109:46&#x2013;51.</Citation></Reference><Reference><Citation>Zeidan AM, Shallis RM, Wang R, et al. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1&#x2013;15.</Citation></Reference><Reference><Citation>Iwanaga M, Hsu WL, Soda M, et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol. 2011;29:428&#x2013;434.</Citation></Reference><Reference><Citation>Nisse C, Haguenoer JM, Grandbastien B, et al. Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France. Br J Haematol. 2001;112:927&#x2013;935.</Citation></Reference><Reference><Citation>Strom SS, Gu Y, Gruschkus SK, et al. Risk factors of myelodysplastic syndromes: a case-control study. Leukemia. 2005;19:1912&#x2013;1918.</Citation></Reference><Reference><Citation>Schnatter AR, Glass DC, Tang G, et al. Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. J Natl Cancer Inst. 2012;104:1724&#x2013;1737.</Citation></Reference><Reference><Citation>Sperling AS, Leventhal M, Gibson CJ, et al. Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of de novo MDS. Leuk Lymphoma. 2020;61:728&#x2013;731.</Citation></Reference><Reference><Citation>Shallis RM, Gore SD. Agent Orange and dioxin-induced myeloid leukemia: a weaponized vehicle of leukemogenesis. Leuk Lymphoma. 2022;63:1534&#x2013;1543.</Citation></Reference><Reference><Citation>Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9&#x2013;16.</Citation></Reference><Reference><Citation>DeZern AE, Malcovati L, Ebert BL. CHIP, CCUS, and other acronyms: definition, implications, and impact on practice. Am Soc Clin Oncol Educ Book. 2019;39:400&#x2013;410.</Citation></Reference><Reference><Citation>Xie Z, Zeidan AM. CHIPing away the progression potential of CHIP: a new reality in the making. Blood Rev. 2022;58:101001.</Citation></Reference><Reference><Citation>Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366:eaan4673.</Citation></Reference><Reference><Citation>Silver AJ, Jaiswal S. Clonal hematopoiesis: pre-cancer PLUS. Adv Cancer Res. 2019;141:85&#x2013;128.</Citation></Reference><Reference><Citation>Steensma DP. Clinical consequences of clonal hematopoiesis of indeterminate potential. Blood Adv. 2018;2:3404&#x2013;3410.</Citation></Reference><Reference><Citation>Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488&#x2013;2498.</Citation></Reference><Reference><Citation>Genovese G, K&#xe4;hler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477&#x2013;2487.</Citation></Reference><Reference><Citation>Jiang L, Wang L, Shen C, et al. Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes. Am J Cancer Res. 2020;10:4476&#x2013;4487.</Citation></Reference><Reference><Citation>Malcovati L, Gall&#xec; A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017;129:3371&#x2013;3378.</Citation></Reference><Reference><Citation>Weeks LD, Niroula A, Neuberg D, et al. Prediction of risk for myeloid malignancy in clonal hematopoiesis. ASH Publications; 2022.</Citation></Reference><Reference><Citation>Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013;122:4021&#x2013;4034.</Citation></Reference><Reference><Citation>Chattopadhyaya S, Ghosal S. DNA methylation: a saga of genome maintenance in hematological perspective. Hum Cell. 2022;35:448&#x2013;461.</Citation></Reference><Reference><Citation>Russler-Germain DA, Spencer DH, Young MA, et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell. 2014;25:442&#x2013;454.</Citation></Reference><Reference><Citation>Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376:536&#x2013;547.</Citation></Reference><Reference><Citation>Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014;32:2691&#x2013;2698.</Citation></Reference><Reference><Citation>Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223&#x2013;232.</Citation></Reference><Reference><Citation>FDA approves oral combination of decitabine and cedazuridine for myelodysplastic syndromes. 2020. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-oral-combination-decitabine-and-cedazuridine-myelodysplastic-syndromes. Accessed March 5, 2023.</Citation></Reference><Reference><Citation>Ma J, Ge Z. Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network Meta-analysis. Front Pharmacol. 2021;12:701690.</Citation></Reference><Reference><Citation>Chen LL, Lin HP, Zhou WJ, et al. SNIP1 recruits TET2 to regulate c-MYC target genes and cellular DNA damage response. Cell Rep. 2018;25:1485&#x2013;500.e4.</Citation></Reference><Reference><Citation>Quivoron C, Couronn&#xe9; L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20:25&#x2013;38.</Citation></Reference><Reference><Citation>Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496&#x2013;2506.</Citation></Reference><Reference><Citation>Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25:1147&#x2013;1152.</Citation></Reference><Reference><Citation>Guan Y, Greenberg EF, Hasipek M, et al. Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. Commun Biol. 2020;3:493.</Citation></Reference><Reference><Citation>Agathocleous M, Meacham CE, Burgess RJ, et al. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature. 2017;549:476&#x2013;481.</Citation></Reference><Reference><Citation>Guan Y, Tiwari AD, Phillips JG, et al. A therapeutic strategy for preferential targeting of TET2 mutant and TET-dioxygenase deficient cells in myeloid neoplasms. Blood Cancer Discov. 2021;2:146&#x2013;161.</Citation></Reference><Reference><Citation>Huijskens MJ, Wodzig WK, Walczak M, et al. Ascorbic acid serum levels are reduced in patients with hematological malignancies. Results Immunol. 2016;6:8&#x2013;10.</Citation></Reference><Reference><Citation>Cimmino L, Dolgalev I, Wang Y, et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell. 2017;170:1079&#x2013;95.e20.</Citation></Reference><Reference><Citation>Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616&#x2013;3627 quiz 3699.</Citation></Reference><Reference><Citation>Sulkowski PL, Corso CD, Robinson ND, et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017;9:eaal2463.</Citation></Reference><Reference><Citation>Patnaik MM, Hanson CA, Hodnefield JM, et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia. 2012;26:101&#x2013;105.</Citation></Reference><Reference><Citation>Watts JM, Baer MR, Yang J, et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2023;10:e46&#x2013;e58.</Citation></Reference><Reference><Citation>FDA approves ivosidenib as first-line treatment for AML with IDH1 mutation. 2019. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-first-line-treatment-aml-idh1-mutation. Accessed March 5, 2023.</Citation></Reference><Reference><Citation>FDA approves olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation. 2022. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olutasidenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-idh1-mutation. Accessed March 5, 2023.</Citation></Reference><Reference><Citation>FDA granted regular approval to enasidenib for the treatment of relapsed or refractory AML. 2017. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-granted-regular-approval-enasidenib-treatment-relapsed-or-refractory-aml. Accessed March 5, 2023.</Citation></Reference><Reference><Citation>Sebert M, Cluzeau T, Beyne Rauzy O, et al. Ivosidenib monotherapy is effective in patients with IDH1 mutated myelodysplastic syndrome (MDS): the IDIOME phase 2 study by the GFM group. Blood. 2021;138:62.</Citation></Reference><Reference><Citation>Sallman DA, Foran JM, Watts JM, et al. Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): updated enrollment and results of a phase 1 dose-escalation and expansion substudy. J Clin Oncol. 2022;40:7053.</Citation></Reference><Reference><Citation>Stein EM, Fathi AT, DiNardo CD, et al. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020;7:e309&#x2013;e319.</Citation></Reference><Reference><Citation>Venugopal S, Dinardo CD, Takahashi K, et al. Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS). J Clin Oncol. 2021;39:7010.</Citation></Reference><Reference><Citation>Gbyli R, Song Y, Liu W, et al. In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. Leukemia. 2022;36:1313&#x2013;1323.</Citation></Reference><Reference><Citation>Molenaar RJ, Radivoyevitch T, Nagata Y, et al. IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors. Clin Cancer Res. 2018;24:1705&#x2013;1715.</Citation></Reference><Reference><Citation>Chandhok NS, Wei W, Bindra R, et al. The PRIME trial: PARP inhibition in IDH mutant effectiveness trial. A phase II study of olaparib in isocitrate dehydrogenase (IDH) mutant relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. Blood. 2019;134:3909.</Citation></Reference><Reference><Citation>Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol. 2011;29:504&#x2013;515.</Citation></Reference><Reference><Citation>Chen L, Chen JY, Huang YJ, et al. The augmented R-loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations. Mol Cell. 2018;69:412&#x2013;25.e6.</Citation></Reference><Reference><Citation>Nguyen HD, Yadav T, Giri S, et al. Functions of replication protein a as a sensor of R loops and a regulator of RNaseH1. Mol Cell. 2017;65:832&#x2013;47.e4.</Citation></Reference><Reference><Citation>Lee SC, North K, Kim E, et al. Synthetic lethal and convergent biological effects of cancer-associated spliceosomal gene mutations. Cancer Cell. 2018;34:225&#x2013;41.e8.</Citation></Reference><Reference><Citation>Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K, et al. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer. 2021;127:3552&#x2013;3565.</Citation></Reference><Reference><Citation>Dalton WB, Helmenstine E, Pieterse L, et al. The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing. Blood Adv. 2020;4:1192&#x2013;1196.</Citation></Reference><Reference><Citation>Seiler M, Yoshimi A, Darman R, et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018;24:497&#x2013;504.</Citation></Reference><Reference><Citation>Buonamici S, Yoshimi A, Thomas M, et al. H3B-8800, an orally bioavailable modulator of the SF3b complex, shows efficacy in spliceosome-mutant myeloid malignancies. Blood. 2016;128:966.</Citation></Reference><Reference><Citation>Steensma DP, Wermke M, Klimek VM, et al. Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021;35:3542&#x2013;3550.</Citation></Reference><Reference><Citation>Siu LL, Rasco DW, Vinay SP, et al. METEOR-1: a phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours. Ann Oncol. 2019;30:v159.</Citation></Reference><Reference><Citation>Study to investigate the safety and clinical activity of GSK3326595 and other agents to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Available at: https://clinicaltrials.gov/ct2/show/NCT03614728?term=GSK3326595&amp;draw=2&amp;rank=2. Accessed March 5, 2023.</Citation></Reference><Reference><Citation>Nguyen HD, Leong WY, Li W, et al. Spliceosome mutations induce R loop&#x2013;associated sensitivity to ATR inhibition in myelodysplastic syndromes. Cancer Res. 2018;78:5363&#x2013;5374.</Citation></Reference><Reference><Citation>Brunner AM, Liu Y, Mendez LM, et al. Inhibition of ATR with AZD6738 (ceralasertib) for the treatment of progressive or relapsed myelodysplastic syndromes and chronic myelomonocytic leukemia: safety and preliminary activity from a phase Ib/II study. Blood. 2021;138:1521.</Citation></Reference><Reference><Citation>Jiang Y, Gao SJ, Soubise B, et al. TP53 in myelodysplastic syndromes. Cancers (Basel). 2021;13, 5392.</Citation></Reference><Reference><Citation>Weinberg OK, Siddon A, Madanat YF, et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022;6:2847&#x2013;2853.</Citation></Reference><Reference><Citation>Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549&#x2013;1556.</Citation></Reference><Reference><Citation>Sallman DA, Komrokji R, Vaupel C, et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016;30:666&#x2013;673.</Citation></Reference><Reference><Citation>Degtjarik O, Golovenko D, Diskin-Posner Y, et al. Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Nat Commun. 2021;12:7057.</Citation></Reference><Reference><Citation>Bykov VJ, Zhang Q, Zhang M, et al. Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy. Front Oncol. 2016;6:21.</Citation></Reference><Reference><Citation>Sallman DA, DeZern AE, Steensma DP, et al. Phase 1b/2 combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Blood. 2018;132:3091.</Citation></Reference><Reference><Citation>Aprea therapeutics announces results of primary endpoint from phase 3 trial of eprenetapopt in TP53 mutant myelodysplastic syndromes (MDS). 2020. Available at: https://ir.aprea.com/news-releases/news-release-details/aprea-therapeutics-announces-results-primary-endpoint-phase-3. Accessed March 5, 2023.</Citation></Reference><Reference><Citation>Mishra A, Tamari R, DeZern AE, et al. Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2022;40:3985&#x2013;3993.</Citation></Reference><Reference><Citation>Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138:271&#x2013;285.</Citation></Reference><Reference><Citation>Chao MP, Weissman IL, Majeti R. The CD47-SIRP&#x3b1; pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012;24:225&#x2013;232.</Citation></Reference><Reference><Citation>Sallman DA, Malki MMA, Asch AS, et al. Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results. J Clin Oncol. 2022;40:7017.</Citation></Reference><Reference><Citation>Mehta GD, Kumar R, Srivastava S, et al. Cohesin: functions beyond sister chromatid cohesion. FEBS Lett. 2013;587:2299&#x2013;2312.</Citation></Reference><Reference><Citation>Gligoris TG, Scheinost JC, B&#xfc;rmann F, et al. Closing the cohesin ring: structure and function of its Smc3-kleisin interface. Science. 2014;346:963&#x2013;967.</Citation></Reference><Reference><Citation>Losada A, Hirano M, Hirano T. Identification of Xenopus SMC protein complexes required for sister chromatid cohesion. Genes Dev. 1998;12:1986&#x2013;1997.</Citation></Reference><Reference><Citation>Kon A, Shih LY, Minamino M, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet. 2013;45:1232&#x2013;1237.</Citation></Reference><Reference><Citation>Mondal G, Stevers M, Goode B, et al. A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers. Nat Commun. 2019;10:1686.</Citation></Reference><Reference><Citation>McLellan JL, O'Neil NJ, Barrett I, et al. Synthetic lethality of cohesins with PARPs and replication fork mediators. PLoS Genet. 2012;8:e1002574.</Citation></Reference><Reference><Citation>Tothova Z, Valton AL, Gorelov RA, et al. Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML. JCI. Insight. 2021;6.</Citation></Reference><Reference><Citation>Kontandreopoulou CN, Diamantopoulos PT, Tiblalexi D, et al. PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. Blood Adv. 2021;5:4794&#x2013;4805.</Citation></Reference><Reference><Citation>Parker JE, Mufti GJ, Rasool F, et al. The role of apoptosis, proliferation, and the Bcl-2&#x2013;related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 2000;96:3932&#x2013;3938.</Citation></Reference><Reference><Citation>Raza A, Mundle S, Iftikhar A, et al. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol. 1995;48:143&#x2013;154.</Citation></Reference><Reference><Citation>Economopoulou C, Pappa V, Papageorgiou S, et al. Cell cycle and apoptosis regulatory gene expression in the bone marrow of patients with de novo myelodysplastic syndromes (MDS). Ann Hematol. 2010;89:349&#x2013;358.</Citation></Reference><Reference><Citation>Fischer MA, Arrate M, Childress MA, et al. Variable response to BCL2 inhibition in MDS is enhanced across MDS subtypes with synergistic combination of BCL2 + MCL1 inhibition. Blood. 2019;134:2982.</Citation></Reference><Reference><Citation>Zeidan AM, Borate U, Pollyea DA, et al. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol. 2023;98:272&#x2013;281.</Citation></Reference><Reference><Citation>Garcia JS, Wei AH, Borate U, et al. Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study. Blood. 2020;136:55&#x2013;57.</Citation></Reference><Reference><Citation>Pellagatti A, Cazzola M, Giagounidis A, et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia. 2010;24:756&#x2013;764.</Citation></Reference><Reference><Citation>Raza A, Mundle S, Shetty V, et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol. 1996;63:265&#x2013;278.</Citation></Reference><Reference><Citation>Maratheftis CI, Andreakos E, Moutsopoulos HM, et al. Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes. Clin Cancer Res. 2007;13:1154&#x2013;1160.</Citation></Reference><Reference><Citation>Kristinsson SY, Bj&#xf6;rkholm M, Hultcrantz M, et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol. 2011;29:2897&#x2013;2903.</Citation></Reference><Reference><Citation>Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer. 2017;17:5&#x2013;19.</Citation></Reference><Reference><Citation>Zhao Y, Cai W, Hua Y, et al. The biological and clinical consequences of RNA splicing factor U2AF1 mutation in myeloid malignancies. Cancers (Basel). 2022;14, 4406.</Citation></Reference><Reference><Citation>Choudhary GS, Pellagatti A, Agianian B, et al. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. elife. 2022;11, e78136.</Citation></Reference><Reference><Citation>Garcia-Manero G, Winer ES, DeAngelo DJ, et al. Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or myelodysplastic syndrome. J Clin Oncol. 2022;40:7016.</Citation></Reference><Reference><Citation>Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382:140&#x2013;151.</Citation></Reference><Reference><Citation>Wolfraim LA, Fernandez TM, Mamura M, et al. Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med. 2004;351:552&#x2013;559.</Citation></Reference><Reference><Citation>Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-&#x3b2; superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20:408&#x2013;414.</Citation></Reference><Reference><Citation>Fenaux P, Kiladjian JJ, Platzbecker U. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood. 2019;133:790&#x2013;794.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. FDA approves luspatercept-aamt for anemia in adults with MDS. 2020. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-luspatercept-aamt-anemia-adults-mds.</Citation></Reference><Reference><Citation>Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet. 2005;6:611&#x2013;622.</Citation></Reference><Reference><Citation>TERT telomerase reverse transcriptase. Available at: https://www.ncbi.nlm.nih.gov/gene/7015. Accessed March 5, 2023.</Citation></Reference><Reference><Citation>Gertler R, Rosenberg R, Stricker D, et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol. 2004;22:1807&#x2013;1814.</Citation></Reference><Reference><Citation>Sanders RP, Drissi R, Billups CA, et al. Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol. 2004;22:3790&#x2013;3797.</Citation></Reference><Reference><Citation>Tabori U, Ma J, Carter M, et al. Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J Clin Oncol. 2006;24:1522&#x2013;1528.</Citation></Reference><Reference><Citation>Gandini S, Zanna I, De Angelis S, et al. TERT promoter mutations and melanoma survival: a comprehensive literature review and meta-analysis. Crit Rev Oncol Hematol. 2021;160:103288.</Citation></Reference><Reference><Citation>Dessain SK, Yu H, Reddel RR, et al. Methylation of the human telomerase gene CpG island. Cancer Res. 2000;60:537&#x2013;541.</Citation></Reference><Reference><Citation>Guilleret I, Yan P, Grange F, et al. Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int J Cancer. 2002;101:335&#x2013;341.</Citation></Reference><Reference><Citation>Zinn RL, Pruitt K, Eguchi S, et al. hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res. 2007;67:194&#x2013;201.</Citation></Reference><Reference><Citation>Renaud S, Loukinov D, Abdullaev Z, et al. Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res. 2007;35:1245&#x2013;1256.</Citation></Reference><Reference><Citation>Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009;113:1315&#x2013;1325.</Citation></Reference><Reference><Citation>Dong W, Qian Y, Yang L. Telomerase, hTERT and splice variants in patients with myelodysplastic syndromes. Leuk Res. 2014;38:830&#x2013;835.</Citation></Reference><Reference><Citation>Bock O, Serins&#xf6;z E, Schlu&#xe9; J, et al. Different expression levels of the telomerase catalytic subunit hTERT in myeloproliferative and myelodysplastic diseases. Leuk Res. 2004;28:457&#x2013;460.</Citation></Reference><Reference><Citation>Briatore F, Barrera G, Pizzimenti S, et al. Increase of telomerase activity and hTERT expression in myelodysplastic syndromes. Cancer Biol Ther. 2009;8:883&#x2013;889.</Citation></Reference><Reference><Citation>Cong Y, Shay JW. Actions of human telomerase beyond telomeres. Cell Res. 2008;18:725&#x2013;732.</Citation></Reference><Reference><Citation>Kang HJ, Choi YS, Hong SB, et al. Ectopic expression of the catalytic subunit of telomerase protects against brain injury resulting from ischemia and NMDA-induced neurotoxicity. J Neurosci. 2004;24:1280&#x2013;1287.</Citation></Reference><Reference><Citation>Masutomi K, Possemato R, Wong JM, et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci U S A. 2005;102:8222&#x2013;8227.</Citation></Reference><Reference><Citation>Maida Y, Yasukawa M, Furuuchi M, et al. An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature. 2009;461:230&#x2013;235.</Citation></Reference><Reference><Citation>Wu X, Song B, Zhang J, et al. Human telomerase reverse transcriptase transfection reduces apoptosis in human penile smooth muscle cells and slows down cellular aging. J Sex Med. 2012;9:494&#x2013;504.</Citation></Reference><Reference><Citation>Zhang Z, Yu L, Dai G, et al. Telomerase reverse transcriptase promotes chemoresistance by suppressing cisplatin-dependent apoptosis in osteosarcoma cells. Sci Rep. 2017;7:7070.</Citation></Reference><Reference><Citation>Steensma DP, Fenaux P, Van Eygen K, et al. Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study. J Clin Oncol. 2021;39:48&#x2013;56.</Citation></Reference><Reference><Citation>Phase III IMerge trial of imetelstat in lower-risk MDS. 2023. Available at: https://ascopost.com/news/january-2023/phase-iii-imerge-trial-of-imetelstat-in-lower-risk-mds/. Accessed March 5, 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37195765</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-336X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>3</Issue><PubDate><MedlineDate>2023 May-Jun 01</MedlineDate></PubDate></JournalIssue><Title>Cancer journal (Sudbury, Mass.)</Title><ISOAbbreviation>Cancer J</ISOAbbreviation></Journal><ArticleTitle>Myelodysplastic Syndromes/Neoplasms-Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and Treatments.</ArticleTitle><Pagination><StartPage>109</StartPage><EndPage>110</EndPage><MedlinePgn>109-110</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PPO.0000000000000663</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Michal G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>From the VA Connecticut Cancer Center, West Haven.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeidan</LastName><ForeName>Amer M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Section of Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Comprehensive Cancer Center, New Haven, CT.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer J</MedlineTA><NlmUniqueID>100931981</NlmUniqueID><ISSNLinking>1528-9117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Conflicts of Interest and Source of Funding: A.M.Z. is a Leukemia and Lymphoma Society Scholar in Clinical Research. A.M.Z. received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Cardiff oncology, Incyte, Takeda, Novartis, Shattuck Labs, Geron, Aprea, and ADC Therapeutics. A.M.Z. participated in advisory boards and/or had a consultancy with and received honoraria from AbbVie, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Servier, Boehringer-Ingelheim, Novartis, Astellas, Daiichi Sankyo, Geron, Taiho, Seattle Genetics, BeyondSpring, Takeda, Ionis, Amgen, Janssen, Genentech, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, Notable, Orum, Mendus, Foran, Syros, and Tyme. A.M.Z. served on clinical trial committees for Novartis, Abbvie, Gilead, Syros, BioCryst, Abbvie, ALX Oncology, Geron, and Celgene/BMS. For M.G.R., none were declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>11</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37195765</ArticleId><ArticleId IdType="doi">10.1097/PPO.0000000000000663</ArticleId><ArticleId IdType="pii">00130404-202305000-00001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ma X. Epidemiology of myelodysplastic syndromes. Am J Med. 2012;125(7 Suppl):S2&#x2013;S5. doi:10.1016/j.amjmed.2012.04.014. PMID: 22735748; PMCID: PMC3394456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2012.04.014. PMID: 22735748; PMCID: PMC3394456</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189&#x2013;199.</Citation></Reference><Reference><Citation>Steensma DP. Historical perspectives on myelodysplastic syndromes. Leuk Res. 2012;36:1441&#x2013;1452. ISSN 0145-2126, https://doi.org/10.1016/j.leukres.2012.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.leukres.2012.08.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9&#x2013;16.</Citation></Reference><Reference><Citation>Kar SP, Quiros PM, Gu M, et al. Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis. Nat Genet. 2022;54:1155&#x2013;1166. https://doi.org/10.1038/s41588-022-01121-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-022-01121-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200&#x2013;1228. doi: https://doi.org/10.1182/blood.2022015850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022015850</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703&#x2013;1719. https://doi.org/10.1038/s41375-022-01613-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-022-01613-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeidan AM, Bewersdorf JP, Buckstein R, et al. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the international workshop for myelodysplastic syndromes. Leukemia. 2022;36:2939&#x2013;2946. doi:10.1038/s41375-022-01724-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-022-01724-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard E, Tuechler H, Greenberg PL, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1. doi:10.1056/EVIDoa2200008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/EVIDoa2200008</ArticleId></ArticleIdList></Reference><Reference><Citation>Frumm SM, Shimony S, Stone RM, et al. Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS. Blood Rev. 2023;101056. https://doi.org/10.1016/j.blre.2023.101056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2023.101056</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeidan AM, Platzbecker U, Bewersdorf JP, et al. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood. 2023;141:2047&#x2013;2061. doi:10.1182/blood.2022018604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022018604</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
  recorded_at: Wed, 17 May 2023 17:59:14 GMT
recorded_with: VCR 6.1.0
